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Abstract 
The development of sepsis is associated with complex cardiovascular changes, 
some of which can be micmked in animals by administration of 
lipopolysaccharide (LPS). Animal models have identified a number of 
mediators important in these changes. The work described within this thesis 
aimed to investigate the role of adrenomedullin (AM) and adenosine in 
regulating vascular function in vivo in normal and LPS-treated rats. Integrated 
haemodynamics were assessed in Sprague Dawley rats following implantation 
of pulsed Doppler flow probes, allowing changes in renal, mesenteric and 
hindquarters vascular conductance to be measured across time. 
Adrenomedullin (AM), a hypotensive peptide involved in cardiovascular 
regulation, is upregulated in sepsis. Intermedin (IMD) is related to AM and 
shares some of its functions. However, the in vivo integrated responses to IMD 
have yet to be determined. In normal rats, both peptides caused marked 
vasodilatations in all regions. with hypotension and tachycardia. IMD was a 
more potent vasodilator than equimolar AM. 
Next, mechanisms involved in IMD signalling were investigated and 
compared to AM. Both AM and IMD-mediated renal and mesenteric 
vasodilatation were attenuated by AM22-52 and some components of IMD were 
sensitive to L-NAME, suggesting IMD causes both endothelial-dependent and 
-independent vasodilatations. No role for KA TP channels was found, but there 
was an enhanced response to AM in the presence ofU37883A; this was due to 
1 
inhibition of the renin-angiotensin system as assessed by the angiotensin II 
receptor antagonist losartan. 
To assess whether vascular sensitivity to AM and IMD was affected in an LPS 
model of endotoxaemia, rats were treated with LPS and responses to peptides 
were assessed at 1.5 h, 6 hand 25 h. Vascular hyporesponsiveness to both AM 
and !MD occurred at 1.5 h, but had returned by 25 h regardless of the LPS 
administration protocol. Thus, vascular hyporesponsiveness appears to be a 
common phenomenon during the early stages of LPS-induced endotoxaemia. 
The role of adenosine was then examined in the haemodynamic sequelae of 
sepsis, since evidence suggests that adenosine-mediated vasodilatations help to 
maintain regional perfusion in animal models. In control rats, endogenous 
adenosine caused bradycardia and vasodilatation, whereas there was evidence 
of regional vasoconstriction in LPS-treated rats. In control aniI:nals, exogenous 
adenosine caused hypotension, tachycardia and vasodilatation, but in LPS-
treated rats, the adenosine-induced renal (at 1.5 h) and hindquarters (at 6 h) 
vasodilatations were abolished. As enhanced At receptor-mediated 
vasoconstriction could explain the results in LPS-treated rats, responsiveness 
to an At-receptor agonist (CCPA) or antagonist (DPCPX) was assessed. There 
was no evidence for enhanced vasoconstrictor responsiveness to CCP A in 
LPS-treated rats, but DPCPX caused renal vasodilatation, consistent with 
endogenous adenosine mediating renal vasoconstriction. 
11 
Finally, the effects of a subdepressor infusion of adenosine on the 
haemodynamic responses to AM and IMD were assessed, and vice versa, to 
determine whether any synergism exists between these agents. No synergism 
was found between adenosine and AM, but there was functional antagonism 
between adenosine and IMD in the mesenteric vasculature. 
Collectively, these studies suggest that the development of novel 
cardiovascular therapies for treatment of sepsis should be designed to take into 
account the vascular region, and the time elapsed from onset. 
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Chapter 1 
General Introduction 
1 
1 General Introduction 
The word 'sepsis' originates from the Greek for 'putrefaction', and was first 
used by Hippocrates (460-377 Bc) in reference to illness caused by an 
unknown poison which led to rapid and unpreventable death. Despite 
substantial medical and theoretical advancement over the intervening years, 
prognosis for patients suffering from sepsis is still poor, and it remains one of 
the leading causes of death worldwide. Sepsis refers to a syndrome 
characterised by an exaggerated and unpredictable systemic inflammatory 
response, and involves complex cardiovascular, immunological, respiratory, 
metabolic and neurological changes. The heterogeneous nature of the 
syndrome leads to difficulties in its correct diagnosis and management, with 
current treatments centred on supportive therapies that have limited efficacy if 
the patient presents symptoms of septic shock. Therefore, continued research 
into sepsis is crucial to identify novel therapeutic targets. 
The development of sepsis is associated with biphasic changes m 
haemodynamics. A hyperdynamic circulation ensues during the onset of 
sepsis, when patients have an elevated cardiac output and a decrease in total 
peripheral resistance resulting in the maintenance of normal blood pressure. 
These features can be mimicked by administering low-dose lipopolysaccharide 
(LPS); a component of Gram-negative bacteria which is used routinely to 
model the disorder in human volunteers and animals. During late sepsis, as the 
status of the patient deteriorates, a hypodynamic circulation develops which is 
characterised by a low cardiac output and widespread regional vasodilatations 
that lead to resistant or 'unrelenting' hypotension. This can be mimicked by 
2 
higher doses of LPS. This involves impaired regulation of, and vascular 
hyporesponsiveness to, a wide variety of mediators, including adrenomedullin 
(AM), intennedin (!MD) and adenosine. 
The calcitonin family of pep tides includes AM and IMD. Both peptides elicit a 
potent hypotensive response when given to conscious and anaesthetised 
animals, and cause marked vasodilatations, mediated by endothelial-dependent 
and -independent mechanisms. The purine nucleoside, adenosine, also causes 
widespread vasodilatation and hypotension in vivo, and as a component of 
ATP, acts to couple metabolic demand to blood flow. 
Impaired regulation of, and vascular hyporesponsiveness to, vasoactive 
mediators is involved in the development of resistant hypotension during 
sepsis. For example, protein levels of AM are increased in the plasma of septic 
patients and vascular responsiveness to the peptide is reduced in late sepsis. 
Endogenous adenosine has also been implicated in the development of 
regional vasodilatations during sepsis. Such findings have led researchers to 
suggest that both AM and adenosine are involved in the development of the 
haemodynamic sequelae associated with the pathophysiology of sepsis. 
The first part of this Introduction will discuss sepsis, with reference to its 
epidemiology, pathophysiology and study. The second part will focus on AM 
and the recently discovered AM-2, or intennedin (IMD), and discuss what is 
currently known about their function in normal and pathophysiological states; 
with specific reference to sepsis. Finally, the third part will discuss the role of 
adenosine in the cardiovascular system and its role in the pathogenesis of 
sepsIs. 
3 
1.1 Sepsis 
1.1.1 Epidemiology 
Septic shock is a major cause of mortality in Intensive Care Units (ICU) 
worldwide. A study by Angus et al. (2001) estimated there are 751,000 cases 
of severe sepsis each year in US hospitals, with a mortality rate of 28.6%; 
although some estimates put this as high as 40-50% (Tsiotou et al., 2005; 
Vincent et al., 2006). Furthermore, it was highlighted that in the US alone this 
amounts to an annual national cost of $16 billion, or $22,100 per case. An 
Intensive Care National Audit & Research Centre analysis of a clinical 
database over a 9-year period in the UK (1996-2004), calculated the number of 
admissions to ICUs with severe sepsis as 92,672, totalling 27% of all 
admissions. Between 1996 and 2004, the proportion of admissions increased 
from 23.5% to 28.7%. So, whilst the overall percentage mortality is slowly 
decreasing (from 34.3% in 1996, to 30.8% in 2004), the overall number of 
deaths is increasing (Harrison et al., 2006). These data provide an indication of 
both the human cost, and the financial burden of sepsis on healthcare services 
worldwide. In addition, even if the patient survives the initial septic episode, 
there remains an increased risk of mortality for up to 5 years (Quartin et al., 
1997). 
Difficulty lies with the diagnosis and treatment of sepsis; it is a heterogeneous 
condition with multiple causes, and involves the interplay of many systems. A 
Consensus Conference of American College of Chest Physicians/Society of 
Critical Care Medicine held in 1991, aimed to standardise definitions relating 
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to the sepsis syndrome and define specific parameters that should be present 
for a diagnosis to be made (Bone et al., 1992). Traditionally used definitions 
such as 'septicaemia' were replaced with 'systemic inflammatory response 
syndrome' in cases with no documented infection, and 'sepsis' where infection 
is present. Furthermore, the terms 'sepsis', 'severe sepsis' and 'septic shock' 
were used to describe a continuum of the same disorder. The exact definitions 
for these terms, along with the symptoms necessary for diagnosis, are given in 
Table 1.1. In addition, diagnosis is complicated by the underlying status of the 
patient; pre-existing morbidities are common in patients who develop sepsis, 
particularly in those with a compromised immune system (Le., increased risk 
in RN patients) and those receiving chronic treatment through intravascular 
catheters (i.e., increased susceptibility in patients with a central venous 
catheter) (O'Brien et al., 2007). Other factors affecting the development, 
progression and outcome of sepsis are age (i.e., increased risk in over 65s), 
gender (i.e., slightly increased risk in males) and ethnicity (Le., Caucasian 
populations less susceptible than African Americans) (O'Brien et al., 2007). 
Whilst these guidelines have helped improve and standardise the diagnosis of 
sepsis, they fail to identify the nature of the underlying infection. A recent 
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study of sepsis in European ICUs (SOAP study; Vincent et al., 2006) found 
that only 60% of septic patients presented positive microbial cultures. Of 
these, the most common culture was positive for Gram-positive bacteria 
(40%), with Staphylococcus strains accounting for the majority of cases 
(including MRSA accounting for 14% of this subgroup). This was closely 
followed by cultures positive for Gram-negative bacteria (38%), of which 
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Pseudomonas strains and Escherichia coli were the most common species 
(14% and 13%, respectively). Fungi were identified in 17% of patients with a 
positive blood culture, whilst 18% presented a mixed culture (Vincent et al., 
2006). A reliable, clinically available test for Gram-negative bacteria is 
important since some antibiotics release endotoxin from micro-organisms 
(Jarisch-Herxheimer reaction), leading to induction of the cytokines TNF-a, 
IL-6 and IL-8 which may be detrimental to patients with already high 
endotoxin levels (for review see Lepper et al., 2002). 
Once a diagnosis of sepsis is made, volume resuscitation, broad-spectrum anti-
microbial therapy, vasopressor treatment (commonly noradrenalin), life-
support, where required are given (O'Brien et al., 2007). The value of 
supportive treatments is limited once the patient has symptoms of severe 
sepsis or septic shock. The only therapy currently available that specifically 
targets the inflammatory response is the anti-coagulant, recombinant activated 
protein C (rAPC or drotrecogin alfa (activated», since the ability to produce 
endogenous APC is impaired in septic patients. As this treatment can cause 
excessive bleeding in patients with pre-existing coagulation problems, it is 
used with caution and only in patients with a high risk of death (for review see 
O'Brien, 2007; Toltl, 2008). 
The most common site of infection in patients presenting sepsis is the lungs 
(44-64%) (Angus et al., 2001; Vincent et al., 2006), followed by the abdomen 
6 
Table 1.1 The Sepsis Syndrome 
Term 
Infection 
Bacteraemia 
SIRS 
Sepsis 
Severe sepsis 
Septic shock 
MODS 
Definition 
Inflammatory response to microorganisms, or 
invasion of normally sterile host tissue by 
. . 
mIcroorganIsms 
Presence of viable bacteria in the blood 
Systemic inflammation arising from an 
unknown cause 
Systemic inflammation in the presence of 
infection 
Sepsis associated with organ dysfunction, 
hypoperfusion or sepsis-induced hypotension 
Persistent sepsis-induced hypotension (despite 
fluid resuscitation) plus hypoperfusion 
abnormalities and organ dysfunction 
Continuum of organ dysfunction 
Diagnosis 
> 1 of the following: 
• body temperature >38°C or <36°C 
• heart rate >90 beats min- I 
• respiratory rate >20 breaths min-I 
• white blood cell count >12000 cu mm-I or 
<4000 cu mm-I 
As above, with infection from a confirmed 
source 
• Symptoms may include lactic acidosis, 
oliguria, acute alteration of mental state 
• Sepsis-induced hypotension: systolic BP of 
<90 mmHg or its reduction by 40 mm Hg 
As above, with evidence of MODS 
• Altered organ function; organ(s) unable to 
maintain normal homeostasis 
• Can be primary or secondary 
Adapted from Bone et al. (1992, 1993). SIRS: systemic inflammatory responses syndrome; MODS: multiple organ dysfunction syndrome 
(22%), blood (20%) unnary tract (14%) and infections ansmg from 
intravascular catheters (8%) (Vincent et al., 2006). Furthermore, loss of the 
intestinal epithelial barrier function in an inflammatory environment may 
allow the translocation of harmful bacteria from the gut to the blood in 
instances where the gut is not the main source of infection, leading to 
secondary infections and the development of systemic inflammation (for 
review see Rittirsch, 2008). 
1.1.2 Pathophysiology of sepsis 
In normal physiology, the immune system is tightly regulated to maintain the 
correct level of protective versus damaging responses in tissues. Conversely, 
host detection of a pathogen can cause overstimulation of the innate immune 
response; subsequent loss of inflammation control leads to the development of 
sepsis. The presence of pathogen-associated molecular patterns (PAMPs) on 
harmful microorganisms is identified by pattern recognition receptors (PRR); 
these include the Toll-like receptors (TLR), of which TLR-2 and TLR-4 are 
activated upon recognition of LPS (Kirschning et al., 1998; Yang et al., 1998; 
Rittirsch 2008). Interestingly, polymorphisms in proteins of the Toll-family 
may account for variable responses to septic insults in individuals, with the 
TLR-4 Asp299Gly allele causing enhanced sensitivity to LPS and increased 
susceptibility to Gram-negative infections (Lorenz et al., 2002). The signalling 
pathway induced by LPS binding to TLR-4 is shown in Figure 1.1. Briefly, 
recognition of the P AMP-containing pathogen, LPS, by TLR-4 triggers a 
signalling cascade, which leads to the translocation of NF-KB to the nucleus 
where it causes transcription and translation of pro-inflammatory mediators. 
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Figure 1.1 LPS signalling cascade 
a) LPS activates the alternative pathway of the complement cascade, increasing 
levels of complement products, C3b and C5a, which function to enhance 
phagocytosis, and promote the development of a local inflammatory response, 
respectively. 
b) LBP (LPS binding protein), produced by the liver, is constitutively active at 
low levels but upregulated after administration of LPS. LBP bound to LPS is 
detected by the opsonic receptor CD-14, which, along with LBP, is required 
for LPS sensing by the cell. The LPS/LBP/CD-14 complex activates TLR-4 
which is bound to MD-2, a cell-surface molecule required for TLR-4 
activation and positioning on the plasma membrane. Intracellular signalling 
requires the cytoplasmic TIR (Tol//IL-l receptor homology) domain of TLR-4 
which is bound by adapter proteins, including MyD88 (Myeloid differentiation 
primary response gene (88)) to facilitate binding of the next factors in the 
cascade. This involves activation of lRAK (Interleukin-I receptor associated 
kinase 4) which is required for the innate immune response to LPS, followed 
by TRAF6 (TNF receptor-associated factor-6) which ultimately leads to 
translocation of NF-KB (Nuclear factor) from the cytoplasm to the nucleus. 
Here, it induces transcription and translation of pro-inflammatory mediators, 
including TNF (Tumour necrosis factor), IL-1/6/8 (Interleukin-l/6/8), IFN-a/{3 
(Interferon- a/(3) and MIPIa.-I{3 (macrophage inflammatory protein-I) which 
leads to activation of pro-inflammatory mediators and cell-adhesion 
molecules. 
(For review see Cohen, 2002; Beutler & Rietschel, 2003). 
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Lipopolysaccharide is also an activator of the alternative pathway of the 
complement system leading to increased levels of the anaphylatoxin and pro-
inflammatory product, C5b. These mechanisms act in concert to produce a 
pro-inflammatory environment, sometimes referred to as the systemic 
inflammatory response syndrome (SIRS) (Toltl et al., 2007) (A potential 
source of confusion since this tenn is also used in the diagnosis of sepsis, 
section 1.1.1.) which is further exacerbated by down-regulation of anti-
inflammatory mediators. In severe sepsis, there is an over- compensatory 
increase in anti-inflammatory mediators (such as IL-lO and IL-lra), referred to 
as compensatory anti-inflammatory syndrome (CARS); this leads to 
immunosuppression in already ill patients and can result in further 
complications caused by secondary infections (for review see Told et al., 
2007). 
Inflammation is also under control of the autonomic nervous system by the 
'inflammation reflex'. Nonnally, inflammatory homeostasis is controlled by 
the two opposing arms of the autonomic nervous system. Activation of the 
cholinergic system suppresses the release of pro-inflammatory mediators, 
whilst activation of the adrenergic system leads to increased levels of 
circulating catecholamines and enhanced production of pro-inflammatory 
mediators. Dysregulation of these systems is involved in the development of 
sepsis; activation of the sympathetic nervous system in early sepsis enhances 
inflammation through an increase in circulating catecholamines (for review 
see Rittirsch et al., 2008). 
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Enhanced inflammation leads to apoptosis of dendritic cells, lymphocytes, 
monocytes and neutrophils; this further exacerbates the pro-coagulatory 
environment in sepsis. Increased levels of apoptosis may be involved in the 
development of immunosuppression, loss of GI and respiratory tract cells and 
ultimately organ dysfunction in septic patients (O'Brien, 2007, review). In 
severe cases, sepsis-mediated dysregulation of coagulation results in 
disseminated intravascular coagulation, leading to microcirculatory 
impairment due to of increased fibrin deposition (Rittirsch, 2008). 
Metabolic disturbances are a further complication of sepsis. In addition to 
tissue hypo-perfusion, impaired cellular oxygen extraction due to 
mitochondria failure ('cytopathic hypoxia') leads to the development of 
hypoxaemia and organ failure during sepsis (for review see Carre & Singer, 
2008). The failure of tissues to extract oxygen leads to high venous 02 
measurements in septic patients (Sair et al., 1996), and heterogeneity of tissue 
oxygenation in experimental models of shock (Dyson et al., 2007). Many of 
the pathophysiological features of sepsis can be attributed to disturbances of 
the microcirculation; in fact, sepsis has been referred to as a 'disorder of the 
microcirculation' (Trzeciak et al., 2008). 
1.1.2.1 Cardiovascular changes during sepsis 
The cardiovascular pathophysiology of sepsis and severe sepsis is marked by 
defined haemodynamic changes that rapidly deteriorate as the disorder 
progresses through the spectrum. These changes are biphasic and characterised 
by an early hyperdynamic phase (often called 'warm shock' as patients are 
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'flushed') which progresses into a hypodynamic stage ('cold shock' as patients 
are cold to the touch) as the status of the patient declines. A hyperdynamic 
circulation is characterised by an increase in cardiac output, regional 
perfusion, oxygen delivery and consumption. During this stage, patients 
remain nonnotensive due to the increase in cardiac output, in spite of the 
systemic vasodilatation. Surgical intervention, treatment with drugs and 
supportive therapy can be effective during the hyperdynamic phase. This 
distinct haemodynamic pattern is documented in adults with sepsis, and in 
paediatric sepsis arising through central venous catheter infection (Brierley & 
Peters, 2008). Severe sepsis is associated with a hypodynamic circulation 
which is characterised by a fall in cardiac output and blood flow leading to 
'unrelenting' or 'resistant' hypotension. During this phase, the patient 
becomes increasingly unresponsive to treatment and the chance of recovery is 
significantly reduced (for review see Fowler et al., 2003; Buras et al., 2005; 
Tsiotou et al., 2005). 
Observed systemic cardiovascular changes during sepSIS arIse through 
unbalanced activation and inhibition of vasodilator and vasoconstrictor 
systems, impaired cardiac function and endothelial dysfunction. Endothelial 
cells release factors involved in coagulation homeostasis, and vascular smooth 
muscle relaxation and hyperpolarisation; therefore, endothelial dysfunction 
further exacerbates the hypotension and coagulopathy observed in sepsis (for 
review see Trzeciak et al., 2008). For example, loss of vascular responsiveness 
to adrenergic agents is a common trait in both clinical and experimental sepsis, 
despite increased levels of circulating catecholamines; this contributes to the 
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resistant hypotension seen in the late stage of the disease. Diminished vascular 
responsiveness to a-adrenoceptor agonists, 5' -hydroxytryptomine, potassium 
and prostanoids, as well as the endothelial-dependent vasodilators 
acetylcholine (ACh), salbutamol and bradykinin have been demonstrated in 
vivo and ex vivo in animals or vessels treated with LPS (Beasley et al., 1990; 
Parker et al., 1994; Waller et al., 1994; Piepot et al., 2003). Impaired 
endothelial-dependent dilatation has also been demonstrated in healthy human 
volunteers treated with a mild-inflammatory stimulus (Hingorani et al., 2000). 
Changes in vascular reactivity lead to alterations in blood flow distribution, 
regional hypoperfusion and contribute to tissue hypoxia and organ 
dysfunction. Evidence from in vivo and in vitro studies show enhanced nitric 
oxide (NO) production and excessive activation of ATP-sensitive potassium 
channels (KATP channels) are major factors in the development of vascular 
hyporesponsiveness in sepsis (Sorrentino et al., 1999; O'Brien et al., 2001; 
Wu et al., 2004; for review see Buckley et al., 2006). 
A role for KA TP channels in the development of regional vasodilatations, and 
vascular hyporesponsiveness during sepsis has been previously reported 
within 5 h of LPS administration, and at 24 h, in both conscious and 
anaesthetised rats (Gardiner et al., 1999a; Sorrentino et al., 1999). Enhanced 
KATP channel activity may be due to increased activation via the upregulation 
of mediators such as NO, adenosine and CGRP (Buckley et al., 2006), and/or 
via increased KATP channel subunit expression, following LPS-treatment 
(Czaika et al., 2000). 
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It is well documented that there are variable changes in NO synthase (NOS) 
activity during sepsis. An early increase in levels of the endothelial, 
constitutive isoform (eNOS), and a late increase in levels of the inducible 
isoform (iNOS), which peak between 4 and 12 h have been shown following 
LPS treatment in both in vivo and in vitro systems (Gardiner et al., 1996; 
O'Brien et al., 2001; Connelly et al., 2005; Vo et al., 2005; Y a m a g t ~ c h i i et al., 
2005). Evidence suggests that eNOS-derived NO may act as a pro-
inflammatory mediator in early sepsis, owing to its ability to stimulate iNOS 
expression (Connelly et al., 2005; Vo et al., 2005). Interestingly, eNOS 
knockout mice, as well as having decreased iNOS activity, also exhibited 
decreased mortality following a septic insult and more stable haemodynamics 
compared to wild type septic animals (ConneHy et al., 2005). Thus, 
endothelial-derived NO appears to be detrimental in sepsis due to its pro-
inflammatory and depressor actions. The requirement of eNOS-derived NO 
for the induction of iNOS during sepsis is illustrated by studies which show 
that several hours exposure to LPS is required for iNOS upregulation (O'Brien 
et a/., 2001). Furthermore, endothelial derived NO is reduced by short-term 
LPS exposure due to impaired bioavailability of eNOS (Graier et al., 1994). 
Therefore, early changes in eNOS expression may be responsible for impaired 
endothelial-dependent relaxation, whilst vascular smooth muscle contraction is 
affected following long-term LPS exposure and elevated iNOS expression. 
Abnormal cardiac function has long been associated with infection and sepsis. 
Indeed, at the beginning of the eighteenth century, the 'heat of the blood' in 
septic patients was calculated by the 'pounding of the pulse' as the two were 
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believed to intrinsically linked (Mackenzie, 2001). It is now known that the 
development of sepsis results in cardiac abnormalities characterised by 
myocardial depression and impaired cardiomyocyte contractility. Although, 
cardiac contractility may be depressed, there is an early increase in cardiac 
output in sepsis owing to reduced afterload as a result of systemic 
vasodilatation. A reproducible pattern of cardiac dysfunction occurs 1-4 days 
from the onset of sepsis, and consists of reduced left ventricular (LV) ejection 
fraction, enhanced LV end-diastolic volume index, increased cardiac output 
and the maintenance of normal stroke volume index which was associated 
with ventricular dilatation (Parker et al., 1995). Cardiac function of survivors 
was found to return to normal from day 4 onwards. Interestingly, non-
survivors of sepsis maintained normal cardiac parameters throughout their 
time in the ICU (Parker et al., 1985). 
Parillo's group found that serum taken from septic patients with reduced LV 
ejection fraction contained a 'myocardial depressant substance' which 
depressed the contractility of rat cardiomyocytes in vitro (Parillo, 1989). The 
group later showed this 'myocardial depressant substance' to include 
synergism between the pro-inflammatory cytokines TNF-a and IL-l{3, which 
caused increased production of NO by iNOS (Kumar et al., 1996; 1999). A 
recent study by this group found the inflammation-induced depression of in 
vitro cardiomyocyte contractility could be prevented by the pleiotropic 
cytokine, transforming growth factor-{3, suggesting a novel therapy for 
resolution of cardiac depression in sepsis (Kumar et al., 2007). 
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1.1.3 Animal Models of Sepsis 
To study the pathophysiological changes associated with sepsis in vivo, several 
animal models of the disease have been developed; these can be divided into 
two categories: 
1.1.3.1 
(i) Administration of a toxin/pathogen (e.g., LPS/ E.coli) 
(ii) Disruption of a natural protective barrier causing exposure to 
endogenous toxinlbacteria (e.g., by caecalligation and puncture 
(CLP) 
Administration of a toxin/pathogen 
Gram-negative bacteria differ from Gram-positive bacteria by having a cell 
wall comprising inner and outer lipid membranes separated by a periplasmic 
space containing peptidoglycan. Lipopolysaccharide (LPS) is a component of 
the outer cell envelope found in all Gram-negative bacteria, but is absent from 
Gram-positive bacteria. Lipopolysaccharide is made up of an outer O-antigen 
component that is structurally diverse across strains, and a lipid-A component 
that serves to anchor LPS to the bacterial cell wall. Evidence suggests this 
lipid-A component is responsible for the toxicity of LPS and is recognised by 
the host immune system as 'non-selr (for review see Cohen, 2002). 
Endotoxin can be detected using the limulus amebocyte lysate (LAL) assay or 
the chemiluminescent endotoxin activity assay (EAA) (Hurley et al., 1994; 
Marshall et al., 2002), and is found in patients suffering from sepsis as well as 
in a variety of other inflammatory conditions. Furthermore, endotoxaemia is 
not always associated with systemic inflammation, and has been reported in 
paediatric cardiopulmonary bypass patients, in pancreatitis and cirrhosis and 
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even in athletes' following long-distance marathons and triathlons (for review 
see Hurley, 1995). In the case of endurance athletes, this is often accompanied 
by gastrointestinal complaints as a consequence of reduced gut perfusion, 
subsequent mucosal damage and infiltration of endotoxin (J eukendrup et al., 
2000). 
When give!} to experimental animals and to human volunteers, endotoxin 
causes symptoms similar to those seen during clinical sepsis, including fever, 
tachycardia, tachypneoa and leukocytosis (Taviera de Silva et al., 1993; 
Hurley, 1995; Remick et al., 2005). There is one interesting report of a 
laboratory worker who developed symptoms within 3 h from self-
administration of LPS (Img kg-I); these included a decrease in systemic 
vascular resistance, reduced blood pressure, elevated cardiac output, 
disseminated intravascular coagulation, renal and hepatic dysfunction and non-
cardiogenic pUlmonary oedema (Taviera de Silva et al., 1993). LPS-based 
models of sepsis have been criticised on the basis that they lead to a rapid and 
substantial cytokine induction, causing a massive elevation in plasma levels of 
TNF-a, a cytokine which is only rarely detectable in clinical patients with 
sepsis. However, high LPS and TNF levels are seen in infants with 
meningococcal meningitis (for review see Riedermann, 2003). It IS 
acknowledged as a drawback to this approach since the detection of 
endotoxaemia is variable in septic patients (for review see Hurley, 1995). 
Gardiner et al. (1995a) developed an experimental model of Gram-negative 
endotoxaemia by chronically infusing Long-Evans rats with LPS ( 1 5 0 ~ g g kg-I 
h-I i.v.) for 32 h. At this dose, LPS infusion led to the development of a 
haemodynamic profile similar to that seen in clinical patients during the 
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establishment of the hyperdynamic phase. This model has been used to assess 
the relative contribution of vasoactive agents to the haemodynamic sequelae of 
sepsis, as evidence suggests there are clear temporal and regional variations 
(WaIler et al., 1994; Tarpey et al., 1998; Bennett et al., 2004). For example, 
using this model, vascular hyporesponsiveness to the vasoconstrictor effects of 
norepinephrine, angiotensin, endothelin and methoxamine was demonstrated 
in a time-dependent manner during LPS infusion (Gardiner et al., 1996; 
Tarpey et al., 1998; Bennett et al., 2004). These findings are not restricted to 
vasoconstrictors; diminished vascular responses to the vasodilators 
acetylcholine, salbutamol and bradykinin have also been shown (WaIler et al., 
1994) (Table 1.2). 
Using this model it was shown that NO and angiotensin 11 were involved in 
the early (0-2 h) haemodynamic response during LPS infusion; endothelin was 
found to be involved from 2-8 h, whilst at 24 h arginine vasopressin activity 
was enhanced (Gardiner et al., 1996; Tarpey et al., 1998). Investigations into 
the role of NO in the haemodynamic sequelae of sepsis revealed that the peak 
period of iNOS activity did not correlate with the period of maximum 
haemodynamic stability indicating the involvement of mediators other than 
NO/or via mediators induced by NO. Furthermore, inhibition of iNOS activity, 
although preventing/limiting some regional vasodilatations during LPS 
infusion, also led to a detrimental mesenteric vasoconstriction, due to 
enhanced release of endothelin (Gardiner et al., 1995). The overall finding of 
this study was that NOS inhibition could be beneficial during the early stages 
of endotoxaemia (0-8 h), but was detrimental during the later stages (8-24 h). 
A study using vasopressin-deficient Brattleboro rats found an important role 
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for this vasoconstrictor in the maintenance of haemodynamic stability during 
LPS-infusion (Tarpey et al., 1998). 
These studies show that LPS treatment leads to a changing haemodynamic 
profile in animal models and suggests that the changing influence of 
vasoconstrictor and vasodilator systems may have implications for the 
development of novel sepsis therapies. 
In recent years, the incidence of Gram-positive sepsis has risen dramatically 
leading to an increase in sepsis-related mortality. In 2003, it was estimated that 
approximately 50% of reported sepsis cases in the US were related to Gram-
positive bacteria (Wang et al., 2003). This is largely due to the spread of 
antibiotic-resistant strains of bacteria such as methicillin-resistant 
Staphylococcus aureus (MRSA). Two major wall components of Gram-
positive bacteria, peptidoglycan (PepG) and lipoteichoic acid (LTA) can 
stimulate an inflammatory response in vivo, in a similar but less potent manner 
than LPS, although their exact roles in the development of sepsis are poorly 
understood. At present, there are little in vivo data available, since Gram-
positive wall components are difficult to purify, poorly soluble and expensive, 
although their use in sepsis models is likely to increase in the near future (for 
review see Wang et al., 2003). 
Since the development of sepsis in human patients is not always associated 
with endotoxin, other models have been developed which use pure or mixed 
bacterial flora as the infecting agent(s). One model administers rats with faecal 
slurry (obtained from several donor rats) directly into the peritoneum (for 
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review see Buras et al., 2005; Parker et al., 2001). A drawback with this 
method is that it causes a variable response as the exact composition of 
bacterial flora present is not controlled. In order to control for dosage and 
content of the bacterial infecting agent, Goldfarb et al. (1996) developed a 
porcine model of bacterial sepsis which involved the implantation of an E. 
coli-laden fibrin clot into the peritoneal cavity, with the resultant 
cardiovascular changes being comparable to those seen in human sepsis 
(Goldfarb et al., 1996). 
1.1.3.2 Exposure to endogenous toxinlbacteria 
The exposure of usually sterile tissue to harmful pathogens can occur through 
the disruption of a natural protective barrier. A commonly used sepsis model, 
which falls into this category, is induction of polymicrobial sepsis by caecal 
ligation and puncture (eLP). Ligation of the caecum below the ileocaecal 
valve and its subsequent puncture pennits the leakage of faecal content into 
the peritoneum. This mimics the process of septic peritonitis and produces a 
biphasic cardiovascular response similar to that seen in clinical patients, with a 
hyperdynamic phase seen 2 to 10 h after eLP, followed by a hypodynamic 
phase seen after 16 h. Mortality rates in rats subjected to eLP are 
approximately 10% at 24 h and 94% at 48 h (for review see Fowler et al., 
2003; Buras et ai, 2005). This model, although used routinely in sepsis 
research, has been criticised because the exact composition of infecting flora is 
difficult to control. 
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The CLP model more precisely mimics peritonitis and polymicrobial sepsis, 
whereas LPS administration models endotoxaemia (see above). Difficulty lies 
in drawing comparisons between studies which use different models as they 
differ in the infecting agent used, the disorder they describe and the 
inflammatory response they produce. It is therefore important to have several 
different animal models aVc>.ilable to enable the study of sepsis in as· many 
situations as are present in reality. This will become increasingly apparent as 
better diagnostic tests and personalised treatments become available. 
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Renal Mesenteric Hindguarters 
Vasodilators 2h 6h 2S h 2h 6h 2S h 2h 6h 2Sh 
Acetylcholine I ~ ~ ~ ~ +-+ ~ ~ ~ ~ +-+ t +-+ t 
Salbutamol1 ~ ~ ~ ~ +-+ +-+ +-+ +-+ ~ ~ ~ ~ ~ ~
Bradykinin 1 +-+ ~ ~ ~ ~ t +-+ +-+ ~ ~ ~ ~ t 
Vasoconstrictors 2h 6h 2S h 2h 6h 25 h 2h 6h 2S h 
Norepinephrinez ~ ~ ~ ~ +-+ ~ ~ ~ ~ +-+ ~ ~ ~ ~ +-+ 
V ·2 asopressm +-+ +-+ +-+ +-+ t +-+ +-+ +-+ t 
Angiotensin3 ~ ~ ~ ~ ~ ~ ~ ~ +-+ ~ ~ ~ ~ ~ ~ +-+ 
Endothelin3 +-+ ~ ~ ~ ~ +-+ ~ ~ ~ ~ ~ ~ ~ ~ +-+ 
Methoxamine1 +-+ , +-+ ~ ~ , , , ~ ~ +-+ 
Table 1.2 Altered vascular responsiveness to vasoactive mediators in the presence of LPS as shown by the haemodynamic group at the 
University of Nottingham. 
, Reduced vascular responsiveness; +-+ no change in vascular responsiveness; t enhanced vascular responsiveness 
References: lWaller et al. (1994); 2Bennett et al. (2004); 3Tarpey et al .• (1998) 
1.2 The calcitonin family of peptides 
1.2.1 Introduction 
The calcitonin family of peptides comprises, calcitonin, two calcitonin-gene-
related-peptides (a-CGRP and (3-CGRP), amylin, adrenomedullin (AM) and 
the recently discovered intennedin (IMD), (also called AM-2; see later) 
(Poyner et al., 2002; Roh et al., 2004; Takei et al., 2004). These peptides arose 
early in vertebrate evolution (Ogoshi et al., 2006), have diverse functions in 
physiological homeostasis and, apart from calcitonin, have potent vasodilator 
effects in the mammalian cardiovascular system (for review see Chang et al., 
2004). Amylin is co-secreted with insulin from pancreatic {3-cells, and is 
essential for optimal glucose metabolism, calcitonin is required for calcium 
homeostasis, and is used therapeutically in the treatment of bone disorders, 
whilst CGRP and AM are involved in neurotransmission, as well as 
cardiovascular and respiratory regulation. Evidence suggests that AM is 
essential for vascular and lymphatic morphogenesis during embryonic 
development, as shown by the embryonic lethality of AM knockout mice 
(Shindo et al., 200 I; Fritz-six et al., 2008). 
Peptides related to calcitonin are of low molecular weight and share a unique 
structure consisting of an intramolecular ring of six amino acids flanked by a 
disulphide bond and an amidation signal at the C-tenninus. Evidence suggests 
this structure confers the biological activity of these peptides (Sakata et al., 
1993; Lippton et al., 1994; Gibbons et al., 2006). Indeed, truncated fragments 
of these peptides which lack the amidated C-tenninus have no biological 
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activity, and are used as receptor-specific antagonists (for review see Poyner et 
al., 2002). 
1.2.2 Calcitonin family receptors 
Calcitonin family peptides signal through a unique receptor system comprising 
several distinct proteins. T h ~ ~ first, a polypeptide comprising 7-transmembrane 
domains, is referred to as calcitonin-receptor-like-receptor (CL), and the 
second, a single membrane spanning domain protein is referred to as receptor-
activity-modifying-protein (RAMP) (McLatchie et al., 1998; for review see 
Poyner et al., 2002; Martinez et al., 2004). Together, these two proteins 
function as a receptor. The CL component is coupled to a type 11 G-Protein-
Coupled-Receptor (GPCR), which, when activated, increases adenylate 
cyclase activity, leading to an increase in intracellular cAMP and subsequent 
smooth muscle relaxation. In contrast to CL, the RAMP proteins are located in 
the endoplasmic reticulum and transport the receptor complex to the cell 
surface where it can be activated by ligand(s) (McLatchie et al., 1998; Wang, 
2001). The combination of CL with a RAMP isoform confers ligand 
specificity; CL complexed with RAMP 1 gives rise to a CGRP-specific 
receptor, termed CGRP1 (which is blocked by the fragment CGRP8-37). whilst 
CL with either RAMP2 or RAMP3 is AM specific (termed AMI and AM2 
receptors, respectively) (for review see Wang, 2001; Poyner et al., 2002). A 
further GPCR (CT) can function as a calcitonin receptor by itself, or as an 
amylin receptor in combination with the RAMPs. CT bound to RAMPs also 
has some affinity for CGRP (for review see Poyner et al., 2002; Brain and 
Grant, 2004) and may function as a CGRP2 receptor which refers to the 
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component ofCGRP signalling not blocked by CGRPs-37 (for review see Brain 
and Grant, 2004). 
Immunohistochemical analysis suggest that CURAMP combinations are 
found throughout the vasculature (Roh et al., 2004), with different populations 
of receptor subtypes accounting for variation in tissue specificity of the 
ligands. Analysis of human and mouse transcriptomes showed the majority of 
CL to be complexed with RAMP2, to fonn an AM receptor, in nonnal 
physiology (Gibbons et al., 2006). In addition to CL and RAMP, it was 
suggested that an accessory protein (RCP) may accompany CGRP receptors at 
the cell membrane and help couple the receptor to the signal transduction 
pathway (Nandha et al., 1996). 
Within the vasculature, CURAMP complexes are located on the endothelium 
and vascular smooth muscle, leading to both endothelial-dependent and -
independent vasodilatation. Briefly, activation of receptors on endothelial 
cells, leads to an increase in intracellular Ca2+, which, in turn, causes 
activation of endothelial NOS, and subsequent release of NOS through the 
conversion of L-arginine to L-citrulline. The released NO then diffuses into 
the underlying vascular smooth muscle where it activates soluble guanylate 
cyclase and causes relaxation through an increase in cGMP. Alternatively, NO 
may activate KATP channels in the vascular smooth muscle, leading to 
membrane hyperpolarisation and subsequent relaxation. Receptors located on 
the vascular smooth muscle, cause vascular relaxation through activation of 
the cAMPIPKA signalling pathway (for review see Poyner et al., 2002). 
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1.2.3 Adrenomedullin (AM) 
Adrenomedullin was discovered by Kitamura et al. (1993) in an assay 
developed to identify novel vasoactive proteins from human 
phaeochromocytoma tissue extracts. Using this assay, VIP and CGRP had 
previously been identified by their ability to raise cAMP levels in platelets 
(Kitamu.a et al., 1993). 
Adrenomedullin was classified as a calcitonin family peptide due to its slight 
sequence homology with CGRP (27%) and amylin (20%), which was 
restricted to the conserved C-terminal region of the mature peptide (Kitamura 
et al., 1993). AdrenomedulIin is formed from post-translational processing of 
the 185 amino acid precursor peptide, preproAM, which contains a 20 amino 
acid sequence for proadrenomedullin N-terminal 20 peptide (P AMP) (Sakata 
et al., 1993), which also has some vasodilator activity (Champion et al., 1996). 
Adrenomedullin is found in very high concentrations in phaeochromocytoma 
tissue (1900 ± 450 fmol mg- I ) and in normal individuals, AM is present in the 
highest concentration in the adrenal medulla (150 ± fmol mg-I ) and at 
significantly lower levels in the kidney and lung (Kitamura et al., 1993). 
Adrenomedullin is also present in the plasma, and is produced from a variety 
of cells, including endothelial cells, vascular smooth muscle cells, adipocytes, 
cardiac myocytes, macrophages and fibroblasts (Zaks-Zilberman et al., 1998; 
for review see Brain & Grant, 2004). Elevated plasma AM levels have been 
reported in a number of human diseases including heart failure, myocardial 
infarction, sepsis, renal failure, hypertension, hyperthyroidism, pulmonary 
hypertension and insulinoma (Shoji et al., 1995; Cheung et al., 2004; 
Ishimitsu et al., 2006). During sepsis, AM levels can increase in excess of 20-
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fold, whilst in pregnancy AM levels can increase 4-fold, although decreased 
AM levels have been identified in women with complicated pregnancies, 
including pre-eclampsia (Gibbons et al., 2006). Recently, a pilot study found 
that co-infusion of AM and human atrial naturietic peptide had beneficial 
effects in patients with acute decompensated heart failure, these included a 
reduction in mean and pulmonary arterial pressure, reduced systemic and 
pulmonary vascular resistance, and elevated cardiac output without any 
change in heart rate. Furthermore, aldosterone was reduced and urine volume 
and sodium excretion was elevated (Nishikimi et al., 2009). Thus, AM may 
present a novel therapy for the treatment of cardiovascular disease in humans. 
1.2.3.1 Physiological functions of AM 
Adrenomedullin is a multi functional peptide which is most commonly known 
for its effects on the cardiovascular system. Shindo et al. (2001) demonstrated 
that AM null mouse embryos die in utero due to extreme vascular 
abnormalities, indicating that AM is essential for vascular development during 
embryogenesis (Shindo et al., 2001). It was later shown that RAMP2 is 
essential for AM-mediated angiogenesis and maintenance of vascular 
integrity, as RAMP2 null mice also died mid-gestation, whilst heterozygotes 
had significantly impaired vascular integrity (Shindo et al., 2008). 
Adrenomedullin is also essential for lymphatic development, and lymphatic 
endothelial cells from AM knockout mice undergo reduced proliferation 
(Fritz-Six et a!., 2008). Whilst mice heterozygous for the AM gene have 
normal survival rates, they have significantly higher blood pressure compared 
to wild type animals and this is associated with a decrease in NO production 
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(Shindo et al., 2001). Furthennore, heterozygotes showed a greater infarction 
size and increased mortality compared to wild type animals when subjected to 
30 min regional myocardial ischaemia and 120 min reperfusion. Additionally, 
this phenotype could be rescued by pre-treatment with exogenous AM, 
suggesting that this peptide exerts some protection against the deleterious 
effects of myocardial infarction, a r o l ~ ~ involving eNOS and PKB 
phosphorylation (Hamid & Baxter et al., 2006). 
Mice with only one copy of the AM gene also exhibit a more extreme 
cardiovascular response to CLP-induced sepsis which progresses directly into 
a hypodynamic state, compared to wild-type controls. These mice also have 
extreme oedema fonnation suggesting that AM may limit penneability of the 
endothelium (for review see Li et al., 2007; Kahn et al., 2008). A limitation in 
the study of AM is the lack of available tools to specifically antagonise 
endogenous AM, since AM knockout mice are lethal (see above). However, a 
preliminary study by Albertin et al. (2005), showed that it may be possible to 
target the AM gene by siRNAs, thus presenting a method by which knockout 
of AM function could be assessed in adult animals in vivo (Albertin et al., 
2005). 
Adrenomedullin is important in fluid and electrolyte homeostasis, and has a 
number of effects on renal function, including promotion of sodium and 
urinary excretion at doses which have no effect on blood pressure (Charles et 
al., 1997). Furthennore, vascular responsiveness to AM is significantly 
increased during pregnancy and is believed to be involved in generating the 
low blood pressure common during gestation (Ross & Yallampalli, 2007). 
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Adrenomedullin gene expression and production have also been observed in 
some human tumour cells, where it has been shown to promote growth and 
indirectly inhibit apoptosis (reviewed by Ishimitsu et al., 2006). There is also 
some evidence that myocardial AM expression is upregulated by HIF -1 under 
hypoxic conditions, indicative of a protective role during myocardial 
infarction (Hofbauer et al., 2002). Whilst AM is best characterised for its role 
in controlling vascular tone through vasodilatation, the peptide also affects the 
blood vessels in other ways. For example, AM can inhibit apoptosis in 
cultured rat endothelial cells, promote vascular regeneration and re-
endothelisation during wound healing, and limit vascular damage by reducing 
the production of reactive oxygen species (for review see Kato et al., 2005). 
1.2.3.2 Cardiovascular responses to AM 
Since AM shares some (27%) sequence homology with CGRP, the most 
potent vasodilator known, it was hypothesised that AM may have similar 
hypotensive and vasodilatory effects when given to experimental animals. A 
role for AM in the cardiovascular system has been confirmed in vivo and in 
vitro. The main findings of these studies are summarised below, and the 
mechanisms through which AM exerts these effects are summarised in Table 
1.3. 
(i) In vivo 
In their 1993 paper, Kitamura et al. showed that AM caused a long-lasting 
hypotension when given to anaesthetised rats, confirming it to have 
comparable effects to CGRP, albeit being less potent (Kitamura et al., 1993). 
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This has since been repeated and confinned in a variety of species including 
rats (He et al., 1995; Gardiner et al., 1995; Nandha et al., 1995), sheep 
(Charles et al., 1997; Parkes et al., 1995) and humans (Troughton et al., 2000). 
These studies have also consistently shown that AM administration in 
different species of animals, including humans, causes an increase in cardiac 
output (He et al., 1995; Parkes & May et al., 1997; Charles et al., 1997; 
Troughton et al., 2000) and occasionally heart rate (Gardiner et al., 1995), 
although the mechanism through which AM-mediated tachycardia occurs is 
unclear. Evidence that AM has little effect on heart rate in anaesthetised 
animals suggests that AM-mediated tachycardia is largely mediated by 
sympathetic activation (Nandha et al., 1996; Parkes & May et al., 1997; 
Sabates et al., 1997). However, some studies using ganglion, sympathetic and 
parasympathetic blocking drugs are suggestive of a direct, albeit small, 
positive inotropic effect of AM (Parkes & May, 1997). 
In vivo studies have shown that the blood pressure lowering effect of AM is a 
consequence of its potent vasodilator action in the rat renal, mesenteric and 
hindquarters vascular beds (Gardiner et al., 1995; Elhawary et al., 1995); cat 
pulmonary, mesenteric and hindquarters vascular beds (Lippton et al., 1994; 
Champion et al., 1996, 1997), dog coronary and renal vascular beds (Miura et 
al., 1995; Sabates et al., 1997), and sheep coronary vascular bed (Parkes & 
May, 1997). Using micro spheres, He et al. (1995) demonstrated that AM 
administration in conscious rats led to significant increases in blood flow to 
the lungs, heart, liver, spleen, kidneys, adrenal gland and gastrointestinal tract, 
indicating AM-mediated vasodilatations in those regions. Interestingly, in that 
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study, AM administration caused reduced blood flow to skeletal muscles and 
testis and had no effect on cerebral blood flow (He et al., 1995). 
The mechanisms of AM's-action in the cardiovascular system are not fully 
understood but are known to involve activation of AMI and AM2 receptors 
(see section 1.2.2) although it has been shown that AM can activate CGRPI 
receptors in some regions (for review see Table 1.3; Poyner et al., 2002). 
(i) In vitro 
Administration of AM to perfused rat mesenteric beds caused concentration-
dependent vasorelaxation which was approximately ten-times less marked 
than CGRP-mediated vasorelaxation, and was sensitive to treatment with the 
CGRP receptor antagonist CGRPS-37, suggesting a role for CGRPI receptors 
(Nuki et al., 1993). A vasorelaxant response to AM was demonstrated in 
isolated blood-perfused rat lung, which was independent of NO, CGRPI 
receptors, prostaglandins, KATP channels or adenosine Al receptors. It is 
possible that AM receptors were involved in AM-mediated pulmonary 
vasodilatation in that study, since the effects of the AM receptor antagonist, 
AM22-52, were not investigated (Heaton et al., 1995). Adrenomedullin is well 
known for its role in fluid and electrolyte homeostasis, and has been shown to 
dilate afferent and efferent arterioles to the same extent, and to decrease renal 
vascular resistance in isolated rat kidneys, through activation of CGRPl 
receptors and through NO release (Hirata et al., 1995). 
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Mechanism Agent used Seecies Ef/ect Reference 
CGRP1 in vivo CGRPS-37 Cat No effect on AM-mediated hind-limb Champion et al. (1997) 
Rat vasodilatation Elhawary et al. (1995); 
No effect on AM-mediated hypotension Nandha et al. (1996) 
Dog No effect on AM-mediated coronary vasodilatation Sabates et al. (1997) 
in vitro BmN09BS Mouse Vasorelaxation of I!erfused mesentery Grant et al. {2004) 
AMllZ in vivo AM22-s2 Rat Inhibition of regional haemodynamic responses to Gardiner et al. (1999) 
AM 
in vitro Attenuation of AM-mediated increase in cAMP in Ross & Yallampalli 
mesenteric vessels from I!regnant rats (2007) 
NO in vivo L-NAME Cat No effect on AM-mediated mesenteric relaxation Champion et al. (1996) 
Rat Some attenuation of AM-mediated hindquarters Gardiner et al. (1995) 
vasodilatation 
L-NIO Dog Attenuation of AM-mediated renal vasodilatation Miura et al. (1995) 
in vitro L-NA Rat Attenuation of AM-mediated mesenteric 
vasore laxation 
KATP in vivo U37883A Cat No effect on AM-mediated hind limb Champion et al. (1997) 
Dog vasodi latation Sabates et al. (1997) 
Glibenclamide Dog Attenuation of AM-mediated coronary Miura et al. (1995) 
vasodilatation 
No effect on AM-mediated renal vasodilatation 
in vitro Glibenclamide Rat Abolished AM-mediated mesenteric membrane Goto et al. (2000) 
hyperpolarisation 
Other in vivo Phosphodiesterase Cat Augmentation of AM response in cat hind limb Champion et al. (1997) 
inhibition 
Adenosine receptor Dog Attenuation of AM-mediated coronary Sabates et al. (1997) 
inhibition vasodilatation 
in vitro Endothelial denudation Rat Attenuation of AM-mediated mesenteric Champion et al. (2001) 
vasorelaxation 
Table 1.3 Mechanisms of AM action in the cardiovascular system 
It is well documented that AM has a direct stimulatory effect on 
juxtaglomerular cells, causing them to increase renin secretion independent of 
any effects on blood pressure or renal blood flow (Parkes et al., 1995; Charles 
et al., 1997; Troughton et al., 2002). Adrenomedullin infusion in both healthy 
volunteers and sheep increased plasma renin activity 2-3 fold with no 
subsequent effect on the levels of aldosterone (Charles et al., 2003). This 
failure of AM to cause a secondary increase in aldosterone or vasopressin, has 
led to some speculation that AM may be a functional antagonist of angiotensin 
11, causing uncoupling of the renin-angiotensin ratio (Yamaguchi et al., 1995; 
1996; Charles et al., 1997; 2002; Troughton et al., 2000). However, the effects 
of AM on aldosterone secretion are contradictory in the literature. Whilst some 
studies suggest AM has no effect on aldosterone levels (see above), others 
have shown a direct inhibition of aldosterone secretion (Yamaguchi et al., 
1995; 1996), or stimulation of aldosterone secretion from adrenal zona 
glomerulosa cells (Kapas et al., 1998). 
1.2.3.3 Adrenomedullin and sepsis 
Adrenomedullin mRNA and protein are elevated in rats during CLP sepsis (Yang et 
al., 2001) and LPS-induced endotoxaemia (Shoji et al., 1995; Sugo et al., 1995; 
Zaks-Zilberman et al., 1998; Cheung et al., 2004; Li et al., 2005). Since mature AM 
is not stored in cells, its regulation occurs at the level of transcription. Shoji et al. 
(1995) found that AM gene transcription was elevated in the aorta, heart, lungs, 
adrenal glands, kidney, skeletal muscle, brain, thymus, submaxillary gland, liver 
and the gut, following i.p. injection of LPS in rats (Shoji et al., 1995). Furthermore, 
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it was suggested that vascular endothelial and smooth muscle cells are a major 
source of circulating AM, and contribute to the elevated plasma levels of the 
peptide during sepsis (Shoji et al., 1995). 
Expression of AM mRNA was induced by the pro-inflammatory cytokines, IL-1P 
and TNF-a, and by iNOS in rat aortic smooth muscle cells, endothelial cells, 
mesengial cells and hepatocytes, possibly via binding of NFKB to the promoter 
region of the AM gene (Sugo et al., 1995; Hofbauer et al., 2002). It is not clear, 
however, whether AM was upregulated directly by pro-inflammatory cytokines or 
indirectly following upregulation of cytokine-induced iNOS expression. 
Nevertheless. since I L - l ~ . . TNF-a and iNOS are all upregulated during sepsis (Yang 
et al., 2001), this provides a mechanism to account for the sepsis-mediated increase 
in AM (see above). Moreover, evidence suggests that AM expression is directly 
upregulated by LPS in vascular smooth muscle cells (Sugo et al., 1995). Therefore, 
any LPS-mediated increase in AM production may be amplified by the action of 
pro-inflammatory cytokines, which are themselves upregulated by LPS. 
Interestingly, AM has also been shown to limit the increase in pro-inflammatory 
cytokines following a septic insult, as mice heterozygous for the AM gene show an 
exaggerated inflammatory response to LPS. with elevated TNF-a and IL-l levels, 
and increased liver damage relative to wild type mice (Dackor & earon, 2007). 
Thus, AM appears to function as an anti-inflammatory mediator, providing negative 
feedback to limit the induction of TNF -a and IL-l gene expression during sepsis. 
Since the development of a hyperdynamic circulation in early sepsis is preceded by 
a rise in plasma AM, it has been suggested that this peptide may be an essential 
mediator of the haemodynamic changes in early sepsis (for review see Koo et al., 
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2001; Wang, 2001). Administration of AM-specific antibodies to rats made septic 
by eLP prevented the development of the hyperdynamic circulation (that is, 
increased cardiac output and stroke volume, and decreased total peripheral 
resistance) (Wang et al., 1998), supporting this hypothesis. When given 
prophylactic ally, AM was able to prevent the development of a hypodynamic 
circuJation and limit the increase in arterial lactate accum'llation in LPS-treated 
sheep. Furthermore, in the same study, when given therapeutically, it was shown 
that AM-treatment reversed a hypodynamic circulation back to a hyperdynamic 
state (Ertmer et al., 2007). It has been suggested that myocardial dysfunction during 
hyperdynamic sepsis is prevented by a compensatory increase in AM which acts 
directly on cardiomyocytes to augment con tractility and maintain cardiac output (Li 
et al., 2005). There is some evidence to suggest that decreased vascular 
responsiveness to AM is responsible for the transition from a hyperdynamic to a 
hypodynamic circulation in late sepsis (Le. after 16 h in eLP rats). This is supported 
by evidence showing reduced AM-mediated relaxation of isolated aortic rings and 
isolated perfused small intestine 20 hand 10 h from the onset of eLP sepsis, 
respectively (Wang et al., 1999). Evidence suggests that an AM specific binding 
protein may be responsible for this. 
Elsasser et al. (1999) identified a binding protein for AM in the plasma of several 
species including human and rat (Elasser et al., 1999), which was subsequently 
found to be identical to human complement factor H (Pio et al., 2001). Association 
of adrenomedullin binding protein (AMBP-I) with AM enhanced the AM-induced 
increase in cAMP levels in rat-2 fibroblasts and augmented AM-induced growth 
and proliferation of a human T-47D breast cancer cell line. Moreover, when in 
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association with AM, the co-factor activity of AMBP-1 (i.e. factor H), and hence 
cleavage of C3b, was significantly enhanced (Pio et al., 2001). This mechanism 
may account for the anti-inflammatory effects of AM. AMBP-1 contains 
glycosaminoglycan binding sites which are involved in cell-surface attachment (Pio 
et al., 2001). Therefore, as well as protecting AM from degradation, AMBP-1 may 
increase the concentration of AM at its receptors and prolong its effects. In vitro 
studies using aortae isolated from eLP-treated rats showed reduced vascular 
sensitivity to the vasorelaxlmt effects of AM associated with decreased levels of 
AMBP-l rather than AM receptor components. Furthermore, treatment with 
AMBP-1 prevented the vascular hyporesponsiveness to AM in sepsis (Zhou et al., 
2002) suggesting that AMBP-1 was responsible for the loss of responsiveness to 
AM in later sepsis, and that therapeutic administration of this peptide may be 
helpful in preventing the transition from the hyperdynamic to the hypodynamic 
phase of sepsis (Zhou et al., 2002). AMBP-I gene expression was reduced in the 
liver (the main production site of the protein) at 20 h from CLP sepsis induction in 
rats, and AMBP-1 protein level is reduced in both the liver and the plasma at this 
juncture (Cui et al., 2005). Furthermore, using a LPS-neutralizing agent, it was 
shown that LPS is the agent responsible for the downregulation of AMBP-1 during 
sepsis, a fact confirmed by significant reductions of the protein seen in LPS-treated 
animals (Cui et al., 2005). This suggests that reduced vascular responsiveness to 
AM during late sepsis may be due to LPS-induced downregulation of AMBP-1. 
In a series of studies by Ping Wangs group (Yang et al., 2002; Zhou et al.,2004; 
2007), it was found that co-administration of AMIAMBP-1 could limit the adverse 
effects caused by CLP-induced sepsis in vivo. For example, co-administration of 
AMI AMBP-I in rats prevented the eLP-induced increase in total peripheral 
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resistance, decrease in oxygen delivery, and decrease in cardiac output and could 
limit liver damage and the increase in haematocrit at 20 h from the onset of sepsis, 
resulting in an overall reduction in mortality. Furthermore, the decrease in portal, 
intestinal and renal blood flow was prevented at this juncture, whereas coronary 
blood flow was elevated. A further study found there was increased apoptosis of 
aortic endothelial cells 20 h from the onset of CLP sepsis which could be prevented 
by co-treatment with AM and AMBP-l, suggesting a mechanism to account for the 
protective effects of these agents in sepsis. Co-administration of AMI AMBP-l 
could also maintain vascular responsiveness to endothelial-dependent relaxation in 
isolated thoracic aorta and pulmonary arteries taken from rats 20 h after induction 
of CLP sepsis, by preventing the downregulation of eNDS. In terms of clinical 
relevance, this work identifies a novel approach to the treatment of bacterial, and 
Gram-negative sepsis, and suggests that AM and AMBP-l may play an important 
role in the progression of sepsis into septic shock. 
1.2.4 Intermedin (IMD) 
In an attempt to identify peptides involved in osmoregulation, Ogoshi et al. 
(2003) identified 5 AM-like sequences from the pufferfish genome, and 
subsequently isolated cDNAs encoding AM like peptides which were named 
AMl-5 (Ogoshi et al., 2003). The same group identified AM-2-like sequences 
in mouse, rat, and human genome databases, which they named AM-2 (Takei 
et al., 2004). Simultaneously, a phylogenetic profiling approach identified 
AM-like sequences in the genomes of mammals and teleost fish which were 
similar to, but distinct from, AM (Roh et al., 2004). Based on the detection of 
this peptide in the intermediate lobe of the pituitary, the product of this gene 
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was named intermedin (IMD) (Roh et al., 2004). Sequence analysis has since 
found AM-2 and !MD to be the same peptide, which will be referred to in this 
thesis as !MD. 
Sequence and structural analysis of !MD found it may be a novel member of 
the calcitonin family, homologous to AM, based on exon-intron structure and 
synteny of neighbouring genes (Roh et al., 2004; Takei et al., 2004b). 
Phylogenetic analysis clustered these peptides into a group, separate from 
CGRP and amylin, leading Takei et al. (2004) to suggest that, within the 
calcitonin family, there exists an AM subfamily, consisting of two peptides in 
vertebrates (named AMI and 2) and 5 in fish (named AMI to 5). Cloned IMD 
cDNA in mouse, rat and human, had 71 % sequence homology between the 
mouse and pufferfish mature peptide sequence. This compared to 50% 
homology for AM between the same species. In addition, 90% similarity was 
reported between mouse and rat precursor sequences with only one amino acid 
differing between the mature sequences, suggesting IMD to be more highly 
conserved between species than AM (Takei et al., 2004a). 
In the same way that AM is formed from preproAM (Sakata et al., 1993; see 
above), IMD is formed by proteolytic cleavage of the 148 amino acid 
precursor peptide, preproIMD, encoded by the IMD gene. Sequence analysis 
has revealed several biologically active fragments that can be derived through 
its cleavage. The mature form of human IMD is a 47 amino acid, IMDI-47, 
although a shorter fragment, IMDS-47, has also been identified (Roh et al., 
2004). Sequence analysis further revealed a putative cleavage site between 
Arg93-Arg94, producing a 53 amino acid fragment !MDI-S3 (Yang et al., 
2005). Whilst, the physiological significance of these different fragments is 
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yet to be fully understood, there is some evidence to suggest that IMD1-S3 is an 
endogenously produced fragment (Yang et al., 2005). 
1.2.4.1 Tissue distribution of [MD 
Intermedin mRNA was identified in the pituitary and stomach of rats and in 
the gastrointestinal t n ~ c t t of humans, with the highest levels found in the 
stomach and jejunum (Roh et al., 2004). Furthermore, Takei et al. (2004) 
found high IMD expression in the submaxillary gland, kidney, mesentery, 
stomach, ovary (but not testis), lymphoid tissues and pancreas of mice. 
Interestingly, no expression was found within the adrenal gland, which 
contrasts with the high AM expression reported in this area (Kitamura et al., 
1993). The expression of IMD in the ovary suggests that there may be a role 
for this peptide either within the female reproductive system or during 
embryonic development (see later). 
One study showed plasma levels of IMD to be significantly higher than 
circulating AM and CGRP in normal rats (205±59 pg mrl vs. 10-100 pg mrl 
and 2-25 pg mrl, respectively), although radioimmunoassay for AM may not 
take into account peptide bound to AMBP-l (Elsasser et al., 1999; Taylor et 
al., 2004). Tissue examination found IMD protein to be most abundant in 
kidney (31 ± 1 ng Ilg-1) and stomach (30± 1 ng Ilg-1), and at lower levels in the 
hypothalamus (5±0.8 ng Ilg-1). In contrast, Roh et al. (2004), found the highest 
IMD content in the pituitary (intermediate lobe) and stomach of mice, 
suggesting there may be some variation between species. In agreement with 
previous studies (Takei et al., 2004; Roh et al., 2004), the level ofIMD protein 
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in the adrenal was found to be below the level of sensitivity (Taylor et al., 
2005). These results show a difference between the localisation of IMD 
protein in comparison to AM, which has highest expression levels in the lung, 
kidney, heart, spleen, duodenum and adrenal gland (Kitamura et al., 1993). 
This raises the possibility that a number of the diverse functions originally 
attributed to AM, may actually be medi:lted by another member of the' AM 
family', such as IMD, acting through the same receptors. 
Human autopsy tissue showed IMD-like immunoreactivity in the 
hypothalamus, heart and kidney (Takahashi et al., 2006: Morimoto et al., 
2007), and IMD expression was found in a number of cell types/tissues 
implicated in cardiovascular and central nervous system regulation (Morimoto 
et al., 2007). 
1.2.4.2 Cardiovascular responses to IMD 
Since IMD shares some sequence and structural homology with AM, and can 
activate the same receptors (see above, and later), Roh et al. (2004) suggested 
that IMD may share some of the cardiovascular effects of AM and CGRP. A 
review of available in vitro and in vivo data from cardiovascular studies is 
summarised below. 
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Adrenomedullin 
Human Y R Q S M N N F Q G L R S 
Rat Y R Q S M N - - Q G S R S 
Mouse :£ R.!J. S M N - - ..Q G S R S 
Takifugu T K R. S 
In termedin 1-4 
C R F G T ~ T ~ Q K L A H Q I I YQFTDKDKDNVAP 
CRFGT TMQKLAHQIYQFTDKDKDGMAP 
CRFGT TFQKLAHQIYQFTDKDKDGMAP 
c--- .-.. - - -
CSLGT TVHDLAFRLHQLGFQYKI DI AP 
R SKI S P 
RNKI S P 
RNKI S P 
VDKI SP 
Human T Q A Q L L R V ~ C V L G G ~ Q V V N L S H R L ~ Q L M G ' A G R Q D S A P V D P S S P H S Y _ ' '
Rat p I H A Q L L R V C V L G T Q V Q N L S H R L \\ Q L' V R P S G R R D SAP V D P S S P H S Y NH2 
Mouse PHAQLLRV CVLGT Q V Q N L S H R L \ \ Q L V R ~ A G R R D S A P V D P S S P H S Y N H 2 2
Takifugu .... - I S H G_ Q L M. R V C V L G T Q V Q N L S H R L Y Q k I G Q S G KED S S P M N P Q S P H S Y NH2 
Figure 1.2 Sequence homology between mammalian and PufferfLSh (Takifugu) AM (top) and IMD (bottom). 
Lines denote a conserved disulphide bridge, flanking an intramolecular ring of 6 amino acids. Shaded areas denote amino acids conserved 
between 3 or more species. Letters denote amino acids. Adapted from Takei et al. (2004 
Q G Y NH2 
Q G Y NH2 
Q G Y NH2 
Q G Y NH2 
(i) In vitro studies 
Kobayashi et al. (2004) observed IMD-mediated vasodilatation in isolated 
porcine coronary and carotid arteries which were equipotent to those induced 
by AM, and also in supramesenteric arteries. In the coronary artery, IMD-
mediated vasorelaxation could be inhibited by CGRPg.37, but not by AM22.s2, 
suggesting a role for CGRP receptors, but not AM receptors, in the coronary 
vasculature in vitro. In that study there was no effect of IMD on isolated 
femoral, pulmonary or renal porcine arteries. Coronary vasodilatation has also 
been demonstrated in pre-constricted rat aortic ring preparations (Pan et al., 
2005). Kandilci et al. (2006; 2008) studied the effects of IMD and selected 
antagonists on the isolated, buffer-perfuscd lung of Wistar rats, and found that 
IMD perfusion caused significant pulmonary vasodilatation (under 
preconstricted conditions) mediated by activation of CGRP) receptors and 
release of NO in an endothelial-dependent manner, which involved large 
conductance Ca2+ activated K+ channels (BKCa2+) but not KATP channels 
(Kandilci et al., 2006; 2008). However, no IMD-induced vasodilatations were 
seen in isolated porcine pulmonary artery preparations when preconstricted 
with prostaglandin F2a (Kobayashi et al., 2004). Intermedin-mediated 
vasorelaxation has been demonstrated in isolated rat mesenteric artery, which 
involves both the NO-cGMP and the AC-PKA pathways, with a role for 
BKCa2+ but not KATP channels (Chauhan et al., 2007), in line with the findings 
of Kandilci et al. (2006; 2008; see above). Therefore, evidence suggests that 
IMD stimulation causes activation of BKCa2+ channels, 
Mechanism Agent used _Sp_l!cil!s _ Effect Reference 
CGRP. in vivo CGRPS-37 Rat Attenuation ofIMD-mediated hypotension Roh et al. (2004) 
AM lIz 
NO 
KATP 
Others 
in vitro CGRPS-37 
BmN4096 
in vivo AM22-52 
in vitro 
in vitro L-NAME 
in vitro GLB 
in vitro 
COX 
inhibition 
AC,GC 
inhibition 
Rat 
Pig 
Rat 
Rat 
Attenuation of IMD-mediated hypertension (CNS) Ren et al. (2006) 
Inhibition ofIMD-mediated cAMP increase in L6 skeletal Roh et al. (2004) 
myoblasts 
Attenuation of IMD-mediated coronary vasorelaxation 
Attenuation of IMD-mediated pulmonary vasorelaxation 
Inhibition of IMD-mediated increase in cAMP in spinal cord cells 
Kobayashi et al. (2004) 
Kandilci et al. (2006) 
Owji et al. (2008) 
Rat No effect (see above) Owji et al. (2008) 
Rat No effect on IMD-mediated hypotension Roh et a/. (2004) 
Attenuation of IMD-mediated hypertension (CNS) Ren et al. (2006) 
Pig No effect on IMD-mediated aortic vasorelaxation K o b a y a s ~ i i e ~ a l . . (2004) 
Rat Attenuation of IMD-mediated pulmonary vasorelaxation Kandilci et al. (2006) 
Rat Attenuation of IMD-mediated mesenteric vasorelaxation Chauhan et al. (2007) 
Rat 
Rat 
Rat 
No effect on IMD-mediated pulmonary vasorelaxation __ _ _ _K'!Jldilci etaL(2006) 
IMD non-selectively activated CGRPJ, AM 112 receptors in Roh et al. (2004) 
transfected 293T cells 
No effect ofmecIonfenate on IMD-mediated pulmonary 
vasorelaxation 
Attenuation of IMD-mediated mesenteric vasorelaxation by 
SQ22536, Rp-cAMPs and ODQ 
Kandilci et al. (2006) 
Chauhan et al. (2007) 
Table 1.4 Mechanisms of IJ1D action in the cardiovascular system 
resulting in hyperpolarisation, subsequent inhibition of Ca2+ influx through 
voltage gated Ca2+ channels, resulting in relaxation of vascular smooth 
muscle. 
In addition to the potent effects of IMD on the vasculature, there is increasing 
evidence of a direct role for IMD in modulating cardiac function. In isolated 
rat hearts, perfusion with IMD enhanced cardiac function, increased coronary 
blood flow and decreased intraventricular pressure, without any effect on heart 
rate (Yang et al., 2005). However, a study in anaesthetised rats found that high 
doses of IMD inhibited cardiac function, whilst a low dose had no effect (Pan 
et al., 2005). Studies on isolated murine ventricular myocytes indicate that 
IMD (as well as AM and CGRP) augmented cardiac contractility by enhancing 
intracellular Ca2+ release, in a PLC-dependent manner (Dong et al., 2006). The 
authors suggested that whilst transient increases of IMD may have a 
cardioprotective effect, chronic IMD expression may be detrimental to cardiac 
function, increasing the risk of developing heart failure via chronic PKC 
activation (Dong et al., 2006). Augmentation of cardiac contractility by IMD 
presents a direct mechanism through which the peptide may increase cardiac 
output in vivo. 
Although at lower levels than AM, IMD and its receptor components were 
expressed in the hearts of normal rats, and were upregulated in left ventricular 
cardiomyocytes from spontaneously hypertensive rats, whilst AM levels were 
unaffected (Bell et al., 2008; Zeng et al., 2009). Furthermore, the role of IMD 
in enhancing cardiac contractility was blunted in left ventricular 
cardiomyocytes from hypertensive rats, despite increased levels of the peptide 
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(Bell et al., 2008; Zeng et al., 2006). Zhao et al. (2006) designed a study to 
assess whether myocardial Th1D expression was affected in NO-deficient 
hypertension and found that preproIMO mRNA was elevated almost 9-fold 
compared to a modest 1.6-fold increase in preproAM expression. This is in 
contrast to normal hearts in which AM is expressed at higher levels than IMO 
in both ventricles. !n accordance with the findings described above, left 
ventricles from hypertensive rats exhibited an increase in both mRNA 
expression and protein levels of all CL and RAMP receptor components (Zhao 
et al .• 2006). Thus, upregulation of both !MD and its receptor components 
may be a common cardioprotective phenomenon, at least in animal models of 
hypertension. 
Yang et al. (2005) were the first to provide evidence that IMOI-53 may be a 
physiologically significant endogenously-cleaved product of preproIMD, and 
found the fragment to have an almost identical cardioprotective effect to AM 
during cardiac ischaemia-reperfusion. Reperfusion with !MOl-53 ameliorated 
ischaemia-reperfusion-induced bradycardia, myocardial injury and impairment 
of cardiac function, and increased myocardial cAMP content to the same 
extent as AM, suggesting that the cardioprotective effect of IMOI-53 may be 
mediated via cAMP-dependent mechanisms. Furthermore, IMO I-53 binding 
was also potentiated during ischaemia-reperfusion, with maximum binding 
capacity increased by 118%. In contrast, however, preproIMD protein content 
was reduced 4-fold in ischaemia-reperfused myocardia relative to control, 
suggesting the majority of !MD under such conditions is membrane bound. 
Like AM, IMDI-53 was also found to limit oxidative stress induced by 
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ischaemialreperfusion, as shown by reduced production of myocardial lipid 
peroxide in the presence of IMDI-53 (Yang et ai, 2005). 
(ii) In vivo studies 
Whilst in vitro studies provide evidence of a cardiac role for IMD, studies 
investigating the systemic effects of the peptide are less clear, and it is 
currently unknown whether IMD has a direct effect on the heart to increase 
heart rate, or whether this is secondary to the IMD-mediated fall in blood 
pressure. Ganglion blockade with mecamylamine, inhibited IMD-induced 
tachycardia, suggesting this may be a reflex response to the fall in blood 
pressure (Abdelrahman et al., 2006). In contrast, physical denervation of aortic 
baroreceptors in rats reduced IMD-induced tachycardia and renal sympathetic 
nerve activity, but did not abolish it (Fujisawa et al., 2006), suggesting that 
whilst IMD causes autonomic nervous reflex activation, there may be some 
residual IMD action on the heart which is direct. However, since the 
cardiopulmonary baroreceptors were left intact, involvement of these low-
pressure receptors cannot be ruled out (Fujisawa et 01.,2006). 
When IMDI47 and IMDS47 (10 and SOnmol rarl each) were administered Lp. 
to normal and hypertensive rats, both forms dose-dependently decreased blood 
pressure and increased heart rate. Interrnedinl47 was more potent than IMD847 
at both doses, and high dose AM (50 nmol rar l ) was more potent than both 
(Roh et al., 2004). Comparison of the cardiovascular effects of IMDI-47 and 
IMDI-53 with AM showed that IMDI-47 caused the most potent fall in blood 
pressure, whilst IMDI-53 had an effect comparable to AM. Thus, evidence 
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suggests that different cleavage products of prepro-IMD may act on the 
cardiovascular system with different potencies (Ren et al., 2006). 
In anaesthetised mice, IMD caused a potent and long-lasting hypotensive 
response which was greater than that exerted by equimolar doses of AM 
(Takei et al., 2004). Pan et al. (2005) showed that high doses of IMD (150 
nrnol i.v.) in Wistar rats caused a decrease in mean arterial pressure, decreased 
left ventricular end-systolic pressure and maximal rate of left-ventricular 
development, with no significant effect on heart rate. The dose used here, 
however, was considerably larger than that used by others. Intermedin infusion 
in conscious sheep led to significant reductions in blood pressure, increases in 
cardiac output and heart rate, with a concurrent fall in total peripheral 
resistance (Charles et al., 2006). This was the first description of the 
haemodynamic effects of !MD in a large animal in vivo, and indicates its 
cardiovascular effects may be comparable between species. 
Since IMD has been localised to the kidney (Takei et al., 2004b; Taylor et al., 
2005; Takahashi et al., 2006), it was suggested that it may have some role in 
renal function, particularly since intrarenal arterial AM infusion has been 
shown to dose-dependently increase renal blood flow, urinary output and 
urinary sodium excretion in anaesthetised dogs and rats (Hirata et al., 1995; 
for review see Samson, 1999). Indeed, Fujisawa et al. (2004; 2006) showed 
that !MD significantly increased renal blood flow, urine volume and urinary 
sodium excretion to a level comparable to that seen following equimolar AM 
treatment, in both conscious and anaesthetised rats. The duration of the AM-
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induced increase in renal blood flow was longer than that induced by IMD, in 
both studies (Fujisawa et al., 2004; 2006). 
In conscious sheep, IMD infusion was shown to have no signi ficant effect on 
renal function (urine volume, urine sodium, potassium, or creatinine levels); 
consistent with an earlier study which found no significant effects of AM 
infusion on renal fl!nction in the same species (Charles et al., 1997; 2006). 
This may indicate species differences in the renal actions of these peptides 
since both AM and IMD affected renal haemodynamics in rats and mice 
(Fujisawa et al., 2004, 2006; Takei et al., 2004). However, IMD infusion 
significantly increased plasma aldosterone levels in sheep, secondary to an 
increase in plasma renin activity, whereas AM caused no significant change in 
levels of aldosterone, despite a significant increase in plasma renin activity 
(Charles et al., 1997; see above). Thus, angiotensin 11 inhibition may be a 
function unique to AM (see above), which is not shared by IMD (Charles et 
al., 1997; see above). 
The identification of IMD mRNA within the brain has led some researchers to 
propose a role for IMD in the central nervous system (CNS). Since AM and 
CGRP have hypertensive effects when administered intracerebroventriculary 
(i.e. v), Taylor et al. (2005) studied the effects of IMD in the CNS of rats. In 
contrast to its hypotensive effects when given both i.v and i.p, when 
administered Le.v, IMD exerted dose-dependent hypertensive and tachycardic 
effects that were partly attenuated upon CNS administration of CORPs-37. In 
addition, IMD administered i.c.v. provoked an anorexic effect in fasted rats. 
Ren et al. (2006) compared the effects of Le.v. IMD I-47. IMD 1-S3 and AM in 
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rats and found both fonns of IMD to increase blood pressure to a greater 
extent than AM, with IMDI-53 having more potent effects than IMD I-47. 
The potent hypertensive effect of IMD1-s3 in the CNS was blocked by i.c.v. 
AM22-52 and CGRPs-37, in line with the study of Taylor et al. (2005), which 
suggested a role for the CGRP receptor in theCNS. To examine the effects of 
endogenous IMDI-S3 in central regulation of blood pressure, a prepro-IMD 
antibody that antagonised the effects of exogenous IMDI-53 in the CNS was 
used. However, in the absence of exogenous peptide, the antibody had no 
effect on either blood pressure or heart rate, suggesting endogenous IMDI-s3 
has little effect on CNS-mediated cardiovascular function in nonnal animals. 
The same methods are yet to be applied to the study of endogenous IMD in the 
periphery, or in pathophysiological conditions in which endogenous IMD may 
be upregulated. 
1.2.4.3 Other functions of 1MD 
There is increasing evidence to support a role for IMD in the female 
reproductive system as an intermediate lobe-derived prolactin-releasing factor, 
since IMD expression is increased in lactating animals, and can be stimulated 
by estrogens. Furthermore, this function of IMD may be mediated by the AM2 
receptor (Chang et al., 2004). Due to the homology between AM and IMD, it 
is tempting to speculate that IMD may also have some functional role during 
pregnancy, particularly since elevated mRNA levels have been seen in the 
ovaries of mice (Takei et al., 2004); and a role for AM has been identified 
this, however, remains to be demonstrated. Like AM, vascular responsiveness 
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to IMD was enhanced in mesenteric arteries isolated from pregnant rats via 
enhanced NO production (Chauhan et al., 2007). 
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1.3 Adenosine 
1.3.1 Introduction 
The physiological significance of adenosine was first realised in the 1920s, 
when it was shown to possess both coronary vasodilator and anti-arrhythmic 
properties in cat, dog and guinea pig hearts (Drury & Szent-Gyorgyi, 1929). A 
number of years later, Berne (1963) developed the 'Ado Hypothesis for the 
metabolic regulation of coronary blood flow', which described adenosine as 
an endogenous dilator of coronary vessels, released following a reduction in 
the myocardial 02 supply-to-demand ratio (Berne, 1963). Further studies in 
the mid-1980s, on both humans and animals, demonstrated that an increase in 
adenosine plasma levels resulted in both bradycardia and hypotension (for 
review see Berne, 1986). Adenosine is now known to dilate mUltiple vascular 
beds, and is involved in many physiological processes including immune 
regulation, respiration, activation and coagulation of platelets, oxyradical 
production, neuronal signalling, inhibition of lipolysis and synaptic 
transmission (for review see Berne, 1986; Motew et ai, 1998; Law et ai, 2003; 
Adanin et ai, 2002; Hask6 & Cronstein, 2004). Adenosine is currently used 
clinically to treat patients with paroxysmal supraventricular tachycardia which 
involve re-entry through the atrioventricular node (DiMarco et al., 1983; 
Riccardi et al., 2008). 
Adenosine is a nucleoside composed of the purine, adenine, linked via a 
glycosidic bond to a ribose sugar (Figure 1.3), and is found ubiquitously 
throughout the body. It is involved in both energy storage and transfer as a 
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component of ATP/ADP, and in signal transduction as a component of cAMP. 
As a degradation product of ATP, adenosine is released into both extra- and 
intracellular compartments following the dephosphorylation of AMP by 5-
(ecto)-nucleosidase, and via S-adenosylhomocysteine (SAH) hydrolysis. The 
amount of adenosine produced via SAH hydrolysis is relatively small and 
accounts for the generation of physiological amounts of adenosine. Adenosine 
produced in this way is not sensitive to changes in cellular oxygen levels (for 
review see Conlon et al., 2005). Typically, basal tissue levels of adenosine are 
< 50 nM, but can be elevated to levels of up to 1000 nM under conditions of 
increased metabolic demand (Rivkees et al., 2001). 
Adenosine has been described as a 'reactive molecule', 'reactive metabolite' 
or 'metabolic vasoregulator' since it exerts little effect on resting physiology. 
Periods of increased metabolic demand, such as exercise, or decreased oxygen 
supply, such ischemia or hypoxia, lead to transient accumulation of adenosine 
in those areas affected. Furthermore, it has been demonstrated that in 
conditions of reduced oxygen, activity of the enzyme 5' -nucleosidase (scc 
above) is elevated, providing a direct link between metabolic demand and 
adenosine production (for review see Mubagwa et al., 1996). High levels of 
adenosine activity are seen in skeletal muscle and hepatosplanchnic organs, 
which both require regular changes in perfusion to satisfy fluctuations in 
metabolic demand (Motew et al., 1998). 
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Figure 1.3: Chemical structure of adenosine 
1.3.2 Adenosine receptors 
Adenosine interacts with a family of four cell-surface, G-protein-coupled 
receptors belonging to the PI purinergic family, named AI, A2a, A2b and A3, 
and adenosine receptor-mediated effects have been confirmed experimentally 
in almost every tissue and system studied (for review see Conlon et al., 2005). 
AI. A2a and A2b receptors share approximately 80-95% sequence homology 
across species in which they have been identified, suggesting an important 
conserved role, whereas the AJ subtype shows significant variation between 
species (for review see Conlon et al., 2005). Expression of adenosine 
receptors in Chinese hamster ovary cells showed activation of AI and A3 
subtypes to cause inhibition of adenylate cyclase activity, whilst activation of 
both A2 subtypes induced an increase in adenylate cyclase activity (Fredholm 
et al., 2001). It was also shown that the order of potency of adenosine at these 
receptors was AI>A3>A2a>A2b, with AI receptor having the highest affinity for 
adenosine and A2b the lowest. Therefore, AI activation occurs at physiological 
(low) levels of adenosine whilst A2b activation requires pathophysiological 
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(high) levels of adenosine (Fredholm et al., 2001); i.e., At receptors are 
activated by adenosine in the nanomolar range whereas A2 receptors require 
adenosine in the micromolar range (Murray & Churchill, 1984). 
Adenosine receptors are non-selectively blocked by the alkylxanthines, 
caffeine and theophylline (Evoniuk et al., 1987; Wonnald et al., 1989), in fact 
the physiological effects of caffeine are induced by its inhibitory effect on 
these receptors. In the 1980s, studies characterised the selectivity of adenosine 
receptor agonists and antagonists by their effect on 'A2-mediated hypotension' 
and 'At-mediated bradycardia', with little or no consideration for regional 
effects - a view now known to be too simplistic (for example, Evoniuk et al., 
1987; Fredholm et al., 1987).Whilst there are multiple phannacological tools 
available for the study of adenosine receptors in vivo and in vitro, their use is 
often confounded due to poor selectivity, making interpretation of such studies 
difficult. For example, the non-xanthine adenosine receptor antagonist CGS-
15943A, whilst non-selective, has higher affinity for A2 than A1-receptors 
(Ghai et al., 1987). Using the A2 agonist CV -1808, and the AI-selective 
agonists CADO and CPA, Webb et al. (1990) showed A2 activation leads to 
regional vasodilatation and increased renin release, whilst At-activation leads 
to bradycardia, mesenteric vasoconstriction and inhibition of renin secretion 
(Webb et al., 1990). Each adenosine receptor subtype will now be discussed in 
more detail. 
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1.3.2.1 Adenosine Al receptors 
Adenosine Al receptors are widely expressed in the brain, fat, and testis, and 
less prominently in the heart, kidneys, liver and bladder (Dixon et al., 1996). 
Al receptors are linked to the inhibitory G-protein subunit Gi, leading to 
inhibition of adenylate cyclase and reduced intracellular cAMP formation. 
This has an inhibitory effect on the heart, leading to cardiac depression and 
bradycardia. Owing to the negative chronotropic effect of adenosine, AI-
selective antagonists have been developed for the treatment of cardiac disease 
and the resolution of supraventricular tachycardias (DiMarco et al., 1983; 
Cotter et al., 2008). The results of a Phase I trial piloting the AI-selective 
antagonist, rolofylline, have recently been published (Cotter et al., 2008) and 
suggest this drug may maintain renal function and enhance diuresis in patients 
with acute heart failure, due to inhibition of AI-mediated afferent arteriolar 
constriction. The results of this study were promising and the drug is now in 
Phase 11 clinical trials (Cotter et al., 2008). Although the effects of Al 
activation are most prominent in the heart, activation of vascular Al receptors 
also leads to renal and mesenteric vasoconstriction (Tagawa & Vandor, 1970; 
Webb et al., 1990) In mice lacking the AI receptor the vasodilator effect of 
adenosine was augmented, suggesting activation of this receptor in vivo 
opposes A2-mediated vasodilatation to some extent (Hansen et al., 2005). 
There is some evidence to suggest that Al activation can cause vasodilatation 
in some regions of skeletal muscle (Merkel et al., 1992; Marshall et al., 1993; 
see later; Danialou et al., 1997). This adenosine receptor subtype can be 
activated by the selective agonists R-PIA and CCPA, and is antagonised by 
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the compounds DPCPX, WRCOS7 and N0861 (for review see Feoktistov & 
Biaggioni, 1997). 
1.3.2.2 Adenosine A2 receptors 
Adenosine A2 receptors were divided into A2a and A2b receptors due to their 
high and low affinity for adenosine in the rat brain (fC'r review see Feoktistov 
& Biaggioni, 1997). A2a receptors are located on vascular smooth muscle, 
endothelial cells, immune cells, in all brain regions and are widespread in the 
periphery (Dixon et al., 1996). This subtype is linked to the stimulatory G 
protein, Gs, leading to activation of adenylate cyclase and cAMP formation 
when stimulated (for review see Mubagwa et ai, 1996; Nemeth et ai, 2006; 
Linden 2001). This subtype of receptors can be antagonised by ZM243185 
and SCH58261, while APEC and CGS21680 act as selective A2a agonists (for 
review see Linden, 2001). 
Activation of the A2a subtype induces vascular smooth muscle relaxation 
leading to vasodilatation of coronary arteries (Zhao et al., 2003), renal afferent 
arterioles (Tagawa & Vandor, 1970; Murray & Churchill, 1985; Tang et al., 
1999), and mesenteric arteries (Zhao et al., 2003). Systemic vasodilatation 
mediated by this subtype results in hypotension (Webb et al., 1990). 
Activation of A2a receptors on immune cells, also mediates the strong 
immunosuppressant effects of adenosine, and A2a receptor activation on mast 
cells and macrophages leads to inhibition of histamine and TNF-a release via 
an increase in cAMP (Cronstein et al., 1992; Ohta & Sitkovsky, 2001; Zhang 
et al., 2005; Nemeth et ai, 2006). 
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Although there are no selective A2b agonists, these receptors can be 
antagonised by enprofylline (for review see Conlon, 2001). AZb receptors are 
found ubiquitously in rats, and are expressed at various levels in all tissues 
studied, making it the most widespread adenosine receptor subtype in that 
species (Dixon et al., 1996). A2b receptors are expressed at the highest level in 
rat proximal co!on and are widespread in the brain. As well as having 
ubiquitous tissue distribution, this receptor subtype is also found on immune 
cells including fibroblasts and mast cells. While both subtypes of A2 receptors 
are linked to Gs, A2b receptors may also be coupled to Gq, with activation 
leading to Ca+ mobilisation and activation of mitogen-activated protein kinase 
(MAPK). Adenosine-mediated AZb activation has been implicated in mast cell 
activation and asthma, vasodilatation and regulation of cell growth (for review 
see Feoktistov & Biaggioni, 1997; Linden, 2001). 
1.3.2.3 Adenosine AJ receptors 
Adenosine A3 receptors can be antagonised by MRS 1 067 and MRS 1 097, 
whilst IB-MECA acts as a selective agonist of this subtype (Feoktistov & 
Biaggioni, 1997). The A3 receptor subtype is the least well characterised 
adenosine receptor. It is linked to Gi leading to inhibition of adenylate cyclase, 
and hence, vasoconstriction and mast cell degranulation in vivo. (Nieri et al., 
2001). The A3 receptor is expressed only at low levels in rats in the testis, 
heart and retina (Dixon et al., 1996; Fredholm et al., 2001). Interestingly, 
apart from in sheep and human, A3 receptors are not antagonised by 
methylxanthines, which may account for some of the discrepancies in 
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responses to adenosine antagonists In different speCIes (for reVIew see 
Feoktistov & Biaggioni, 1997). 
A review of data concerning the cardiovascular responses to adenosine is 
given below, with specific reference given to the receptor(s) activated where 
known. 
1.3.3 Adenosine and the cardiovascular system 
The effects of adenosine on the cardiovascular system are complex, and vary 
depending upon the receptor(s) activated, the concentration of adenosine and 
the vascular region. When given to experimental animals, adenosine causes a 
fall in blood pressure which involves both cardiac and vascular effects, 
mediated by A1- and Ar receptors, respectively (Drury & Szent-Gyorgyi, 
1929; Ohnishi et al., 1986; Webb et al., 1990; Tang et al., 1999; Nieri et al., 
2001). Adenosine causes dilation of rat and rabbit mesenteric arteries (Mian & 
Marshall, 1995), dilatation, preceded by a transient constriction of rat and 
mouse renal arteries (Tagawa & Vander, 1970; Tang et al., 1999; Hansen et 
al., 2005) and dilatation of coronary arteries (Drury & Szent-Gyorgyi, 1929). 
The study of Webb et al. showed that A2-receptor activation leads to regional 
vasodilatation and systemic hypotension with reflex tachycardia and increased 
renin secretion, whilst activation of AI-receptors causes profound bradycardia, 
depressed cardiac output and hypotension. Thus, while both AI- and A2-
receptor activation leads to marked falls in blood pressure, in the case of the 
former this was mediated by cardiac events, whilst in the latter hypotension 
was mediated by vascular events (Webb et al., 1990). The cardiac and 
vascular effects of adenosine will now be considered in turn. 
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1.3.3.1 Cardiac responses to adenosine 
It has long been known that adenosine has a profound effect on the heart, and 
is used clinically to this effect to resolve paroxysmal supraventricular 
tachycardia (DiMarco et al., 1983). Drury & Szent-Gyorgyi (1929) first 
described the cardiac slowing effect of adenine nuc1eotides in hearts taken 
from multiple species. A number of years later, it was shown that ATP, AMP 
and ADP rapidly reduced heart rate to a similar extent when perfused directly 
into the sinus node of isolated dog hearts. Moreover, this negative 
chronotropic effect was not affected by atropine, suggesting it was 
independent of parasympathetic activation. Since infusion of creatine 
phosphate had no effect on heart rate, it was concluded that adenosine was the 
agent responsible for the cardiac slowing effect of these nucleotides (James et 
al., 1965). Studies in conscious animals have been valuable in elucidating the 
involvement of the autonomic nervous system in the cardiovascular response 
to adenosine. For example, in whole animals, adenosine has been observed to 
cause tachycardia, which is either reduced (Lappe et al., 1991), abolished 
(Ohnishi et al., 1985), or reverted to a bradycardia (Hintz et al., 1985; Watt & 
Routledge, 1986; Belloni et al., 1989) in the presence of cholinergic and 
adrenergic blockade. This suggests that adenosine-mediated tachycardia in 
vivo is largely baroreflex-mediated, and masks an underlying bradycardia 
(Hintz et al., 1985; Ohnishi et al., 1985). Interestingly, this response was 
shown in healthy volunteers, in which infusion of adenosine led to a transient 
bradycardia, which reverted to a tachycardia once respiration rate increased 
and blood pressure decreased (Watt & Routledge, 1986). This bradycardic 
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effect of adenosine is a consequence of a transient impainnent of AV 
conduction (Hintz et al., 1985; Watt & Routledge, 1986; Belloni et al., 1989). 
Adenosine-mediated bradycardia is mediated by the A1-receptor subtype, 
since isolated hearts from A1-receptor knockout mice failed to respond to 
adenosine (Hansen et al., 2005; Tawfik et al., 2006). No difference was shown 
in the basal heart rate between Al-receptor knockout and wild type mice 
suggesting that endogenous adenosine acting on this receptor is not involved 
in the maintenance of resting heart rate (Tawfik et al., 2006). However, hearts 
from A)-receptor knockout mice exhibited a higher basal coronary blood flow 
suggestive of A)-receptor mediated vasoconstriction in this region in nonnal 
mice (Tawfik et al., 2006). 
1.3.3.2 Renal effects of adenosine 
Systemically, adenosine acts as a potent vasodilator (Ohnishi et al., 1985; 
Nieri et al., 2001), indeed, it is this function of the nucleoside that couples 
metabolism to blood flow. However, in the kidney, adenosine has been 
reported to cause both an increase and a decrease in blood flow, owing to the 
opposing effects of A2- and A)-receptor stimulation, respectively (Tagawa & 
Vander, 1970; Hansen, et al., 2005). Several studies have shown that 
adenosine causes a transient renal vasoconstriction which develops into a 
long-lasting renal vasodilatation (Tagawa & Vandor, 1970; Hansen et al., 
2005). 
A study of adenosine receptor abundance in rat kidney showed that the At and 
A2b subtypes are abundant in the preglomerular circulation, with A2b mRNA 
and protein being expressed throughout the whole kidney, whereas in that 
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study, A2a- and A3-receptor subtypes were barely detectable in the 
preglomerular circulation (Jackson et al., 2002). Along with other studies, this 
suggests that the renal vasodilator response to adenosine is mediated by the 
A2b-receptor (Tang et al., 1999; Jackson et al., 2002). 
The overall renal effect of adenosine administration in vivo has been shown to 
be vasodilatation, suggesting that A2-receptor activation predominates in this 
vascular bed, which may relate to high concentrations of exogenous adenosine 
and/or higher distribution of the A2 receptor subtype in the kidney (Murray & 
Churchill, 1985; Jackson et al., 2002). However, a study in conscious dogs 
showed that adenosine infusion led to renal vasoconstriction, and A2a-receptor 
agonists had no effect, suggesting AI-receptors predominate, at least in this 
model (Zhao et al., 2003). As in other systems, the effect of adenosine on 
renal blood flow is concentration-dependent, since AI-receptors have a higher 
affinity for adenosine than do A2a-receptors (Tang et al., 1999). At low 
concentrations, adenosine perfusion in isolated rat kidneys caused a transient 
DPCPX-sensitive vasoconstriction, whilst at higher concentrations adenosine 
caused vasodilatation which was sensitive to A2-receptor blockade. 
Adenosine-mediated renal vasoconstriction is potent but transient, and is 
mediated by activation of afferent arteriolar AI-receptors, an effect that can be 
mimicked and blocked by AI-receptor selective agonists and antagonists, 
respectively (Tang et al., 1999). The observation that adenosine-mediated 
vasoconstriction was absent in afferent arterioles isolated from AI-receptor 
knockout mice, indicates that this response involves activation of AI-receptor 
receptors in this region (Hansen et al., 2005). Interestingly, when perfused 
into isolated kidneys at a high dose, the AI-selective agonist, CHA, caused a 
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marked vasodilatation which was similar to that caused by high dose NECA 
(Murray & Churchill, 1985). 
Acting via A1- and A2- receptors, adenosine leads to inhibition and stimulation 
of renin release, respectively (Tagawa & Vandor, 1970; Murray & Churchill, 
1985; Weihprecht et al., 1990), and has been described as a 'physiological 
brake on renin release' (Jackson et al., 1991). Evidence suggests the inhibitory 
effect mediated via the A1-receptor subtype is a direct effect of adenosine 
acting on the juxtaglomerular apparatus (Weihprecht et al., 1990), whilst A2-
meditated renin stimulation is a result of increased sympathetic nerve activity, 
since this response is not seen in isolated preparations lacking neural input. 
The inhibitory effect on adenosine of renin secretion has been demonstrated in 
isolated rabbit juxtaglomerular cells (Weihprecht et al., 1990), and in rat renal 
cortical slices (Churchill & Churchill, 1985). As with renal blood flow, a 
biphasic dose-dependent renin response is observed following adenosine 
administration in vitro and in vivo, with low concentrations of adenosine 
leading to inhibition of renin secretion and high concentrations stimulating 
renin release, directly via A1- and indirectly via A2-receptors, respectively 
(Tagawa & Vandor, 1970; Churchill & Churchill, 1985). The opposing roles 
of these receptor subtypes in regulating renal function have been revealed in 
studies using receptor specific agonists and antagonists. For example, AI-
receptor activation by CRA led to a marked decrease in renin release from 
perfused rabbit kidneys, an effect which was reversed by AI-blockade by 
DPCPX (Weihprecht et al., 1990). 
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1.3.3.3 Effects of adenosine in skeletal muscle 
During extended periods of hypoxia, adenosine acts on endothelial, cardiac 
and central A1-receptors to bring about femoral muscle vasodilatation, 
decrease in heart rate and decrease in tidal volume and respiratory rate, 
respectively (see Walsh & Marshall, 2006). In a series of studies, Janice 
Marshall's group showed that the hind limb vasodilatation induced during 
systemic hypoxia in anaesthetised rats, was mediated by adenosine receptor 
activation and subsequent opening of KATP channels (Marshall et al., 1993). 
Using a selection of Al- and A2-receptor agonists and antagonists, they later 
showed that whilst both receptor subtypes were present in rat hindlimb and 
contribute equally to adenosine-induced muscle vasodilatation in nonnoxia, 
only AI-receptors were activated by adenosine in hypoxia .. Furthennore, 
DPCPX reversed the increase in femoral vascular conductance evoked by both 
hypoxia and exogenous adenosine suggesting the involvement of endogenous 
adenosine in this response (Bryan & Marshall, 1999). Adenosine-stimulated 
endothelial NO release has been shown from rat aorta in nonnoxia (Ray et al., 
2002) and from rat hindlimb in an AI-dependent manner in both chronic and 
acute systemic hypoxia (Ray & Marshall, 2005; Walsh & Marshall, 2006). 
Interestingly, studying the effects of exercise on muscle vasodilatation, the 
same group showed there was no role for NO in adenosine-induced 
hyperaemia in exercise. Furthennore, during exercise, the hindlimb 
vasodilator response to adenosine was shown to involve direct activation of 
A2a-receptors on vascular smooth muscle. It was therefore concluded that the 
mechanisms through which adenosine leads to muscle vasodilatation in 
exercise and during hypoxia are different (Ray & Marshall, 2009). In human 
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skeletal muscle, AI-, A2a- and A2b-receptors are located on both vascular 
smooth muscle cells and endothelial cells, and both A2-receptor subtypes were 
also found on the plasma membrane and in the cytosol of human skeletal 
muscle cells (Lynge & Hellsten, 2000). Evidence of AI-mediated lower body 
vasodilatation has also been shown in conscious dogs (Zhao et al., 2003). 
Given that adenosine is critical in the regulation of local blood flows in 
response to fluctuations in metabolic demand, the observation that AI-
receptors mediate skeletal muscle vasodilatation is not surprising. Since AI-
receptors have a high affinity for adenosine, AI-receptor mediated 
vasodilatation (as opposed to vasoconstriction for which this subtype is best 
characterised) would increase blood flow to skeletal muscle cells even when 
small amounts of adenosine have been liberated from A TP. 
1.3.4 Adenosine in sepsis 
Studies using the non-specific adenosine-receptor antagonist, 8-PT, have 
shown that endogenous adenosine is involved in the maintenance of perfusion 
in the hepatosplanchnic organs (stomach, pancreas, small intestine, colon, and 
caecum) and skeletal muscle 24 h after the induction of septic peritonitis in 
rats (Motew et al., 1998; Adanin et al., 2002). Thus, an increase in vascular 
resistance was observed following 8-PT treatment in those regions where 
endogenous adenosine was exerting a tonic vasodilator effect. Furthermore, 
this was shown to occur in an NO-dependent manner in both regions, and via 
an NO-independent manner in skeletal muscle (Sam et al., 2000). Based on 
the work of Marshall et al. (see above) it is possible this NO-independent 
mechanism in skeletal muscle is adenosine-mediated opening of KATP 
65 
channels secondary to AI-receptor activation (Marshall et al., 1993; Bryan & 
Marshall, 1999). 
Results show that plasma levels of adenosine were higher in patients admitted 
to an ICU with sepsis, severe sepsis and septic shock compared to healthy 
volunteers and those with hypovolaemic shock (Martin et al., 2000). 
Furthermore, non-survivors always had significantly higher adenosine plasma 
levels than survivors. Interestingly, there were no significant differences in 
adenosine plasma levels between patients suffering from Gram-negative and 
Gram-positive sepsis, suggesting that increased adenosine release may be a 
common feature of clinical sepsis. Thus, the use of adenosine as a prognostic 
index for outcome in septic patients has been suggested, with higher plasma 
levels linked to a better prognosis (Martin et al., 2000). 
Transgenic studies have identified a protective role for adenosine in murine 
endotoxaemia and peritonitis. Mice lacking the A2a-receptor had increased 
systemic inflammation, whilst A1- and A3-knockout mice had significantly 
higher mortality rates compared to wild type mice, associated with increased 
inflammation and enhanced hepatic and renal injury (Sullivan et al., 2004; 
Gallos et al., 2005; Lee et al., 2006). Moreover, stimulation of A2a-receptors 
was associated with decreased live bacteria in the blood, reduced 
inflammation and reduced neutrophil extravasation and adhesion and reduced 
coagulopathy in CLP and LPS-treated mice (Sullivan et al., 2004). 
Adenosine decreases TNF-a release from LPS-activated monocytes and 
human macrophages (Zhang et al., 2005; Ryzhov et al., 2008). Furthermore, 
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mice lacking the A2a-receptor show increased susceptibility to even a mild 
inflammatory response which does not provoke a response in wild type 
animals (Ohta & Sitkovsky, 2001). This study showed that adenosine acting 
via the A2a-receptor subtype plays a central role in limiting inflammation 
during sepsis by down-regulating pro-inflammatory cytokines and preventing 
tissue damage (Ohta & Sitkovsky, 2001). However, another study showed 
increased survival in CLP-induced sepsis following inactivation of A2a-
receptors (Nemeth et al., 2006). Mice lacking the A2a-receptor were shown to 
have improved antigen presentation, decreased apoptosis of lymphocytes in 
the spleen and decreased levels of IL-IO and IL-6, at 16 h and 48 h from the 
onset of sepsis (Nemeth et al., 2006). It is possible that A2a-receptor mediated 
immunosuppressant actions are beneficial during the exaggerated 
inflammatory stage of early sepsis, but detrimental during the 
immunosuppressive stage of late sepsis (see section 1.1). Furthermore, since 
the study of Sullivan et al. (2004), induced sepsis by administration of LPS or 
live E.coli, and that of Nemeth et al. (2006) by CLP, it is possible that the 
response to A2a-reception activation differs according to the cytokine profile 
associated with each model. 
1.3.4.1 Therapeutic potential of adenosine in sepsis 
Since adenosine is able to limit the pro-inflammatory response in early sepsis, 
it has been suggested (Adanin et al., 2002; Cohen et al., 2002; Law et al., 
2003) that blocking the breakdown of adenosine may be a novel therapy in the 
ICU. Adenosine has a half life of seconds, due to its rapid catabolism by 
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adenosine deaminase (ADA) into ammonia and inosine (for review see Martin 
et al., 2000). Adenosine deamination can be blocked by 2-deoxycofonnycin 
(Pentostatin (PNT» which binds ADA and prevents adenosine catabolism. 
Pentostatin has successfully been used in the treatment of hairy cell leukaemia 
and myocardial ischemia, and its therapeutic potential in sepsis has attracted 
some attention (Adanin et al., 2002; Cohen et al., 2002; Law et al., 2003). 
Evidence suggests that adenosine is as an important modulator of the early 
immune response to sepsis, since in vitro studies have shown that adenosine 
inhibits TNF-a production. Adanin et al. (2002) assayed TNF-a levels in 
serum and tissue in rats treated with LPS or faecal slurry, and with either PNT 
or the adenosine receptor antagonist 8-SPT. They showed that PNT 
significantly attenuated the LPS-induced increase in TNF-a in a dose-
dependent manner, while 8-SPT significantly increased TNF-a levels 24 h 
after peritoneal sepsis induction (Adanin et al., 2002). Furthennore, 
administration of PNT significantly attenuated microvascular dysfunction and 
increased survival in mice 48 h after induction of sepsis via CLP (Cohen et aI, 
2002), consistent with the ability of adenosine to limit microvascular 
dysfunction during sepsis by inhibiting neutrophil-mediated injury to 
endothelial cells. 
Clinically, this suggests that prevention of adenosine breakdown via PNT 
could be used as a prophylactic treatment in high-risk scenarios. including in 
pre-surgical patients (Adanin et al., 2002). A beneficial effect of PNT as a 
pre-treatment to LPS exposure was also shown by Law et al (2003) who found 
the drug to increase survival in a rat faecal slurry model of peritoneal sepsis 
(Law et al., 2003). Due to the prolonged suppression of pro-inflammatory 
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cytokines by adenosine, a possible side effect of chronic ADA inhibition is 
immunosuppression. Plasma elimination of PNT in humans was reported to be 
5 to 6 h, and white blood cell counts returned to pre-treatment levels after 24 h 
in septic rats. Thus, immunosuppression is only short-term following 
administration ofPNT. 
Overall, evidence suggests that adenosine plays an important role in limiting 
cellular injury during sepsis. However, whilst adenosine acting via A2a 
receptors has a protective role during early sepsis, it also has detrimental 
effects in the later stages of severe sepsis and septic shock when systemic 
hypotension is marked and the immune system is suppressed. 
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1.4 General aim 
The studies presented in this thesis were designed to delineate possible 
mechanisms involved in IMD and AM-mediated vascular responses, and to 
assess factors (AM, IMD, adenosine) contributing to regional changes in 
vascular tone across time, in normal and LPS-treated rats. 
Against this background, the specific aims of the work contained in this thesis 
were: 
1. To compare the regional haemodynamic responses to AM and IMD in 
normal animals. 
2. To investigate possible mechanisms involved in mediating the 
cardiovascular effects of AM and IMD in normal animals. 
3. To characterise regional haemodynamic changes across time in a rat model 
of endotoxaemia based on (a) a low-dose LPS bolus (lmg kgoI) and (b) a 
continuous low-dose LPS infusion (15/Lg kgoI hoI ), and to assess whether 
the vascular responses to AM and IMD are affected at selected time points 
in each model. 
4. To investigate the regional haemodynamic responses to adenosine across 
time in normal and LPS-treated rats, and to establish the contribution of 
adenosine receptors to any changes in responsiveness during 
endotoxaemia. 
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5. To investigate any synergism between adenosine, AM and IMD in normal, 
conscious rats. 
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Chapter 2 
General Methods 
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2.1 Introduction 
The experiments described in this thesis were carried out on male Sprague-
Dawley rats chronically implanted with miniature, pulsed Doppler flow probes 
to measure changes in regional vascular conductances. Specifically, changes in 
renal, mesenteric and hindquarters Doppler shift were measured by way of 
flow probes placed around the left renal artery, superior mesenteric artery and 
distal aorta, respectively. Between 10 and 14 days later, the same animals were 
implanted with intravascular catheters to allow administration of substances 
and the continuous recording of blood pressure and heart rate, and regional 
vascular conductances were derived from Doppler shift signals from renal, 
mesenteric and hindquarters probes. This system has been refined over several 
years, and allows integrated regional haemodynamics to be measured in 
conscious animals for up to 4 days. 
2.2 Pulsed Doppler flowmetry 
2.2.1 The Doppler method 
The use of pulsed Doppler flowmetry to measure regional blood flow in small 
animals was developed by Hartley & Cole (1974), and later refined for use in 
rats by Haywood et al. (1981). Other methods for measuring blood flow, such 
as continuous wave Doppler flowmetry, or electromagnetic flowmetry, require 
bulky probes making them impractical for use in small animals. Pulsed 
Doppler flow probes in contrast, are much smaller, allowing several probes to 
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be implanted in a single animal. A complete probe compnses a single 
piezoelectric crystal with a diameter of Imm (DBF-120A-XS; Crystal Biotech, 
Holliston, MA) which acts as both a transmitter and a receiver. The crystal is 
attached to wire leads and is mounted in a thin, lightweight cuff, which can be 
sutured around blood vessels measuring 1-5mm in diameter. 
When the probe is connected to the flowmeter, the crystal emits a short burst 
of ultrasonic sound at a frequency of 20MHz; this is received back as an 
'echo' signal by the crystal when the signal hits moving targets in its path (in 
this case, red blood cells). Since energy scattered at 20MHz is higher than that 
scattered at lower frequencies, smaller crystals can be used, again optimising 
this system for use in small animals (Hartley & Cole, 1974). The difference in 
frequency between the sound transmitted from the crystal and that received 
back is known as the 'Doppler shift' and can be expressed mathematically by 
the Doppler equation, which is shown below. 
2.2.2 Tile Doppler equation 
Fluid velocity 1 / Velocity of sound in fluid 
! = 2/ V le cos 8 .- angle ~ e t w e e n n flow and o acoustIc axes (45°) 
Doppler difference frequency 1 
(Doppler Shift) frequency of transmitted 
signal (20MHz) 
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The Doppler equation indicates that blood velocity is directly proportional to 
blood flow providing that the diameter of the vessel beneath the probe remains 
constant. This is ensured by the growth of a fibrous capsule around the probe 
cuff during chronic implantation, keeping the crystal anchored to the vessel at 
a constant angle of 45°. Since 10. c and 8 are constant for any individual probe 
in any individual animal, then, J11 is proportional to V. Therefore, changes in 
Doppler shift are a measure of changes in blood flow velocity. Since the vessel 
diameter beneath the probe remains constant, changes in blood flow velocity 
can be used as an index of changes in blood flow distal to the probe. Changes 
in the Doppler shift signal from the probe are related to changes in flow in the 
total vascular bed, and hence flow, downstream of the probe. This system also 
has the benefit of being directionally sensitive allowing the direction of blood 
flow to be determined. 
By manually adjusting the range gate, the time delay between the transmitted 
signal and the reflected signal is adjusted. Adjusting the signal to an optimum 
range allows the velocity of blood cells in the centre of the vessel, where it is 
at its highest, to be sampled. 
The Nyquist or 'sampling' theorem states that correct reproduction of 
analogue-to-digital signals requires that the sampling frequency (pulse 
repetition frequency (PRF) or number of times a crystal emits and receives 
each second) must be greater than half the maximum frequency response. If 
the maximum frequency response is more than half the sampling frequency 
then the phenomenon of 'aliasing' occurs whereby the same sample values 
overlap and the high frequency components of the signal are lost (or appear as 
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an 'alias' signal). Hence, commercially available pulsed Doppler systems 
which use a PRF of 62.5 kHz per second are of limited value in systems 
measuring high velocities. Gardiner et al. (1990) showed that, in conscious 
rats implanted with aortic pulsed Doppler flow probes and treated with 
nitroprusside or methoxamine, a standard PRF of 62.5 kHz was insufficient to 
accurately measure changes in Doppler shift due to aliasing of the Doppler 
signal. In this system, only spectral components of 32.5 kHz or less (half the 
PRF) could be detected. By modifying this system and increasing the PRF to 
125 KHz, the high velocity component of the signal was included (Le., PRF/2 
is 62.5 kHz; therefore frequencies up to this value could be measured). 
Therefore the experiments outlined here used a high-velocity module with a 
PRF of125 kHz (Gardiner et al., 1990). 
2.2.3 Construction of pulsed Doppler flow probes 
Piezoelectric crystals (diameter of 1mm) with attached wires were purchased 
from Crystal Biotech Inc and complete flow probes were constructed in house 
by Julie March in a 3 stage process modified from that described by Haywood 
et al. (1981). 
Stage 1: Mounting the crystal 
Construction of flow probes begins by mounting the piezoelectric crystal into 
a piece of silicon tubing measuring 3-4mm in length. One end of the tubing is 
cut at an angle of 45° and the crystal is placed into the lumen using sharp 
forceps. This is the angle which the crystal will be at relative to the vessel, and 
76 
is the optimum angle for detecting changes in blood velocity. Melted dental 
wax is placed on the angled end of the tubing which holds the crystal in place 
until it is permanently fixed. The other end of the tubing is covered in silastic 
adhesive (Raumedic) onto which a small piece of expanded polystyrene is 
placed to act as an acoustic baffle. This prevents the crystal receiving 
interference from blood flow in adjacent regions. This subunit is then left 
overnight to allow the adhesive to set. 
Stage 2: Silastic cuffformation 
The subunit is mounted onto a needle such that the crystal is sitting at a 45° 
angle. The needle mimics the blood vessel which will eventually sit in that 
position and the use of different sized needles enable probes to be made for 
different sized vessels. The dental wax placed on the subunit in stage 1 is 
melted using a soldering iron and allowed to set on the needle, holding the unit 
in place. The silastic (Raumedic) cuff is then formed by building up silastic 
adhesive around the subunit and needle. This is again left overnight to set in 
place. 
Stage 3: Probe preparation 
The completed probe is removed from the needle by using a scalpel to cut the 
silastic cuff along the underside of the needle. The reSUlting flaps will 
eventually provide the opening through which the blood vessel is positioned 
with the crystal lying underneath. The dental wax is then removed and sutures 
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(6/0 ophthalmic silk, Ethicon, Edinburgh, UK) are sewn into each flap to 
provide ties which can be used to secure the probe onto the vessel. 
2.2.3 
Figure 2.1: A complete Doppler flow 
probe, shown against a pen nib for size 
comparison 
Measurement of blood pressure 
In order for regional vascular conductances to be determined by the use of 
Doppler flow probes, Doppler shift must be recorded simultaneously with 
blood pressure. Continuous recording of blood pressure and heart rate in these 
experiments was achieved by the implantation of intra-arterial catheters. 
Conductance could then be calculated by dividing flow by pressure: 
Conductance = flow/pressure 
Blood pressure was measured by connecting a fluid-filled arterial catheter to a 
pressure transducer (Gould, type 4-442) and transducer amplifier (Gould, 
model 13-4615-50), which interfaced with a custom-designed Haemodynamic 
Data Acquisition System (HDAS; built by the Bioinstrumentation 
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Laboratories at the University ofMaastricht, Netherlands). Pressure changes in 
the catheter system are detected as changes in resistance in strain gauges 
within the pressure transducer, and resistance changes are converted to voltage 
changes by a Wheatstone bridge circuit. The system can be calibrated using a 
mercury manometer such that changes in voltage are converted to changes in 
mmHg by HDAS, and there is a linear relationship between changes in 
pressure and voltage. 
In order to measure pressure effectively, and to achieve optimal damping, the 
measuring system must be capable of following frequencies as high as the ~ ~
5th harmonic of the basic frequency of the signal, which in this case is the heart 
rate and is approximately 40Hz. This system is optimised to reduce damping 
by having the main part of the catheter (minus the 6 inches inserted into the 
caudal artery; see below) consist of rigid tubing (Portex Nylon tubing, with an 
internal diameter of O.58mm), and a custom-designed low volume transducer 
dome containing de-gassed water to eliminate air bubbles and minimal air 
space. 
2.4 Surgical procedures 
2.4.1 Animals 
All experiments were carried out on male Sprague-Dawley rats supplied by 
Charles River UK weighing 400-500g at the time of experimentation. 
Unrestrained animals were housed in groups of up to 4 for at least 1 week 
prior to surgery, and individually afterwards, with free access to food and 
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water throughout. Animals were kept in temperature-controlled holding areas, 
with a 12h light/dark cycle (6am to 6pm), in the Biomedical Services Unit at 
the University of Nottingham. Procedures were carried out with the approval 
of the University of Nottingham Ethical Review Committee and were 
performed in accordance with Home Office Licensing regulations. 
All surgery was carried out under general anaesthesia, provided by fentanyl 
citrate (Sublimaze, supplied by J ansen-Cilac Ltd) and medetomidine 
(Domitor, supplied from Pfizer); 0.3 mg kg-1 of each i.p. Anaesthesia was 
reversed by atipamezole hydrochloride (l mg kg-1 s.c.) (Anti sedan, supplied 
by pfizer) and buprenorphine (0.3 mg kg-1 s.c.) (Vetergesic, supplied by 
Alstoe Animal Health); buprenorphine also provided analgesia. Following 
surgery for probe implantation, a single Lm. injection of ampicillin trihydrate 
(150 mg s.c.) (Amoxycare LA) was given. Surgical plane of anaesthesia was 
assessed by the absence of an interdigit toe pinch, and top-up was provided as 
required. 
1.4.1 Implantation of Doppler flow probes 
At the first surgical stage, rats were chronically implanted with miniature, 
pulsed Doppler flow probes to measure changes in renal, mesenteric and 
hindquarters blood flows. Once rats reached an adequate level of anaesthesia, 
they were weighed and shaved to expose the midline abdomen, the left flank 
above the hindlimb, and at the level of the shoulder blades below the neck. 
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Rats were wrapped in cling film (which acted as a surgical drape), and placed 
in the dorsal recumbent position on a heated table to help prevent heat loss. 
A ventral midline abdominal incision of 6-8cm was made along the line of the 
linea alba extending down the animal from the xiphoid cartilage. Clamps were 
inserted and secured using Transpore tape (Blenderm, 3M, USA) before the 
intestines were wrapped in a sterile saline-soaked paper towel and retracted to 
expose the abdominal cavity. Target vessels were identified under a 
microscope, isolated and freed of any connective tissue using two cotton wool 
buds and blunt dissection. For each vessel, an appropriately sized probe was 
chosen, coupling gel was placed on the face of the crystal and the target vessel 
lifted to allow the probe to be placed around. Signals were confirmed for each 
probe by adjusting the range gate on a Doppler flowmeter before the probe 
was sutured into place around the vessel. This procedure was followed for the 
left renal artery, superior mesenteric artery and the distal abdominal aorta, 
below the level of the ileocaecal artery. Wires were tunnelled through the body 
wall, exiting on the left side; excess wires were placed in an s.c. pouch, and 
the ends of the wires were tunnelled s.C. to exit at a single point at the nape of 
the neck where they were secured with tape and suture. The body wall was 
closed and the abdominal skin sutured and closed with Michel clips. The 
position of flow probes is shown on Figure 2.2. 
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Figure 2.2: Location of 
Doppler flow probes. 
Probes were sutured around the 
left renal artery, superior 
mesenteric artery and the distal 
aorta in rats under anaesthesia. 
RA=renal artery; DA=distal 
aorta; SM=superior mesenteric. 
SM 
DAt . 
(j/ 
2.4.3 Implantation of intravascular catheters 
Venous, and i.p. catheters consisted of 150cm Portex polythene tubing, 
internal diameter of 0.28mm, dead space O.lml; venous catheters used for 
overnight infusions and arterial catheters comprised 2cm or 6cm Port ex 
polythene tubing, respectively (as above) attached (heat sealed) to 85cm 
Portex Nylon tubing, with an internal diameter of 0.58mm. Arterial catheter 
patency was maintained by heparinised saline 30 units mr! saline; venous 
catheter patency was maintained by 15 units mr) saline (CP Pharmaceuticals 
Ltd). 
Surgery for catheter implantation occurred after a recovery period of 10-14 
days and after a satisfactory inspection by the Named Veterinary Surgeon. 
Rats were anaesthetised as above (see section 2.4.1), weighed, and an area of 
skin was shaved over the right jugular vein between the larynx and the 
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sternum. The probe wires were freed from the nape of the neck, stripped of 
insulation and soldered into a micro-connector (Microtech Inc., Boothwyn, 
PA, USA, part no GF-6), which was secured using a small piece of tape. 
Animals were then wrapped in cling film which acted as a surgical drape and 
also helped to maintain body temperature. 
2.4.3.1 Intravenous catheters 
An incision of approximately 1 cm was made over the right jugular vein, which 
could be detected as a slight pulsation beneath the skin. The vein was isolated 
and cleared of connective tissue by blunt dissection. Catheters (2 or 3) were 
then tunnelled s.c. from the nape of the neck using the opening made during 
probe implantation, to the new incision over the vein. A small pair of forceps 
was used to lift the vessel clear of surrounding tissue and lignocaine was 
dripped onto the vein to prevent it going into spasm. Sutures were then used to 
tie off the rostral end of the jugular vein, a small cut was made in the upper 
surface of the vessel and the catheters were introduced with the aid of a wire 
introducer and advanced for a length of 2cm. Once all catheters were in, they 
were tied in place with 4/0 silk thread, and the excess lengths were pulled 
through the back of the neck and the incision was closed with sutures. 
2.4.3.2 Intra-arterial catheters: 
With the rat in the dorsal recumbent position, an incision of 1-2cm was made 
at the base of the tail on the ventral side. The caudal (tail) artery was isolated 
and cleared of connective tissue using blunt dissection. A small pair of forceps 
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was placed underneath the vessel, and lignocaine was dripped onto the artery 
to prevent it from going into spasm. The caudal end of the vessel was tied off 
using silk sutures and a small incision was made in the upper surface of the 
vessel. Using a wire introducer the catheter tip was inserted into the vessel 
and, with the aid of forceps, was advanced 6cm so the tip lay in the distal aorta 
(caudal to the flow probe). The catheter was then tied in place and tunnelled to 
exit the tail on the dorsal side and the ventral tail incision was closed using 
interrupted sutures. The catheter was then tunnelled s.c. with the aid of a blunt 
trochar to exit at the incision at the back of the neck (see above). 
2.4.3.3 Intraperitoneal catheters 
Some experiments required substances to be given via an Lp. catheter. In these 
cases an additional area of skin on the right hand flank above the hind limb 
was shaved whilst the animal was prepared for catheter implantation. The rat 
was placed on its left side and an incision of approximately lcm was made 
using a scalpel blade. Connective tissue was then cleared using blunt 
dissection until the abdominal wall was accessible. The catheter was tunnelled 
from the incision at the back of the neck to the incision on the right flank. 
Whilst firmly holding the abdominal wall with forceps, a small incision was 
made into which the catheter could be advanced into the peritoneal cavity with 
the aid of a rod. Purse-string sutures were used to secure the catheter in place, 
and the skin on the flank was closed. 
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2.5 Experimental set-up 
Following catheter implantation, animals were fitted with a custom-designed 
harness which was placed around their neck and secured around the body 
below the forelimbs. The micro-connector containing the probe wires was 
screwed into place on the top of the harness, and a custom-built probe-
connector was attached. The catheters were tunnelled through a flexible 
spring, which was secured at one end to the top of the harness on the dorsal 
side of the rat, and at the other to a counter-balanced swivel system once the 
animal was placed into a cage; this allowed free movement within the cage 
(Figure 2.3). 
The arterial catheter was attached to a single channel swivel which allowed a 
continuous infusion of heparinised saline (15 units mrt; 0.4 ml hot) to be given 
before and in between experimental periods to maintain catheter patency. In 
experiments where animals were to receive a continuous infusion of LPS, a 
double-channel swivel system was used which enabled 2 substances to be 
given simultaneously. These were made in house by Julie March based on the 
method described by Brown et al. (1976) for single channel swivels, and those 
described by Blair et al. (1980) for double channel swivels. These allow fluids 
to be infused without restraining the animals. Experiments began at least 24 h 
after catheter implantation, in unrestrained, conscious animals. 
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(a) (b) 
Figure 2.3: Custom designed harness (a) and double channel swivel (b). 
Together these allow continuous cardiovascular measurements to be made in 
freely moving, conscious rats. 
On experimental days, the arterial catheter was disconnected from the swivel 
and attached to the transducer dome to allow blood pressure and heart rate to 
be measured. The probe connector was attached to leads on the Doppler 
flowmeter to allow regional haemodynamics to be measured. The signals from 
the probes interfaced with HDAS via the Doppler flowmeter (Crystal Biotech 
VF-I mainframe fitted with high velocity (HVPD-20) modules). The signals 
were sampled by HDAS every 2ms, averaged every cardiac cycle and stored to 
disc at 5s intervals for later analysis, using custom-designed software 
(Datview; University of Limburg, Maastricht, Netherlands) allowing analysis 
of cardiovascular responses over selected intervals. The range gate was 
adjusted for each individual probe (see section 2.2.2) to ensure optimal signals 
were received by each crystal. Substances were then given via the i. v. and/or 
i.p. catheter(s) and cardiovascular responses recorded. 
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2.6 Statistical analysis 
Since the data could not all be considered to be normally distributed, non-
parametric statistical tests were used. Within-group analysis of data was 
performed using Friedman's test (non-parametric version of ANOV A), with 
P<O.05 taken as significant. Between-groups analysis was performed using the 
Wilcoxon test for comparison of paired sets of data, the Mann-Whitney U test 
for comparison of unpaired datasets, and the Kruskall-Wallis test for 
comparisons between mUltiple unpaired datasets. 
2.7 Drugs 
Details of drugs and peptides used in these experiments are given in Table 2.1. 
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Abbreviation Full name Purchased from Preparation/administration Cbapter(s) 
brand name 
AM Adrenomedullin (rat) Bachem (St Helens, UK) • dissolved in distilled water to provide 3,4,5,7 
stock; diluted further with saline 
• given as O.lml i.v. bolus 
Ado Adenosine Sigma (Dorset, UK) • dissolved in distilled water 6,7 
• given as an i.v. infusion at a rate of 
O.15ml min-1 for 3 min 
AIl Angiotensin 11 Bachem (St Helens, UK) • dissolved in sterile isotonic saline 4 
• given as a continuous infusion O.4ml h-1 
AM22-52 Adrenomedullin 22-52 Peptide Institute Inc. • dissolved in sterile isotonic saline, 4 
(Scientific Marketing infused over 6 min at O.4ml h-1 
Associates, Bamet, UK)/ 
Bachem (St Helens, UK} 
Amoxycare Amoxicillin trihydrate Animalcare Ltd (York, • dissolved in sterile isotonic saline 3-7 
LA UK) 
Antisedan Atipamezole hydrochloride Pfizer (Sandwich, Kent, • dissolved in sterile isotonic saline 3-7 
U.K.) 
AVP Arginine vasopressin Bachem (St Helens, OK) • dissolved in sterile isotonic saline 4 
• given as a continuous infusion at O.4ml 
h-1 
CCPA 2-Chloro-Nb -cyclopentyladenosine Sigma (Dorset, OK) • dissolved in a vehicle containing 5% 6 
propylene glycol, 2% Tween-80 in 
saline 
• given as an i.v. infusion at a rate of 
O.15ml min-1 
DPCPX 8-Cyclopentyl-l,3-dipropylxanthine Tocris Cookson • dissolved in a vehicle containing 5% 6 
(A vonmouth) propylene glycol, 2% Tween-80 in 
saline 
• given as O.lml i.v. bolus 
IMD(l-53) Intermedin Bachem (St Helens, UK) • dissolved in distilled water to 3,4,5,7 
provide stock; diluted further with 
saline 
• given as O.lml i.v. bolus 
L-NAME NG-nitro-L-arginine methyl ester Sigma (Dorset, UK) • dissolved in sterile isotonic saline 4 
• given as a continuous infusion at 
O.4ml h-1 
Losartan Losartan potassium Sequoia Research • dissolved in sterile isotonic saline 4,6 
Products (Oxford, UK) • given as O.lml i.v. bolus 
LPS Lipopolysaccharide (E coli serotype Sigma (Dorset, UK) • dissolved in sterile isotonic saline 5,6 
0127 B8) • administered as described in text 
Sublimaze Fentanyl citrate Janssen-Cilag (High • dissolved in sterile isotonic saline 3-7 
W ~ c o m b e , , U.K) 
-
U37883A Biomol (Plymouth • dissolved in sterile isotonic saline 4 
Meeting, P A, USA) • infused at a rate of 2ml h-1 for 30 
mm 
Vetergesic Buprenorphine Alstoe Animal Health • dissolved in sterile isotonic saline 3-7 (York, UK) 
Table 2.1 Drugs used throughout the course of these experiments. 
Chapter 3 
Results (I) 
Regional haemodynamic effects of 
adrenomedullin and intermedin 
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Summary 
Regional haemodynamic responses to AM in conSCIOUS rats have been 
described but, to date, no direct comparison has been made between AM and 
IMD. The work in this Chapter aimed to assess the regional haemodynamic 
effects of IMD, and compare them to those of AM, in conscious rats. 
Responses to IMD (lnmol kg- l i.v.) and AM (1 and 3nmol kg- l i.v.) were 
assessed and compared in Sprague-Dawley rats, implanted with miniature 
pulsed Doppler flow probes to measure renal, mesenteric and hindquarters 
blood flows. 
Intermedin, like AM, caused hypotension, tachycardia, and widespread 
vasodilatation. Intermedin-induced hypotension and mesenteric vasodilatation 
were significantly more marked than those of an equimolar dose of AM. The 
renal vasodilator response to IMD (1 nmol kg-I) was intermediate between 
(and not different from) those of 1 and 3 nmol kg- l AM and the hindquarters 
vasodilator response to IMD was not different from either dose of AM. 
The work in this Chapter shows that, in normal animals, IMD is a strong 
peripheral vasodilator, and has actions in the cardiovascular system similar to 
those of the related peptide, AM. 
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3.1 Introduction 
Adrenomedullin (AM) is a 52 ammo acid peptide isolated from human 
phaeocytochroma and is involved in diverse physiological functions including 
cardiovascular and renal homeostasis (Kitamura et al., 1993; Sakata et al., 
1993; Charles et al., 1997; Ishimitsu et al., 2006), blood and lymphatic vessel 
development (Fritz-Six et al., 2008; Ichikawa-Shindo et al., 2008), 
maintenance of vascular integrity (Shindo et al., 200 I; Kato et al., 2005) and 
protection against oxidative stress (Ishimitsu et al., 2006). In vitro, AM causes 
relaxation of isolated vascular beds (Nuki et al., 1993) and in vivo, AM causes 
dose-dependent hypotension arising from widespread, regional vasodilatations 
(Kitamura et al., 1993; Sakata et al., 1993; Lippton et al., 1994; Gardiner et 
al., 1995; Hirata et al., 1995; Charles et al., 1997; see section 1.2.3). 
Analysis of the teleost fish genome recently identified several AM-like genes 
which were named AM-I-5, (Ogoshi et al., 2004), and AM-2-like sequences 
were found in mouse, rat, and human genome databases (Takei et al., 2004). 
At the same time, Roh et al., (2004) identified genes in mammals and 
pufferfish which shared some sequence homology with AM; expression of this 
gene in the intermedia of the pituitary led its product to be named intermedin 
(IMD) (Roh et al., 2004). The amino acid sequences of AM-2 and IMD were 
found to be almost identical, leading researchers to accept they are the same 
peptide, referred to herein as IMD. 
Proteolytic cleavage of preproIMD yields several biologically active 
fragments, including IMD long, consisting of 47 amino acids, IMD short, 
consisting of 40 amino acids, and IMD I-53, which has unknown physiological 
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significance (Roh et al., 2004; Yang et al., 2005). Whilst most of the studies in 
the literature have used IMD I-47, the studies to be described here have used the 
fragment IMD I-53, since this was the form commercially available at the start 
of this work. Whilst the physiological significance of these preproIMD 
fragments are not yet understood, there is some evidence to suggest that IMD 1_ 
53 is a physiologically relevant cleavage product of the precursor peptide 
(Yang et al., 2005; Ren et al., 2006). 
Since IMD was found to share some sequence and structural homology with 
AM and CGRP, which both have potent actions within the cardiovascular 
system, it was hypothesised that IMD may have similar effects. Indeed, when 
given in vivo, IMD has been shown to cause hypotension in conscious rats 
(Roh et al., 2004; Abdelrahman et al., 2006; Fujisawa et al., 2006; Chauhan et 
al., 2007) anaesthetised mice (Takei et al., 2004) and conscious sheep (Charles 
et al., 2006). This was associated with an increase in cardiac output (Charles et 
al., 2006; Fujisawa et al., 2006a), regional vasodilatations (Fujisawa et al., 
2007) and a decrease in total peripheral resistance (Charles et al., 2006). 
Intermedin-induced tachycardia is reported in some studies (Roh et al., 2004; 
Abdelrahman et al., 2006; Charles et al., 2006; Fujisawa et al., 2006) but not 
all (Pan et al., 2005; Chauhan et al., 2007). In vitro, IMD dilates porcine and 
rat coronary arteries (Kobayashi et al., 2004; Pan et al., 2005), preconstricted 
rat pulmonary vessels (Kandilci et al., 2006) and causes relaxation of isolated 
mesenteric arteries (Chauhan et al., 2007). 
Whilst IMD was shown to increase renal blood flow in vivo (Fujisawa et al., 
2004; Fujisawa et al., 2006), only one study has reported effects of the peptide 
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on regional haemodynamics (Fujisawa et al., 2007). Although that study 
showed IMD to cause regionally selective increases in blood flow, the radio 
labelled microsphere method was used, allowing !MD-mediated changes in 
blood flow to only be shown at one time point. Furthermore, the study by 
Fujisawa et at. (2007) did not compare the regional effects of !MD with those 
of AM. The first aim of this work therefore, was to agsess the regional 
haemodynamic responses to !MOt-53 in conscious, unrestrained rats, and to 
compare them to an equimolar dose of AM. 
94 
3.2 Methods 
Five groups of Sprague-Dawley rats were chronically instrumented with 
miniature, pulsed, Doppler flow probes to measure renal, mesenteric and 
hindquarters vascular conductances, and intravascular catheters (La, i.v, & Lp.) 
to allow administration of substances and continuous derivation of blood 
pressure and heart rate. These procedures are outlined in Chapter 2. To 
investigate the regional haemodynamic responses to AM and IMD, the 
following protocols were followed. 
Regional haemodynamic responses to AM and IMD (lnmol kg-I) were 
assessed in rats that received saline (O.5ml i.p. bolus, or O.4ml h- t i.v. infusion) 
to control for the effects of LPS (i.p. bolus, or i.v. infusion) as will be 
described in Chapter 4. Peptides were given 1.5 h, 6 h and 25 h after a saline 
bolus, or from the onset of a saline infusion, but for the purpose of delineating 
the regional haemodynamic effects of the peptides in normal rats, responses 
described here are those from administration at the 1.5 h time point (i.e. in 
peptide-naIve animals). The dose of peptide (lnmol kg-I) was chosen on the 
basis of previous experiments which showed AM (lnmol kg-I) to cause 
marked and reproducible cardiovascular changes in Long Evans rats (Gardiner 
et al., 1995) and pilot studies which showed IMD at this dose to cause robust 
and reproducible cardiovascular changes. 
Since !MD (lnmol kg-I) was given to 1 group of rats (n=8) administered saline 
(O.5ml Lp.) to control for the effects of a LPS bolus, and in a separate group of 
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rats (n=ll) administered saline (O.4ml h-I) to control for the effects of a LPS 
infusion, these 2 groups were combined (n=19) to describe the responses to 
!MD (lnmol kg-I) in normal animals. Here, AM (lnmol kg-I) was given 
following a saline bolus but not in later experiments in which animals received 
a saline infusion. Therefore, 1 group of rats (n=9) was used to assess the 
effects of AM at a dose of Inmol kg-I in normal animals. 
Adrenomedullin (lnmol kg-I) was given to 1 group of rats (n=9) to control for 
the effects of LPS bolus (see above and Chapter 5). However, since it was 
found that AM at a dose of Inmol kg-I had only modest and poorly 
reproducible effects, a higher dose of AM (3nmol kg-I) was given to a group 
of rats that received a saline bolus to control for the effects of a LPS bolus 
(n=lO), and to a separate group of rats that received a saline infusion to control 
for the effects of a LPS infusion (n=lO), as described above. These 2 groups 
were combined (n=20) to describe responses to AM (3nmol kg-I) in normal 
animals. 
96 
3.3 Results 
Baseline cardiovascular variables for each group of animals are given in Table 
3.1. Prior to administration of AM (lnmol kg-I and 3nmol kg-\ and IMD 
(lnmol kg-I) in 3 separate groups of animals (see above), resting 
cardiovascular variables were similar (P>0.05 Kruskal Waliis test). 
HR MAP RVe MVe HVe 
(beats min-I) (mmHg) (units) (units) (units) 
AM (lnmol kg-I) 320±7 107±3 84±5 77±9 37±3 
AM (3nmol kg-I) 343±6 108±2 82±6 70±5 47±3 
!MD (Inmol kg-I) 339±6 110±2 83±7 68±3 44±3 
Table 3.1 Resting cardiovascular variables prior to administration of AM (1 
and 3nmol kg-I) (n=9 and n=20, respectively) and IMD (lnmol kg-I) (n=J9) in 
conscious rats. Units for vascular conductance (VC) are kHzlmmHg x J rI. 
3.3.1 Regional haemodynamic responses to IMD 
The time-course of !MD responses in conscious rats is shown in Figure 3.3.1. 
Administration ofIMD (lnmol kg-I) caused a fall in blood pressure which was 
significant between 0-20 min and 40-50 min (P<0.05, Friedman's test); this 
was accompanied by an increase in heart rate, which remained elevated 50 min 
after IMD administration (P<O.OS, Friedman's test), and marked increases in 
renal, mesenteric and hindquarters vascular conductances, indicating IMD-
mediated vasodilatations in those regions. The most marked regional 
vasodilator response to IMD occurred in the mesenteric bed which remained 
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dilated 50 min from IMD administration (P<0.05, Friedman's test). The renal 
vascular bed also showed a marked increase in conductance which was 
sustained for 40 min (P<0.05, Friedman's test). Whilst there was IMD-
mediated vasodilatation in the hindquarters, this was less marked and less 
long-lasting than in the other vascular beds, with conductance being 
significantly increased for 20 min from peptide administration. The rank order 
of potency for IMD therefore was mesentery = renal>hindquarters. The effects 
of IMD on Doppler shift (Le. flow) were assessed since vascular conductance 
is determined by both blood flow and blood pressure (see Chapter 2). IMD at a 
dose of Inmol kg') caused clear increases in Doppler shift (Le. flow) in all 3 
vascular beds (Figure 3.3.2). 
3.3.2 Regional haemodynamic responses to AM 
The time course of responses to AM (lnmol kg,l) is shown in Figure 3.3.1a. 
Administration of AM at this dose caused tachycardia and increases in renal, 
mesenteric and hindquarters vascular conductances, which were most marked 
1-2 min from administration and sustained for 20 min (P<0.05 Friedman's 
test) (Figure 3.3.1a). Despite causing regional vasodilatations at this dose, AM 
failed to cause any fall in blood pressure, in fact, from 30-50 min there was a 
small, but significant, increase in blood pressure (P<0.05 Friedman's test). At 
a dose of Inmol kg'), AM caused increases in Doppler shift (Le., flow) in all 3 
vascular beds (Figure 3.3.2). 
Since the Inmol kg') dose of AM failed to cause hypotension and produced 
responses which were poorly reproducible, the protocol was repeated using 
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AM at a dose of 3nmol kg-I, The time course of AM at this dose responses is 
shown in Figure 3.3.1b, and it is apparent that AM caused a marked 
hypotension (which was sustained across the whole 60 min recording period 
(P<0.05 Friedman's test», tachycardia and increases in renal, mesenteric and 
hindquarters vascular conductances, all of which were sustained for 50-60 min 
from AM administration (Figure 3.3.lb). Regional responses to AM occurred 
with the rank order renal>mesenteric>hindquarters. Increases in Doppler shift 
in the renal, mesenteric and hindquarters vascular beds in response to AM 
(3nmol kg-\ indicate AM-mediated increases in blood flow in those regions 
(Figure 3.3.2b). 
3.3.3 Comparison of the regional haemodynamic responses to AM and IMD 
. A comparison of the integrated (O-lOmin) responses to AM (1 and 3nmol kg-I) 
and IMD (lnmol kg-I) 1.5 h after saline treatment is shown in Figure 3.3.3. 
Intermedin-induced hypotension, and increases in renal and mesenteric 
vascular conductance were significantly (P<0.05, Kruskall Wallis test) more 
marked than those of an equimolar dose of AM, whereas IMD-induced 
tachycardia, hypotension and renal vasodilatations were significantly less 
marked than those caused by the higher dose of AM (3nmol kg-I). However, 
increases in mesenteric vascular conductance were not different between the 
IMD (lnmol kg-I) and AM (3nmol kg-I), groups and there was no difference in 
the hindquarters vasodilator response between any of the groups. However, 
when compared over 60 min, the integrated (0-60 min) change in hindquarters 
vascular conductance was significantly greater following treatment with AM 
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(3nmol kg-I) when compared to !MD (Inmol kg-I). The peak increase in 
vascular conductance occurred at 20 min in the AM-treated group and 
vasodilatation in this region was sustained over the whole 60 min recording 
period, whereas the IMD-mediated increase in hindquarters vascular 
conductance had returned to baseline levels by 30 min after administration. 
(Fi.gure 3.3.1b) 
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3.4 Discussion 
Recent identification of novel AM-like genes in teleost fish and mammals has 
led researchers to postulate the existence of a distinct AM family of peptides 
(Takei et al., 2004b; 2008). Adrenomedullin is a potent hypotensive peptide 
involved in cardiovascular regulation, and is upregulated in some 
pathophysiological conditions affecting the cardiovascular system, including 
sepsis and hypertension, and during pregnancy (Wang et al., 2001; Ishimitsu 
et al., 2006; Senna et al., 2008); a similar role for the AM-related peptide, 
IMD, is not yet established. This study was designed to assess the regional 
vascular responses to IMD' and compare them with those of AM in conscious 
rats. 
Here, it is showed that, in normal animals, IMD I•S3, (lnmol kg· l ) caused 
vasodilatations in the renal, mesenteric and hindquarters vascular beds which 
were sufficient to cause a fall in blood pressure, and tachycardia. The most 
marked vasodilatations were seen in the mesenteric and renal vasculature, 
where the increases in vascular conductance were still pronounced at 50 and 
40 min, respectively. The finding that IMD causes hypotension is consistent 
with previous reports, indeed, the first descriptions of the peptide showed it to 
have blood pressure lowering effects in conscious normotensive and 
hypertensive rats, and in anaesthetised mice (Roh et al., 2004; Takei et al., 
2004). This finding has since been extended and confirmed in rats (Pan et al., 
2005; Abdelrahman et al., 2006; Fujisawa et al., 2006, 2007; Chauhan et al., 
2007), and sheep (Charles et al., 2006). Evidence indicates that the 
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hypotensive effects of IMD are due to its action as a potent vasodilator. 
Studies have shown IMD-mediated renal vasodilatation in vivo (Fujisawa et 
al., 2004). and !MD-mediated relaxation of isolated coronary (Kobayashi et 
al., 2004; Pan et al., 2005). carotid (Kobayashi et al., 2004). mesenteric 
(Kobayashi et al., 2004; Chauhan et al., 2007) and pulmonary arteries 
(Kandilci et al., 2006) in vitro. The present results are consistent with IMD 
being a hypotensive and vasodilator peptide. and extend findings of the above 
studies to the in vivo situation 
The findings reported here are consistent with those of Takei et al. (2004) who 
found IMD to have a greater hypotensive effect than an equimolar dose of AM 
in anaesthetised mice (Takei et al., 2004). However, findings regarding the 
relative potencies of IMD and AM vary in the literature depending on the form 
of IMD used (IMDI-47' IMDs-47 or IMD 1-S3). the route and method of 
administration (Lv. or Lp., bolus or infusion). the method of blood pressure 
measurement (invasive or non-invasive) and the species used. For example, 
using the tail-cuff method, Roh et al. (2004) found that Lp. administration of 
AM caused a greater fall in systolic blood pressure than did an equimolar dose 
of IMDl-47. In contrast, Ren et al. (2005) found that i.v. bolus administration 
of IMDl-47 caused a greater hypotensive response than equimolar IMDI-53 and 
AM in anaesthetised rats (Ren et al., 2005). whilst in conscious rats. Taylor et 
al (2004) found Lv. administration of IMD reduced blood pressure by a 
comparable amount to CGRP, but to a lesser degree than did equimolar AM 
(Taylor et al., 2004). Studies have found IMD reduced blood pressure and 
increased renal blood flow to a comparable extent to AM, with the effects of 
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the latter being considerably longer lasting (Fujisawa et al., 2004). Whilst here 
the responses to IMD were significantly more marked than those to equimolar 
AM, some effects of the latter were longer lasting than those of the former, at 
the higher dose. 
A previous study described the regional haemodynamic effects of IMD, but 
this was limited to changes at one time point, i.e., 10 min from onset of IMD 
infusion (Fujisawa et al., 2007). Here, the full profile of regional 
haemodynamic changes following IMD administration is described and 
compared with those of AM in conscious rats. The finding that IMD caused 
renal vasodilatation is consistent with the findings of Fujisawa et al. (2007) 
who showed IMD increased blood flow to the kidney in both normotensive 
and hypertensive rats. They further showed that IMD significantly increased 
the % distribution of cardiac output to the kidney. However, they failed to 
show an increase in mesenteric blood flow following IMD-administration, 
instead showing a small but significant decrease in blood flow to this region in 
hypertensive rats. This is surprising, since there was a clear mesenteric 
hyperaemic vasodilator effect of IMD immediately after administration. As 
outlined above, it is possible that the method of peptide administration 
(infusion vs. bolus), or the strain of rat may have affected the outcome; 
furthermore, Fujisawa et al. (2007) did not state the form of the peptide used, 
and these have different potencies (see above). 
In the present study, IMD caused a significant increase in heart rate in 
conscious rats. Although several studies have reported IMD-mediated 
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tachycardia (Abdelrahman & Pang, 2006; Charles et al., 2006; Fujisawa et al., 
2006, 2007; Ren et al., 2006) others have shown IMD had no effect on heart 
rate, irrespective of it causing a fall in blood pressure, or the presence/absence 
of anaesthesia (Pan et al., 2005; Chauhan et al., 2007). It is not yet clear 
whether IMD has a direct inotropic and/or chronotropic effect on the heart or 
whether the observed tachycardia is baroreflex-mediated, although in vitro 
data suggest that it has a direct effect on cardiac myocyte contractile function 
(Dong et al., 2006). Studies have reported the presence ofIMD and CLlRAMP 
mRNA and protein in the heart of mice, rat and humans (Takahashi et al., 
2006; Zhao et al., 2006; Morimoto et al., 2007; Bell et al., 2008; Zeng et al., 
2009) supporting the view that IMD maybe directly involved in the control of 
cardiac function. 
Cardiovascular responses to Inmol kg-) AM in conscious rats consisted of a 
tachycardia and increases in renal, mesenteric and hindquarters vascular 
conductances. Intermedin-induced vasodilatations were greater than those 
caused by equimolar AM in the renal and mesenteric vasculature, but not in 
the hindquarters, where the response to the 2 peptides was not different. 
Furthermore, IMD caused a significant fall in blood pressure which was not 
seen following treatment with an equimolar dose of AM. Since AM caused 
widespread vasodilatations, this failure to induce a fall in blood pressure 
indicates that cardiac output must have been increased. These results are 
consistent with studies which have shown AM had a modest effect on blood 
pressure but caused relatively large increases in heart rate and cardiac output 
(Parkes, 1995; Parkes et al., 1997). Despite this lack of hypotension, AM at a 
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dose of lnmol kg-I led to a significant tachycardia suggesting it had a direct 
chronotropic effect on the heart. 
The cardiovascular responses to a higher dose (3nmol kg-I) of AM were 
assessed and given that, at this dose, there was a significant hypotension, and 
responses were more robust and more closely matched to those following 
administration of !MD (lnmol kg-I); this higher dose was used in all 
subsequent experiments to be described in this thesis. 
Since vascular conductance is determined by both blood· flow and blood 
pressure, the effects of AM and !MD on flow alone (Le. Doppler shift, refer to 
Chapter 2) were assessed to ascertain whether the observed increases in 
vascular conductance were really due to an increase in flow arising from 
peptide-mediated vasodilatation, or whether it was an autoregulatory response 
to the peptide-mediated hypotension (Figure 3.3.2). Since there were clear 
increases in flow (Le. Doppler shift) in all vascular beds following treatment 
with AM (1 and 3nmol kg-I) and IMD (lnmol kg-I), it can be stated that both 
peptides caused active vasodilatations in those regions. 
In conclusion, the present study shows that the newly discovered calcitonin 
family peptide, IMD, caused marked hypotension when given to conscious 
rats and regional vasodilatations which were equal to or more marked than 
those caused by an equimolar dose of AM. These findings are consistent with 
those of others who have reported IMD to be a potent hypotensive peptide, 
and suggest that, like AM and CGRP, !MD may be an important regulator of 
cardiovascular function. 
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Chapter 4 
Results (11) 
Mecbanism(s) of adrenomedullin and 
intermedin-mediated vasodilatation 
109 
Summary 
In Chapter 3, the regional haemodynamic responses to IMD were described 
and compared to those of AM. Both peptides were shown to elicit a 
comparable haemodynamic profile comprising widespread vasodilatation, 
decrease in blood pressure and a tachycardia. In this Chapter, possible 
underlying mechanisms involved in these actions of IMD and AM were 
investigated. 
Measurements of blood pressure, heart rate and renal, mesenteric and 
hindquarters haemodynamics were made in conscious, chronically-
instrumented rats. 
The AM receptor antagonist, AM22- 52, was equally effective in attenuating the 
renal and mesenteric vasodilator effects oflMD (1 nmol kg-I) and AM (3 nmol 
kg-!), but inhibition of NO synthase was more effective at reducing the 
vasodilator effects ofIMD than AM. Vascular KATP channel blockade with U-
37883A did not inhibit the vasodilator effects of either peptide, although it did 
lead to augmentation of some of the vasodilator effects of AM. Using the All 
receptor antagonist, losartan, this effect was found to involve inhibition of the 
renin-angiotensin system. 
In vivo, the regional haemodynamic profile of IMD resembles that of AM, and 
some of the vasodilator effects of IMD are mediated by AM receptors and NO, 
but not by KA TP channels. 
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4.1 Introduction 
In the preVlOUS Chapter, it was shown that the in vivo integrated 
haemodynamic effects of IMD resemble those of AM in conscious rats. The 
aim of this Chapter was to determine whether the mechanisms involved in 
these vascular actions ofIMD of AM were similar. 
The calcitonin family of peptides (calcitonin, CGRP, amylin, AM and IMD) 
exert their effects on the vasculature via a unique receptor system comprising 
a G-protein coupled receptor, named calcitonin receptor-like receptor (CL), 
and one of three receptor activity-modifying proteins (RAMPI-3). The 
vascular effects of CGRP are mediated by activation of the CGRPl receptor, 
which consists of CL and RAMP 1, and can be antagonised by the fragment 
CGRPS-37. Adrenomedullin functions through two receptors, AMI and AM2, 
which consist of CL complexed with RAMP2 and RAMP3, respectively. 
Adrenomedullin action through these receptors can be antagonised by the 
fragment AM22-52 (for review see Poyner et al., 2002). Agonist binding to 
these receptors activates adenylate cyclase leading to accumulation of cAMP, 
relaxation of vascular smooth muscle and endothelial-independent 
vasodilatation. Studies have also shown that AM can initiate vasodilatation in 
an endothelial-dependent manner via the production of NO and by activation 
ofKATP channels (Gardiner et al., 1995; Sabates et al., 1997; Goto et al., 2000; 
Terata et al., 2000). Whilst the mechanism(s) of AM and CGRP-mediated 
vasodilatation are well documented (for review see Poyner et al., 2002), only a 
limited number of studies have examined those of !MD. Since !MD has some 
structural and sequence homology with both AM and CGRP, some 
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researchers' have suggested that IMD and AM may signal through a common 
pathway(s). 
Currently, evidence suggests that IMD is a non-selective agonist of the 
CURAMP system, functioning through CL complexed to any of the three 
RAMPS (Roh et al., 2004). Furthermore, some findings indicate the existence 
evidence of a unique and unidentified IMD receptor that is distinct from this 
system (Owji et al., 2008; Kandilci et al., 2008). The first evidence that IMD 
was able to interact non-discriminately with CURAMP complexes came from 
studies by Roh et al. (2004) utilising transfected 293T cells, which showed 
IMD could increase cAMP levels through each of the three receptor 
complexes. Furthermore, co-application of CGRPs-37 and AM22-s2 to isolated 
rat pulmonary arteries caused an additive attenuation of IMD-mediated 
vasorelaxation. The remaining IMD-mediated vasodilatation which was 
insensitive to both CGRPS-37 and AM22-s2 matched that seen upon addition of 
the IMD fragment, IMD17-47, which is believed to act as an antagonist at 
specific 'IMD-receptors' (Roh et al., 2004; Kandilci et al., 2008). Along with 
evidence from in vitro and in vivo studies, this suggests a role for both CGRPs_ 
37-sensitive (Kobayashi et al., 2004; Roh et al., 2004; Taylor et al., 2004; Ren 
et al., 2006; Kandilci et al., 2006, 2008) and/or AM22-srsensitive receptors 
(Ren et al., 2006; Kandilci et al., 2008) in regional IMD-mediated 
vasodilatations, as well as a distinct IMD17-47-sensitive receptor yet to be 
identified. A study using isolated perfused rat lung also found evidence of a 
role for NO in IMD-mediated relaxation under pre-constricted conditions, but 
no role for KATP channels (Kandilci et al., 2006), both of which are believed to 
be involved in AM-mediated vasodilatation (Sabates et al., 1997). 
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The aim of the following experiments therefore, was to examme the 
mechanisms through which AM and IMD exert their regional vascular effects 
in conscious rats. To assess the contribution of AM receptors, the AM receptor 
antagonist, AM22-52, and the CGRP I receptor antagonist CGRPs-37, were used. 
The non-selective NOS inhibitor, L-NAME, and the KATP channel blocker, 
U37883A, were used to investigate the role of NO and KATP channels, 
respectively. Due to some unexpected responses to AM following treatment 
with U37883A, which could possibly be explained by the effects of these two 
substances on renin secretion, the AT 1 receptor antagonist, losartan, was used 
to assess the role of renin-angiotensin system in AM and IMD-mediated 
vasodilatation. Experiments were performed with IMD at a dose of Inmol kg" 
., and AM at a dose of 3nmol kg"1 since AM (lnmol kg"l) was ineffective at 
causing a fall in blood pressure (Chapter 3). 
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4.2 Methods 
Eight groups of rats (n=5-IO) were used in the following experiments which 
were completed according to the methods described in Chapter 2. Briefly, rats 
were anaesthetised, and miniature Doppler flow probes were placed around the 
left renal artery, the superior mesenteric artery and the distal aorta allowing 
changes in renal, mesenteric and hindquarters vascular conductances to be 
calculated in response to peptide challenges. Rats were later implanted with 
Lv. and i.a. catheters to allow substance administration and continuous 
derivation of blood pressure and heart rate in unrestrained animals. 
Experiments were performed on Days 1-4, starting 24 h from catheter 
implantation. To investigate the mechanism(s) responsible for mediating the 
vascular effects of AM and IMD the following protocols were followed; all 
substances were given Lv. 
4.1.1 Experiment 1: Effects of repeated dosing of AM and flUD 
Since some of the protocols required repeat dosing with AM and IMD (see 
below), the first experiment was designed to assess whether any tachyphylaxis 
or cross-tachyphylaxis occurred following repeated dosing of AM and IMD. A 
group of rats (n=8) were randomised to receive AM (3nmol kg-I) on Days 1 
and 3, and IMD (lnmol kg-I) on Days 2 and 4, or IMD on Days 1 and 3, and 
AM on Days 2 and 4, with animals only receiving 1 treatment each day. This 
protocol was used as it is consistent with the way in which AM and IMD 
administration was randomised in the experiments described in this chapter. 
This protocol is shown in diagrammatic form below (Figure 4.2.1). 
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Baseline 60 min 
Day 1 t 
AMJorIMD 
Baseline 60min 
Day 2 ... ~ ~ ... ~ ~t 
IMD/or AM 
Baseline 60min 
Day 3 ... • .. • t 
AMJorIMD 
Baseline 60min 
Day 4 ... ~ ~ ... ~ ~
t 
IMD/orAM 
Figure 4.2.1 Following a period of approximately 60 min for measurements 
of resting cardiovascular variables to be taken, animals received either AM on 
Day 1 and 3, and IMD on Day 2 and 4; or IMD on Day 1 and 3, and AM on 
Day 2 and, this was followed by a recording period of 60 min 
4.2.2 Experiment 2: Involvement O!CGRP8_J7-Sensitive receptors 
The involvement ofCGRP1 receptors in the regional vascular responses to AM 
and !MD was assessed using the CGRP peptide fragment, CORPs-37. 
Animals (n=6) received a 6 min infusion of CORPs-37 (500 nmol kg-I h-I) 
followed by IMD (lnmol kg-I) given as a O.1ml bolus between 5 and 10 min 
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later. A separate group of animals (n=5) was used in control experiments, and 
received a 6 min infusion of saline (O.4ml h-I) followed by IMD (lnmol kg-\ 
Responses to AM in the presence of CGRPS-37 were assessed in a group of 
animals (n=5) who received an infusion of CGRPs-37 (500nmol kg-I h-I given 
over 6 mins), followed by bolus a d m i n i s t r ~ t i o n n of AM (l nmol kg-I) between 5 
and 10 min later. A separate group of animals (n=5) were challenged with AM 
(lnmol kg-I) 5-10 min after infusion of saline (0.4 ml h- l for 6 mins) 
Baseline 6 min 5-10 min 60min 
Group 1 • f • .. ~ ~ .. t t CGRP8_37 CGRP8_37 IMDorAM 
on ofT 
Baseline 6min 5-10 min 60min 
• f • .. • .. t t Group 2 
Saline Saline IMDorAM 
on ofT 
Figure 4.2.2 Animals were pre-treated with CGRPS-37 for 5-10 min before 
administration of IMD or AM. A separate group were pre-treated with saline 
before administration of IMD or AM. 
116 
4.2.3 Experiment 3: Involvement of AM22_srsensitive receptors 
The involvement of AM receptors in the regional vascular responses to AM 
and IMD was assessed using the AM peptide fragment, AM22-52, which has 
greater selectivity for AM than CGRP receptors (for review see Poyner et al., 
2002). 
A group of animals (n=6) received a 6 min infusion of AM22-s2 (500 nmol kg-t 
hot) followed by IMD (lnmol kg-I) given as a O.lml bolus between 5 and 10 
min later. A separate group of animals (n=5) was used in control experiments, 
and received a 6 min infusion of saline (OAml hot) followed by IMD (lnmol 
kg-t). The dose of AM22-s2 has previously been shown to attenuate the regional 
vasodilatations to AM (lnmol kg-I) in vivo (Gardiner et al., 1999); this 
protocol is illustrated below (Figure 4.2.3). 
Baseline 6 min 5-10 min 60min 
Group 1 ~ ~ f t .. "t" 
AM22-S2 AM22-S2 IMD 
on off 
Baseline 6 min 5-10 min 60min 
Group 2 ~ ~ t ~ t t .. tt'" 
Saline Saline IMD 
on off 
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Figure 4.2.3 A group of animals were pre-treated with AM22-52 5-10 min 
before administration of IMD. A separate group were pre-treated with saline 
before administration of IMD. 
Effects of AM22-52 on responses to AM were assessed in a single group of 
animals (n=8) randomjsed to receive either a 6 min infusion of saline (0.4 ml 
h- t ) or AM22-52, followed by bolus administration of AM between 5 and 10 min 
later. This was a paired experiment, conducted on a single day with peptide 
challenges occurring 3-4 h apart. This protocol is illustrated in Figure 4.2.3a. 
Baseline 6min 5-10 min 60min 
po f ,. .. .. 1 f f 
Saline Saline AM 
on ofT 
Baseline 6 min 5-10 min 60min 
pm or am ~ 1 1 : = = = = = : P ! " : ' - f ~ = : : : l " ~ t . . . ! " ~ = = : t " ; " ' t ~ " = = = = = = ~ " "
AM22•s2 AM22•s2 AM 
on ofT 
Figure 4.2.3a Animals were pre-treated with either saline in the morning 
and AM22-52 in the afternoon. or AMll-52 in the morning and saline in the 
afternoon. followed 5-10 min later by administration of AM. 
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4.2.4 Experiment 4: Involvement of Nitric Oxide 
Involvement of NO in the vascular responses to AM and IMD was assessed 
using the non-selective NOS inhibitor, ~ - n i t r o - L - a r g i n i n e e methyl ester (L-
NAME; 3mg kg- l hot). This dose and method of administration has been used 
routinely in the Nottingham haemodynamics laboratory over several years, 
and has been shown to inhibit NO-mediated vasodilatation (Gardiner et al., 
1991alb/c, 1995,2006; Wakefield et al., 2003). Since L-NAME itself leads to 
vasoconstriction and hypertension through inhibition of NOS, a suitable 
control was required which changes baseline haemodynamics in a similar 
manner to that ofL-NAME. Control animals were therefore treated with a co-
infusion of angiotensin 11 (All) (200 ng kg-l h-l) and arginine vasopressin 
(AVP) (20 ng kg-t hot). The doses were chosen based on previous work by the 
group in which AIVAVP co-infusion had vasopressor and regional 
haemodynamic effects consistent with those seen during L-NAME infusion 
(Gardiner et al., 2006). 
Animals received a co-infusion of AIVAVP and a challenge of AM (3 nmol 
kg"t) or IMD (l nmol kg-I) on Day 1 and the other peptide on Day 2, 90 min 
after the onset of the AlII A VP infusion. This protocol was repeated on Days 3 
and 4 with animals receiving an infusion of L-NAME instead of AIIIAVP. In 
this way, each animal received each of the 4 treatments and acted as its own 
control. L-NAME was always given on Days 3 or 4 because of its very long 
duration of action. This protocol is illustrated in Figure 4.2.4. 
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15 min 
Day 112 r?-? c t t 
AlII A VP AlII A VP 
on in 
15 min 
Day3/4 c=b c i i 
L-NAME L-NAME 
on in 
90min 
.A. 
90 min 
.A. 
60min 
A 
t 
AMlIMD 
60min 
A 
t 
AMlIMD 
Figure 4.2.4 Animals were pre-treated with AIl/AVP for 90 min before 
receiving either AM or IMD on Day 1, and the other peptide on Day 2. On 
Days 3 and 4 this protocol was repeated in the presence of L-NAME. The 15 
min period at the start of the AIl/AVP and L-NAME infusion represents the 
time taken for the solution to infuse through the dead space of the catheter (i.e. 
0.1 ml) 
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4.2.5 Experiment 5: Involvement of KATP channels 
The role of KA TP channels in AM and IMD-mediated vasodilatations was 
assessed using the KATP channel blocker, U37883A (Teramoto, 1996). This 
antagonist was chosen as evidence suggests it is relatively selective for 
vascular KATP channels. The dose chosen was based on published studies 
showing attenuation ef the effects of the KATP channel opener levcromakalim 
(LCK) at the given dose (Dabisch et al., 2004). 
A group of animals (n=9) was randomised so each animal received saline and 
U37883A (5 mg kg-I) given as a Iml infusion over 30 min, followed 20 min 
later by administration of AM (3 runol kg-I) or IMD (1 runol kg-I). Over the 4 
experimental days, each animal received all treatments and was able to act as 
its own control. Effectiveness of U37883A at blocking KATP channels was 
assessed by the use of LCK (lO J.1g kg- l min- l for 3 min). Figure 4.3.5 
illustrates the protocol followed. 
Whilst U37883A was unable to completely antagonise the effects of LCK, it 
attenuated responses when given 2h after the onset of U37883A infusion. 
Thus, U37883A reduced the LCK-mediated fall in blood pressure by 35% 
when compared to responses to LCK alone (O-3min integrated absolute 
change). Also, LCK-mediated renal, mesenteric and hindquarters 
vasodilatations were reduced by 23%, 18% and 65%, respectively (O-3min 
integrated absolute changes) in the presence of U37883A. This is consistent 
with studies showing that U37883A attenuated, but did not abolish the 
responses to LCK (Dabisch et al., 2004). 
121 
DayJ/2 
Day 3/4 
30 min 30 min 60 min 
.. ~ ~ cl ~ ~ of 
t t t 
Saline 
on 
30min 
t 
t 
U37883A 
on 
Saline 
off 
AMlIMD 
30min 60min 
t! cl t! of 
t t 
U37883A AMIIMD 
off 
3 min 
~ ~ ~
t t 
LCK LCK 
on off 
3 min 
~ ~ ~
t t 
LCK LCK 
on ofT 
Figure 4.2.5 Animals were pre-treated with saline [or 30 min followed 30 
min later by AM or fMD on Day 1 or 2. The protocol was repeated on Day 3 
and 4 in the presence of U37883A pre-treatment. At least 60 min after peptide 
administration animals received a 3 min infusion of LCK. 
4.2.6 Experiment 6: Interactions between NO and KATP channels 
To further examine the contribution of KATP channels to AM and IMD-
mediated vasodilatations in the absence of NO, a separate group of animals 
(n=9) were co-administered L-NAME (3mg kg hot pre-treated for 90 min) and 
saline (Days 1 and 2), or U37883A (Days 3 and 4) (30 min infusion) 
beginning 30 min after the start of the L-NAME infusion. This was followed 
by AM or !MD challenges 30 min after the end of the U37883A or saline 
infusion; the protocol is shown in Figure 4.2.6. 
122 
Day 112 
15min 30min ~ ~n 30min R 30min r===' 
L-NAME L-NAME Sal Sal AMlIMD 
on In on off 
Day 3/4 
15 min 30 min 60 min n 30minR 30min p. 
L-NAME L-NAME U37883A AMlIMD 
on in on off 
Figure 4.2.6 Animals were pre-treated with L-NAME in combination with saline 
(Days 1 and 2) or U37883A (Days 3 and 4) prior to administration of AM on Day 1 
and 3, and IMD on Day 2 and 4; or IMD on Day 1 and 3 and AM on Day 2 and 4. 
4.2.7 Experiment 7: Involvement of the renin-angiotensin system 
Since some of the results obtained in earlier experiments (see results) could be 
explained by differential activation of the renin-angiotensin system (see 
Results), the effects of the angiotensin 11 (ATI) receptor antagonist, losartan, 
were assessed on the regional haemodynamic responses to AM and IMD. 
A group of animals (n=9) was randomised to receive a O.1ml saline bolus 
followed 60 min later by AM (3 nmol kg-I) or IMD (1 nmol kg-I) on either 
Day 1 or Day 2. On Days 3 and 4, animals were given a 0.1 ml bolus of 
losartan (10 mg kg-I) followed 60 min later by either AM or IMD (as above). 
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Losartan was always given on the final experimental days because of its long 
duration of action. This protocol is illustrated in Figure 4.2.7. 
Baseline 60 min 60 min 
DayJ/2 j 
Saline AMlIMD 
Baseline 60 min 60min 
Day 3/4 j 
Losartan AMlIMD 
Figure 4.2.7 Animals received a bolus of saline on Days 1 and 2 followed by 
administration of either AM or IMD. On Days 3 and 4, animals were pre-
treated with losartan followed by administration of either AM or IMD. 
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4.3 Results 
Resting cardiovascular variables for all groups of animals used In these 
experiments are shown in Table 4.1. 
4.3.1 Experiment 1: Effects of repeated dosing of AM and IMD 
There were no differences in baseline cardiovascular variables in animals prior 
to administration of AM on Days 1 or 2, and Days 3 or 4; this was also true for 
animals that were to receive IMD (Table 4.1). 
Following the first treatment with AM (3 nmol kg·I), there was a significant 
tachycardia, hypotension and renal, mesenteric and hindquarters 
vasodilatations. These responses were unchanged following the second 
treatment with AM (3 nmol kg· l ) (P>0.05 for integrated 0-30 min changes for 
each variable) (Figure 4.3.la). 
The first treatment with IMD (1 nmol kg· l ) caused a significant tachycardia, 
hypotension and renal, mesenteric and hindquarters vasodilatations; these 
responses were not different from those seen following the second treatment 
with IMD (1 nmol kg· l ) (P>0.05 for integrated 0-30 min changes for each 
variable) (Figure 4.3.1b). Thus, for both AM and IMD, the haemodynamic 
changes were reproducible following repeated administration. 
4.3.2 Experiment 2: Involvement 0fCGRP8_J,sensitive receptors 
Following pre-treatment with either CGRPS•37 or saline, there were no 
differences in resting cardiovascular variables between groups. In the control 
group, AM (Inmol kg-I) caused a tachycardia but no other significant changes 
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in haemodynamics (see Chapter 3). Following pre-treatment with the CGRPI 
antagonist CGRPs-37, AM-mediated tachycardia was abolished (Figure 4.3.2a). 
In animals who had received a pre-treatment of saline, IMD (lnmol kg-I) 
caused tachycardia, marked increases in renal, mesenteric and hindquarters 
vascular conductances, but no change in blood pressure. Administration of 
CGRPs-37 had no effect on the haemodynamic responc;es to IMD (Figure 
4.3.2b). These data suggest that !MD does not activate CGRPI receptors in 
conscious rats. 
4.3.3 Experiment 3: Involvement of AM22_srsensitive receptors 
There were no differences in resting cardiovascular variables in animals prior 
to administration of AM (3n mol kg-I) following administration of saline or 
AM22-s2. In animals that were to receive !MD (1 nmol kg-I) following AM22-s2, 
there was a significantly higher renal vascular conductance at baseline 
compared to the separate group of animals that were to receive IMD (lnmol 
kg-I) following saline (Table 4.1). 
Under control conditions, AM (3nmol kg-I) caused a marked tachycardia, 
hypotension and increases in renal, mesenteric and hindquarters vascular 
conductances (Figure 4.3.3a). Following treatment with AM22-S2, AM-
mediated tachycardia, hypotension and hindquarters vasodilatation were not 
different from control, but there was a significant attenuation of the AM-
mediated increase in renal vascular conductance (P<0.05 for integrated 0-
30min change). Furthermore, the marked AM-mediated increase in mesenteric 
vascular conductance seen in control conditions was abolished (Figure 4.3.3a), 
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indicating a prominent role for AM22_52-sensitive receptors in AM-mediated 
vasodilatation in this region. 
In control animals, !MD (1 nmol kg-I) caused a tachycardia, small but 
significant hypotension and increases in renal, mesenteric and hindquarters 
vascular conductances. Following treatment with AM22-52, !MD-mediated 
tachycardia, hypotension and hindquarters vasodilatation were unaffected 
(P>0.05 for 0-30min responses), but IMD-mediated renal and mesenteric 
vasodilatations were significantly attenuated (P<0.05 for integrated 0-30 min 
responses) (Figure 4.3.3b). 
4.3.4 Experiment 4: Involvement of Nitric Oxide 
Prior to administration of AM or !MD, resting cardiovascular variables were 
matched in the control (AIIIAVP infused) condition and in the presence ofL-
NAME (Table 4.1). 
Administration of AM during AlII A VP co-infusion caused a marked 
tachycardia and fall in blood pressure accompanied by large increases in renal, 
mesenteric and hindquarters vascular conductances (Figure 4.3.4a). These 
responses to AM were unaffected by L-NAME (P>0.05 for the integrated 0-
30 min changes for each variable). 
In animals infused with AIl/AYP, !MD caused renal, mesenteric and 
hindquarters vasodilatations, along with a fall in blood pressure and 
tachycardia (Figure 4.3.4b). In the presence of L-NAME, there was no 
difference in the !MD-induced tachycardia or hypotension and, although there 
was some attenuation of the IMD-mediated mesenteric vasodilatation, this 
failed to reach statistical significance. However, the renal vasodilator response 
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to !MD was significantly attenuated in animals receiving L-NAME (P<0.05 
for integrated 0-30min changes) suggesting a role for NO in IMD-mediated 
vasodilatation in this region. Whilst !MD-mediated hindquarters vasodilatation 
was abolished (Friedman's test), the integrated (0-30 min) changes were not 
different between the L-NAME and AIVAVP infused conditions (Figure 
4.3.4b). 
4.3.5 Experiment 5: Involvement of KATP channels 
Resting cardiovascular variables are shown in Table 4.1. Prior to 
administration of AM, there was a significant bradycardia, hypertension and 
hindquarters vasoconstriction in U37883A-treated animals compared to the 
saline-treated condition. This pattern was also seen at baseline in animals that 
were to be given IMD except on this occasion mesenteric, but not hindquarters 
vascular conductance was significantly less in the presence of U37883A 
(Table 4.1). 
The control response to AM (3nmol kg-I) was tachycardia, hypotension and 
marked increases in renal, mesenteric and hindquarters vascular conductances, 
as described above. Following treatment with U37883A, there was no change 
in AM-mediated tachycardia, hypotension and hindquarters vasodilatation. 
However, contrary to expectation, pre-treatment with U37883A led to 
significant augmentation of AM-mediated renal and mesenteric vasodilatations 
when compared to controls (P<0.05 for integrated 0-30 min changes) (Figure 
4.3.5a). 
The control response to !MD was tachycardia, hypotension and renal, 
mesenteric and hindquarters vasodilatations, as described above, and these 
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responses were unaffected by pre-treatment with U37883A (P>O.05 for the 
integrated 0-30min changes) (Figure 4.3.Sb). 
4.3.6 Experiment 6: Interactions between NO and KATP channels 
A further group of animals (n=9) was pre-treated with L-NAME plus either 
saline or U37783A prior to administration of either .AM or IMD. Resting 
cardiovascular variables in those animals before peptide administration are 
shown in Table 4.1. Additional treatment with U37883A in the presence ofL-
NAME caused a further increase in blood pressure with hindquarters 
vasoconstriction (P<O.05), bradycardia and mesenteric vasoconstriction 
(P<O.OS in rats to be given IMD only). 
In rats treated with L-NAME together with either saline or U37883A, 
administration of AM caused tachycardia, hypotension, and marked increases 
in renal, mesenteric and hindquarters vascular conductances. The integrated 
(0-30 min) responses were not different in the absence or presence of 
U37883A, with the exception of the tachycardia which was significantly 
(P<O.05) less in the presence ofU37883A (Figure 4.3.6a). 
In rats treated with L-NAME and either saline or U37883A, IMD 
administration caused tachycardia, hypotension and increases in renal, 
mesenteric and hindquarters vascular conductances. In the presence of 
U37883A, IMD-mediated hypotension along with renal and mesenteric 
vasodilatations were significantly (P<O.05) augmented when compared to 
responses in the L-NAME and saline condition (Figure 4.3.6b). 
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4.3.7 Experiment 7: Involvement of the renin-angiotensin system 
Resting cardiovascular variables for each group are given in Table 4.1. Prior to 
administration of AM there were no differences at baseline in the control 
group and the losartan-treated group. However, prior to administration of 
IMD, blood pressure was significantly lower, and hindquarters vascular 
conductance was significantly higher, in the losartan-treated condition (Table 
4.1). 
When given to the saline-treated group, AM caused tachycardia, hypotension 
and marked increases in renal, mesenteric and hindquarters vascular 
conductances, as described above. Following pre-treatment with losartan, AM-
mediated hypotension was significantly augmented as were AM-mediated 
renal and mesenteric vasodilatations (P<0.05 for integrated 0-30 min 
changes). The augmentation of AM-mediated mesenteric vasodilatation was 
particularly marked in the presence of losartan with a maximum increase of 
-70% from baseline between 5 and 10 minutes from administration (Figure 
4.3.7a). 
In the absence of losartan, IMD caused tachycardia and marked increases in 
renal, mesenteric and hindquarters vascular conductances, as described above, 
although, in this experiment, the IMD-induced fall in blood pressure was not 
significant (Friedman'S test). Following pre-treatment with losartan, there was 
no change in the regional haemodynamic responses to IMD (Figure 4.3.7b). 
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Expt. 1 \ Expt. 2 Expt.3 Expt.4 Expt.5 
Dose 1 Dose 2 Saline CGRP Saline AM22-52 AIIIAVP L-NAME Saline U37883A 
8-37 
AM 
HR 374±18 377±21 321± 5 316±17 382±14 391±8 307±13 282±9 359±14 294±8* 
l\fAP 110±4 117±4 111±4 110±3 111±4 107±5 135±5 146±8 115±3 127±2* 
RVC 93±7 93±7 66±3 78±9 94±8 107±5 56±7 53±12 81±9 73±7 
MVC 71±8 65±7 69±11 64±11 69±11 95±14 31±3 28±5 68±4 60±6 
HVC 49±3 46±3 43±8 37±4 47±4 46±4 30±3 30±2 50±4 35±3* 
IMD 
HR 349±13 354±15 329±8 334±13 347±10 338±9 296±12 287±9 353±12 315±1O* 
MAP 111±3 108±4 107±4 113±4 113±7 114±3 133±5 138±6 113±3 129±3* 
RVC 99±9 89±8 69±4 80±8 62±8 92±9t 57±9 57±9 86±9 76±8 
l\fVC 61±5 64±6 75±12 69±9 75±11 82±9 36±5 31±5 70±4 57±4* 
HVC 49±5 48±4 42±8 37±5 43±8 36±3 35±5 34±2 45±4 37±3 
Table 4.1. Resting cardiovascular variables prior to administration of AA{ or IMD in Experiments 1-6. 
Units for vascular conductance (VC) are kHz mmHg-I x 1r!. n=5-10 group-I. 
Expt. 6 \ Expt. 7 
L-NAME L-NAME Saline Losartan 
+ 
U37883A 
285±10 267±11 355±13 369±17 
141±4 159±5* 111±2 104±4 
40±4 40±4 93±12 81±14 
34±4 26±3 77±7 83±7 
23±2 17±2* 42±5 47±5 
298±10 254±9* 336±9 355±7 
138±4 159±2* 111±2 98±4* 
41±4 39±4 90±10 105±12 
40±3 28±4* 74±4 89±9 
24±2 16±2* 37±4 50±5* 
·P<O.05 vs. control (Wilcoxon Test; paired experiment). tp<O.05 vs. control (}.fann Whitney U Test; unpaired experiment). 
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Figure 4.3.1 Effects oJrepeated dosing of (a) AM (3 nmol kg-1 iov.) (n=8) and (b) fMD (1 nmol kg-1 i.v.) (n=8) on regional haemodynamics 
in conscious ratso 
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Figure 4.3.2 Effects O/CGRP8-37 on cardiovascular responses to AA! (lnmol kg-} i.v.) (n=6) (a) or IA{D (lnmol kg-l i.v) (n=6) (b) in conscious 
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Figure 4.3.3 Effects of AM22-51 on responses to (a) AM (3 nmol kg-J i. v_) (n=8) or (b) [MD (l nmol kg-J i. v.) (n=6) in conscious rats. 
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Figure 4.3.4 Effects ofL-NAME (3mg kg-1h- l ) on cardiovascular responses to (a) AM (311mol kg-I iov.) (11=9) or (b) IMD (l11mol kg-] i.v.) (11=8) (b) in 
conscious ratso 
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Figure 4.3.5 Effects ofU37883A (5mg kg-I) on cardiovascular responses to (a) AM (3nmol kg-I i.v.) (n=9) or (b) IMD (lnmol kg-! i.v.) 
(n=9) in conscious rats. 
·P<O.05 versus original baseline (Friedman'S test). #P<O.05 versus control AJ..fIlMD responses (n=9) (Wilcoxon test) 
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Figure 4.3.6 Effects oiL-NAME (3 mg kg-J h-l) alone. and in combination with U37883A (5 mg kg-I) On cardiovascular responses to (a) 
AM (3 nmol kg-I i.v.) (n=9) or (b) IMD (1 nmol kg- l i. v.) (n=9) in conscious rats. 
*P<O.05 versus original baseline (Friedman's test). #P<O.05 versus control (Wilcoxon test) 
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Figure 4.3.7 Effects of losartan (10 mg kg-I) on the cardiovascular responses to (a) AM (3 nmol kg-I i. v.) (n=9) (b) IMD (1 nmol kg-I i. v.) 
(n=9) in conscious rats" ·P<O.05 versus original baseline (Friedman's test). #P<O.05 versus control (Wilcoxon test) 
4.4 Discussion 
Adrenomedullin is a potent vasoactive peptide which causes widespread 
vasodilatation and hypotension in vivo (Lippton et al., 1994; Gardiner et al., 
1995; Nandha et al., 1996; Parkes and May et al., 1997), and relaxation of 
vascular smooth muscle in vitro (Nuki et al., 1993; Santiago et al., 1995). The 
vasorelaxant effects of AM occur through increases in receptor-mediated 
cAMP production, release of NO and activation ofKATP channels (for review 
see Brain and Grant, 2004). Intermedin is a recently identified peptide, which 
shares some structural, sequence and functional homology with AM and is 
also called AM-2 (Roh et al., 2004; Takei et al., 2004). Mechanisms of IMD-
mediated vasodilatation have yet to be fully elucidated but are thought to 
involve the non-selective activation of CURAMP complexes and activation of 
an unidentified IMD receptor (Roh et al., 2004; Takei et al., 2004).; there is 
also limited evidence suggestive of a role for NO in IMD-mediated 
vasorelaxation in isolated rat mesenteric and pulmonary vessels (Kandilci et 
al., 2006, 2008; Chauhan et al., 2007). The aim of these experiments 
. 
therefore, was to compare the mechanisms through which AM and IMD lead 
to regional vasodilatations in conscious rats. 
Earlier studies in this thesis compared the responses of equimolar AM and 
IMD (l nmol kg-I) and found that whilst IMD caused robust responses at this 
dose, AM did not (Chapter 3). The studies described in this chapter therefore 
used AM at a dose of 3 nmol kg-I. Although it was intended that responses to 
each peptide would be matched, it was noted that throughout the course of the 
present experiments, the responses to AM (3 nmol kg-I) appeared to be 
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significantly more marked than those to IMD (1 nmol kg-I); the reasons for 
this are unclear. 
The first set of experiments described in this Chapter show there was no 
tachyphylaxis following repeated dosing of AM or IMD (Figure 4.3.1), and 
hence, the results were not affected by the AM/IMD dosing regimen used. 
Using the AM-receptor antagonist, AM22-52, evidence was found of AM22.52-
sensitive receptor activation in IMD-mediated vasodilatation in the renal and 
mesenteric beds but not in the hindquarters. This pattern is consistent with the 
observed attenuation of AM-mediated vasodilatations in those regions 
following pre-treatment with AM22-52. This suggests that in normal rats, IMD 
predominantly signals through AMI/2 receptors in the renal and mesenteric 
vascular beds. Interestingly, role was found for CGRPs.37-sensitive receptors 
in the regional vasodilator response to IMD (Figure 4.3.2b) suggesting that 
IMD was predominantly activating AM22.5rScnsitive or IMD-specific 
receptors, at least in this system. Whilst there is evidence in the literature that 
IMD action can be inhibited by AM22.52, this is somewhat limited (Ren et al., 
2006; Cui et al., 2008; Kandilci et al., 2008). Furthermore, the lack of effect of 
a CGRPI antagonist is inconsistent with studies which have shown regional 
and systemic responses to IMD were attenuated by CGRPs-37 (Kobayashi et 
al., 2004; Roh et al., 2004; Taylor et al., 2004; Kandilci et al., 2006, 2008; 
Ren et al., 2006). 
Study of the CURAMP receptor system is complicated by a lack of selective 
antagonists, and interpretation of results using these agents should be 
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approached with caution. For example, although there is evidence to suggest 
that AM22-52 is more selective for AMI (CURAMP2) than AM2 (CURAMP3) 
receptors (Hay et al., 2003), there are no tools available to discern the true 
contribution of each. AM22-52 can also inhibit CGRP-, but not AM-mediated 
vasodilatation in the cat hindlimb (Champion et al., 1997). Furthermore, 
AM22-52 by itself has weak agonist activity at AM receptors in the mesenteric 
vascular bed, leading to small vasodilatation in this region during infusion of 
the antagonist (Gardiner et al., 1999). This was also seen here and was 
apparent in baseline data (Table 4.1, Expt. 3), although the change was not 
sufficient to be significant. Adrenomedullin also has some affinity for the 
CGRPI receptor, and CGRP has some affinity for both subtypes of AM 
receptors. Thus, it has been shown that application of the selective CGRPI 
receptor antagonist, BIBN4096BS, blocked the vasodilator action of AM in 
isolated perfused murine mesentery, but not in the aorta, implicating CGRPI 
receptors in AM-mediated vasodilatation in selected regions (Grant et al., 
2004). Interpretation of results from molecular studies should also be cautious, 
as species differences in combinations of CL and RAMP have been shown to 
cause variable results (Hay et al., 2003). Nonetheless, our findings clearly 
show that both AM and IMD-mediated renal and mesenteric vasodilatations 
were attenuated by AM22-s2, suggesting AM, and/or AM2 receptors were 
activated by both peptides in a regionally-selective manner. 
In addition to a role for AM22-srsensitive receptors, an involvement for NO in 
IMD-mediated vasodilatation was demonstrated. Although it only reached 
significance in the renal vascular bed, there was a tendency for all vasodilator 
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responses to !MD to be reduced by L-NAME (Figure 4.3.4). Hence, the 
mesenteric vasodilatation was blunted, and the hindquarters vasodilatation was 
abolished in the presence of L-NAME (Friedman's test), but the integrated (0-
30 min) area was not significantly different from control. This is in line with a 
study showing sensitivity of !MD-mediated relaxation in isolated pulmonary 
and mesenteric arteries to L-NAME (Kandilci et al., 2006, 2008; C h a l ~ h a n n et 
al., 2007). Whilst it might be expected that the reduced vasodilatations would 
be manifest as an overall reduction in the blood pressure response, it is likely 
that along with the overall smaller peripheral vasodilatation, there was a 
smaller increase in cardiac output. This is consistent with studies which found 
no contribution of NO to !MD-mediated hypotension (Taylor et al., 2004; 
Abdelrahman et al., 2007). Clearly findings here demonstrate a role for NO in 
the regional haemodynamic responses to IMD, and illustrate that results can be 
misleading if only blood pressure is measured. 
No role for NO in AM-mediated vascular responses was found in the present 
study, which is at odds with previous work showing a role for NO in AM's 
action (Miura et al., 1995; Gardiner et al., 1995; Terata et al., 2000). Gardiner 
et al. (1995) found AM-mediated hindquarters vasodilatation was attenuated 
by L-NAME in conscious rats, whereas here AM-mediated hindquarters 
vasodilatation was reduced in the presence of L-NAME, but this was not 
significantly different from control conditions. However, the study by 
Gardiner et al. (1995) used a lower dose of AM (1 nmol kg-I) and compared 
integrated responses over 15 min, rather than the 30 min areas compared here. 
It is possible here that the hindquarters response to AM in the presence of L-
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NAME may have been significant if responses were compared over 15 min 
(Figure 4.3.4). 
To summarise, the present findings are consistent with activation of AM22.S2-
sensitive receptors in responses to both AM and IMD in the renal and 
mesenteric vascular beds, and a role for NO in IMD-mediated renal 
vasodilatation, and to a lesser extent in the mesenteric and hindquarters 
vascular beds. No role for NO in the vascular responses to AM was found, 
although there was a tendency for hindquarters vasodilatation to be reduced in 
the presence of L-NAME (Figure 4.3.4). Kandilci et al. (2008) showed that 
endothelial removal abolished IMD-mediated vasorelaxation in isolated rat 
pulmonary artery, consistent with our findings which suggest IMD caused 
vasodilatation via endothelial-dependent mechanisms, at least in some 
vascular beds. 
There is some evidence that the cardiovascular responses to AM are sensitive 
to glibenc1amide and U37883A, indicating a role for KATP channels (Sabates et 
al., 1997; Goto et al., 2000). However, other studies found glibenclamide had 
no effect on the vascular responses to AM (M iura et al., 1995; Terata et al., 
2000). A role for KATP channel activation in the response to IMD has not yet 
been demonstrated, although some studies have shown no effect of 
glibenclamide on the vasorelaxant response to IMD in isolated vessels 
(Kandilci et al., 2006; Chauhan et al., 2007). Blocking KATP channels with 
U37883A should attenuate peptide-mediated vasodilatation in areas where 
these channels are involved. In the present study, U37883A caused no 
attenuation of either AM or IMD-mediated responses, consistent with the 
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suggestion that KATP channels are not involved in the vasodilator responses. 
However, contrary to expectation, when AM was administered following 
treatment with U37883A, there was a significant augmentation of AM-
mediated increases in renal and mesenteric vascular conductances. Since 
administration of U37883A caused an increase in blood pressure and 
vasoconstriction, it could be that the augmented vasodilatation was due to this 
preconstricted state. However, this is unlikely, firstly, because the 
augmentation was evident when the data were analysed as absolute rather than 
% changes (data not shown), and secondly, because the augmentation was· 
regionally-selective and not seen in the hindquarters vascular bed significantly 
constricted by U37883A. Furthermore, !MD-mediated vasodilatation was not 
augmented by U37883A, suggesting that the phenomenon was unique to AM 
and not due to a change in baseline status. 
One difference between AM and !MD may be in relation to their influence on 
the renin-angiotensin system. Hypotension usually causes reflex activation of 
this system, but there is also good evidence that AM has a direct renin-
stimulatory effect on renal juxtaglomerular cells (Parkes et al., 1995; Charles 
et al., 1997, 2002; Troughton et al., 2002). Although there is no evidence for a 
similar effect of IMD, this peptide has been shown to increase aldosterone 
levels secondary to an increase in plasma renin activity (Charles et al., 2006); 
it is not known if this is a direct effect of IMD, and/or is secondary to its 
hypotensive action. Since U37883A has been shown to inhibit renin release, 
by a direct effect on renal juxtaglomerular cells (Humphrey and Ludens, 1998; 
Vallon et al., 1998), it was hypothesised that U37883A might inhibit the direct 
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AM-induced renin release, thereby augmenting the AM-mediated renal and 
mesenteric vasodilatations. To test this hypothesis, a separate group of animals 
were pre-treated with the ATI receptor antagonist, losartan, and subsequently 
given AM and IMD. Losartan pretreatment had no effect on the vascular 
responses to IMD but AM-mediated hypotension and renal and mesenteric 
vasodilatation were significantly augmented (Figure 4.3.7) in its presence, 
consistent with the above hypothesis. Although it has been suggested that AM 
might be a functional antagonist of angiotensin 11 (All) (Yamaguchi et al., 
1995; 1996; Charles et al., 1997; 2002 Troughton et al., 2000). the present 
results do not support such an effect. While the present findings indicate that 
the renin-angiotensin system did not modulate IMD action, it is possible that 
the hypotensive response to IMD in this study was insufficient to trigger a 
reflexive renin release. 
Although an involvement of KATP channels in AM or IMD-mediated 
vasodilatation was not apparent, the possibility existed that thcre may be 
cross-talk between vasodilator mechanisms such that in the absence of one 
(e.g., NO) another (e.g., KATP channels) became more active. Thus, to assess 
the overall contribution of NO and KATP channels to the vascular effects of 
AM and IMD, a group of animals were co-administered L-NAME and 
U37883A prior to peptide challenges. In this series of experiments, the 
cardiovascular responses to IMD in the presence of L-NAME and U37883A 
were surprising. Thus, rather than any expected inhibition of vasodilator 
responses, there was augmentation of IMD-mediated renal and mesenteric 
vasodilatation following combined inhibition of NOS and KATP channel 
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blockade when compared to inhibition of NOS alone. Augmentation of these 
vasodilator responses was reflected in a greater hypotension in the 
experimental group relative to control (Figure 4.3.6b). Since such 
augmentation was not seen with AM, it is plausible that increased vasodilator 
responses to !MD under these conditions were due to baseline 
vasoconstrictions and increased blood pressure which was more apparent in 
the group given !MD in the presence of L-NAME together with U37883A, 
than in the group given AM under those conditions. Consistent with this 
suggestion, the increase in mesenteric vascular conductance was not 
augmented when the data were analysed as absolute rather than % changes. 
However, this does not explain the enhanced response observed to IMD in the 
renal vasculature following NOS inhibition and KATP channel blockade, since 
there was not an enhanced baseline renal vasoconstriction under these 
conditions. There is some evidence that IMD can directly activate large-
conductance Ca2+-activated K+-channels (BKca channels) (Kandilci et al., 
2006, 2007; Chauhan et al., 2007); these channels can also be activated by NO 
leading to hyperpolarisation and relaxation of vascular smooth muscle. During 
treatment with L-NAME therefore, the proportion of closed BKca channels 
may increase due to the removal of an activating stimulus, as a result of which 
there may be an increased number of "available' channels which !MD can 
activate leading to augmentation of lMD-mediated vasodilatation in those 
vascular beds, which have a high popUlation of BKca channels. Whilst L-
NAME by itself attenuated IMD-mediated vasodilatation, the conflicting 
results upon addition ofU37883A may have been due to an enhanced response 
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to IMD in the presence of a 'depolarised' environment; this clearly warrants 
further investigation. 
Another surprising observation was that blockade of KATP channels during 
NOS inhibition attenuated AM-mediated tachycardia when compared to 
animals treated with L-NAME alone. This suggests that cardiac K ATP channels 
were activated in a cAMP-PKA-dependent manner by AM, which is 
surprising as U37883A is believed to be selective for vascular KA TP channels 
(Surah-Narwal et al., 1999; Wellman et al., 1999) and U37883A does not have 
such an effect when given alone. This response is unrelated to differences in 
baseline heart rate; when absolute changes are compared, the differences 
remain significant regardless of some differences at rest (Table 4.1). 
Furthermore, as the addition ofU37883A had no effect on the blood pressure 
response to AM, this attenuated tachycardia was unlikely due to reduced 
sympathetic activation. This is consistent with the findings of ValIon et al. 
(1998). 
In conclusion, the present studies identified a role for AM22.srsensitive 
receptors in mediating IMD action in the renal and mesenteric vascular beds, 
and a role for NO in the renal vascular bed, and to a lesser extent in the 
mesenteric and hindquarters vascular beds. To further assess the contribution 
of AM and CGRP receptors, the two fragments (AM22-s2 and CORPs-37) could 
be given together. Since AM responses sensitive to AM22-S2 were apparent in 
the renal and mesenteric vascular beds, like those of IMD, it is plausible that 
effects in these regions that have previously been attributed to AM may have 
in part been mediated by IMD activating the same receptors. Again, the lack 
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of suitable antagonists of this system will hinder further research into this area 
until agents that are more selective are produced. 
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Chapter 5 
Results (Ill) 
Regional haemodynamic effects of 
adrenomedullin and intermedin in 
lipopolysaccharide-treated rats 
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Summary 
The experiments described in this chapter aimed to investigate the regional 
and temporal haemodynamic responses to AM and IMD in LPS-treated rats, as 
others (Wang et al., 1999) have shown a change in vascular responsiveness to 
AM in animal models of sepsis. 
Male, Sprague-Dawley rats were implanted with Doppler flow probes to 
measure renal, mesenteric and hindquarters blood flows; catheters were 
implanted in the jugular vein, caudal artery and i.p. to allow administration of 
substances. Responses to bolus doses of LPS (lmg kg-l and 3mg kg-l i.p.) or 
LPS infusion (151lg kg-l h-l) were assessed in conscious rats, and vascular 
responses to AM and IMD were determined. 
Following LPS administration (Img kg-I, i.p), there was a marked loss of 
responsiveness to AM and IMD in the renal, mesenteric and hindquarters 
vascular beds at 1.5h, with some recovery at 6h. At 25h, AM and IMD-
induced increases in renal and mesenteric vascular conductances were normal, 
but there remained some hyporesponsiveness in the hindquarters. To assess 
the contribution of the LPS administration protocol, the experiment was 
repeated in animals treated with a continuous low dose infusion of LPS. In this 
model, vascular responsiveness to AM and IMD was still evident at 1.5 h but 
had returned by 6 h. At 25 h there was some enhancement of the vascular 
responses to both peptides which may have been related to an increase in 
resting vascular tone. 
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These results suggest that loss of vascular responsiveness to AM and IMD is 
an early event following LPS-administration in conscious rats. The 
mechanisms responsible for this vascular hyporesponsiveness remain to be 
determined. 
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5.1 Introduction 
The calcitonin family of peptides, including AM and the recently discovered 
!MD, are involved in cardiovascular and renal homeostasis, and studies 
indicate that AM is significantly upregulated in di,sorders affecting the 
cardiovascular system, including sepsis (for review see Ishimitsu et al., 2006; 
Bell & McDermott, 2008, and Introduction). 
Lipopolysaccharide (LPS) is found in the cell wall of Gram-negative bacteria 
and is believed to be involved in the pathogenesis of human Gram-negative 
endotoxaemia. When LPS is administered to experimental animals at an 
appropriate dose, it causes pathophysiological changes that mimic those seen 
in clinical patients, including those with a hyperdynamic circulation (for 
review see Parker & Watkins, 2001). Thus, LPS is used to study the 
cardiovascular sequelae of early sepsis. Gardiner et al. (1995) developed an 
experimental model of hyperdynamic endotoxaemia by continuously infusing 
Long Evans rats with LPS (150llg kg-I h-I) over 32 h (Wall er et al., 1994; 
Gardiner et al., 1995). This model was characterised by a biphasic tachycardia 
and hypotension, with renal, mesenteric and hindquarters vasodilatations, the 
pattern of which changed across time. There was a progressive increase in 
cardiac and stroke index, and total peripheral conductance, 3 h from the onset 
of LPS infusion (Gardiner et al., 1995). This model has since been used to 
assess the involvement of a variety of endogenous mediators during rat 
endotoxaemia (see Chapter 1, Table 1.2) (Wall er et al., 1994; Gardiner et al., 
1996; Bennett et al., 2004). 
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A role for the calcitonin family peptide adrenomedullin (AM), in influencing 
cardiovascular function in sepsis has been suggested, since high AM plasma 
levels have been seen in clinical patients (Wang, 2001), and AM mRNA and 
protein levels are upregulated following LPS-treatment in vivo (Shoji et al., 
1995; Hattori et al., 1998; Yang et al., 2001; Cheung et al .. 2004; Li et al., 
2005) and in vitro (Sugo et al., 1995; Zaks-Zilberman et al., 1998). Evidence 
suggests that AM has some involvement in the development of a 
hyperdynamic circulation in early sepsis (Wang et al .• 1999; Koo et al., 2001) 
and that the transition to a hypodynamic circulation in late sepsis may be due 
to a decrease in vascular sensitivity to the peptide (Wang et al., 1999; Ertmer 
et al., 2007). Furthermore, mice heterozygous for the AM gene have increased 
sensitivity to the inflammatory effects of LPS (Dackor & Caron, 2007), whilst 
mice over expressing AM in their vasculature, are resistant to some of the 
deleterious effects of LPS (Shindo et al., 2000). Since the newly discovered 
member of the calcitonin family IMD shares some sequence and structural 
homology with AM, can activate AM receptors, and has an effect on the 
cardiovascular system comparable to that of AM (Roh et al., 2004; Takei et 
al., 2004; see Chapters 3 & 4), it is possible that IMD may share some of the 
functions of AM during sepsis, although IMD has yet to be studied in this 
context. 
The aims of this study were, therefore, to establish whether or not regional 
vascular sensitivity to the vasodilator effects of AM and IMD were affected 
across time, in LPS-treated rats. But it was first necessary to establish the 
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optimal LPS dosing regimen in Sprague Dawley rats. In their study, Gardiner 
et al. (1995) used Long Evans rats bred in house in Nottingham, but, as these 
were not available at the onset of the present work, outbred Sprague Dawley 
rats were obtained from Charles River UK. For some reason, the latter were 
very sensitive to the effects of LPS leading to an unacceptable number of 
deaths when it was given at a dose of 150Jlg kg-I h· l . Thus, studies were first 
completed to determine an appropriate LPS-administration protocol in this 
strain, prior to an evaluation of the effects of repeated administration of AM 
and IMD across time following LPS administration. 
Because the results of the studies with AM and IMD showed reduced vascular 
sensitivity to the peptides during early sepsis (i.e., 1.5 h, see later), a time 
when endogenous AM levels have been shown to be elevated (for review sce 
Wang et al., 1999), a further experiment was conducted using the AM reccptor 
antagonist, AM22-s2. to assess the role of endogenous AM in the 
haemodynamic changes 1.5h after LPS administration. 
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5.2 Methods 
The following experiments were performed in 9 groups of Sprague-Dawley 
rats, prepared for haemodynamic recording with the 2-stage surgical procedure 
outlined in Chapter 2. Briefly, animals were anaesthetised and chronically 
implanted with miniature pulsed Doppler flow probes which were sutured 
around the left renal artery, the superior mesenteric artery and the distal aorta, 
to measure changes in renal, mesenteric, and hindquarters Doppler shift; this 
was used as an index of blood flow. After a recovery period of 10-14 days, 
animals were again anaesthetised and implanted with catheters (La, Lv, & Lp.) 
to allow continuous derivation of blood pressure and heart rate, and 
administration of substances. 
5.2.1 Experiment 1: Cardiovascular effects of LPS administration hy i.p. 
holus or i. v. infusion 
To determine the optimum LPS dosing regime for producing an hyperdynamic 
circulation in Sprague Dawley rats, 3 separate groups of animals received 
either LPS given as an Lp. bolus at a dose of Img kg-! (n=9) or 3mg kg- t 
(n=8), or a saline bolus (O.Sml i.p.) (n=7). A further group of animals received 
a saline infusion (0.4 ml hot) for 25 h beginning on Day 1, and a continuous 
LPS infusion for 25 h beginning on Day 3, at a dose of 15Jlg kg-I h-I i.v. which 
is to-fold lower than that used by Gardiner et al. (1995). Cardiovascular 
variables were measured for up to 26 h. 
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5.2.2 Experiment 2: Cardiovascular responses to At./IIMD ill 
ell dotoxaemia 
5.2.2.1 Cardiovascular responses to AMI/MD following bolus administration 
ofLPS 
In the light of results from the experiment above (see Results), the following 
protocols administered LPS as an Lp. bolus at a dose of Img kg-I. 
To assess whether the regional haemodynamic responses to AM or IMD were 
affected in a time-dependent manner during endotoxaemia, rats were treated 
with saline (O.5ml i.p.) at time 0 on Day 1 (as outlined in Chapter 3.2), or LPS 
(lmg kg-I i.p.) at time 0 on Day 3, and challenges of AM (3nmol kg-I) (n=9) 
or IMD (lnmol kg-I) (n=9) were given at 1.5 h, 6 hand 25 h after saline or 
LPS administration. These time points were chosen as they represent a time 
when a hyperdynamic circulation was beginning to develop (1.5 h), was fully 
developed (6 h) or when cardiovascular variables were starting to return to 
nonnal (25 h) (see later). This protocol is illustrated in Figure 5.2.2. 
Day} Day 2 
Oh l.5h 6h 25 h 
t t t 
11 
71 t 
Saline bolus AMlIMD AMlIMD AMlIMD 
Day 3 Day 4 
Oh 1.5h 6h 25 h 
t t f // f 
LPS bolus AMlIMD AMlIMD AMlIMD 
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Figure 5.2.2 Animals received AM or /MD 1.5 h, 6 hand 25 hfrom 
administration of saline at time 0 on Day 1, and LPS at time 0 h on Day 3, 
5.2.2.2 Cardiovascular responses to AMI/MD during a continuous infusion 
ofLPS 
The above experimental protocol was repeated in 2 separate groups of animals 
(n=lO each group) in the presence of a continuous Lv. infusion of saline 
(O.4ml hot) or LPS (15JLg kg-t h- l Lv.). Each animal received 1 peptide 
throughout the course of the experiment. The LPS infusion protocol followed 
is shown in Figure S.2.2a. 
Day 1 Day 2 
Oh 1.5h 6h 25 h 
1/ • f t f 
Saline infusion AMlIMD AMlIMD AMlIMD 
Day 3 Day 4 
Oh 1.5h 6h 25 h 
1/ • f f f 
LPS infusion AMlIMD AMlIMD AMlIMD 
Figure S.2.2a A continuous 26 h infusion ofsaline began at time 0 on Day 1, 
and LPS at time 0 h on Day 3. Animals were administered AM or /MD 1.5 h, 6 
hand 25 h after the onset of the infusion. 
157 
5.2.4 Experiment 3: Cardiovascular responses to AMl1-S1 in LPS-treated 
rats 
To assess whether endogenous AM contributed to the haemodynamic profile 
in LPS-treated rats, a separate group of animals (n=8) were infused with the 
AM fragment, AM22-s2 (SOOnmol kg-1 h-1), for 6 min, beginning 1.5 h, 6 h and 
25 h after LPS treatment (lmg kg-1 i.p. bolus). This fragment has some 
selectivity for AM-sensitive receptors and is currently the only available AM 
receptor antagonist (for review see Poyner et al., 2002). The dose chosen has 
been shown to antagonise some of the cardiovascular effects of exogenous 
AM (Chapter 4). This protocol is illustrated in Figure 5.2.4. 
Day 1 Day 2 
Oh 1.S h 6h 25 h 
6 min 6min 6 min 
t Ft fl fi-
LPS bolus AM22-S2 AM22-S2 AM22-S2 
Figure 5.2.4 Animals were treated with a LPS bolus at time 0 h, and were 
administered AM22-521.5 h, 6 hand 25 h later. 
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5.3 Results 
5.3.1 Experiment 1: Cardiovascular effects of LPS administration 
Baseline cardiovascular variables in groups of animals that were to receive 
LPS at a dose of 1mg kg-} or 3mg kg-}, or saline are shown in Table S.l. Prior 
to bolus administration of LPS (lmg kg-} i.p.) there was a slightly higher 
resting heart rate, and lower resting renal vascular conductance, in comparison 
to the group who were to receive saline (P<O.OS, Kruskall Wallis test). 
5.3.1.1 Cardiovascular changes/ollowing treatment with saline (O.5ml i.p.) 
In animals given a saline bolus, there was a small rise in blood pressure 
(P<O.05, 24 h to 25 h) and a progressive hindquarters vasoconstriction from 6 
h onwards, but no other changes in haemodynamics during the 26 h recording 
period (Figure 5.3.1). 
5.3.1.2 Cardiovascular changes/ollowing treatment with LPS (1 mg kg-I i.p.) 
Cardiovascular changes 0-25 h following administration of LPS (lmg kg-! i.p. 
bolus) are shown in Figure 5.3.1. There was a tachycardia relative to the 
original baseline (P<O.05, Friedman's test), which was sustained over the first 
8 h, peaking 6h after LPS administration, but by 25 h the resting heart rate was 
no longer different from baseline (P>O.05, 24 hand 25 h). The tachycardia 
was accompanied by a triphasic blood pressure response, comprising an early 
rise (P<O.OS, 0.25 hand 0.5 h) followed by a fall (P<0.05, 1 h to 1.75 h), with 
blood pressure returning to baseline by 2h. There was then a second period of 
hypotension (P<O.OS, 5 h to 7 h), after which blood pressure returned to 
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baseline. In the renal vascular bed, there was a sustained increase in vascular 
conductance which remained elevated relative to original baseline (P<0.05, 
Friedman's test) from 0 to 24 h after LPS-administration. Changes in the 
mesenteric and hindquarters vascular beds mirrored the changes in blood 
pressure. That is, an early (0.25 to 0.5 h) transient vasoconstriction (P<0.05 in 
the hindquarters), followed by a marked transient vasodilatation (P<0.05, 1 h 
to l.25 h in the mesentery, and 1 h to 2 h in the hindquarters), before returning 
to baseline (hindquarters), or a second phase of vasoconstriction (mesenteric). 
Both vascular beds underwent a second phase of vasodilatation (P<0.05, 5 h 
to 8 h), with vascular conductance returning to baseline levels by 24 h. 
5.3.1.3 Cardiovascular changes following treatment with LPS (3mg kg" i.p.) 
Cardiovascular changes 0-25 h following administration of LPS (3mg kg-· i.p. 
bolus), are shown in Figure 5.3.l. Responses to LPS at this dose were similar 
to those seen with Img kg-\, comprising a sustained tachycardia (P<0.05, 0 h 
to 8 h) which was accompanied by a triphasic blood pressure response. There 
was a sustained increase in renal vascular conductance, which remained 
elevated relative to original baseline Ih from LPS onwards (P<0.05, 1 h to 25 
h). Changes in the mesenteric and hindquarters vascular beds followed the 
triphasic pattern observed using the lower dose of LPS, except the early 
mesenteric vasoconstriction was more marked (P<O.05, 1.25 h to 1.75 h) and 
the first phase of mesenteric vasodilatation was less marked than that seen at 
the lower dose (P>0.05, 1 h to 1.5 h) In the hindquarters, the second phase of 
vasodilatation was sustained for the remainder of the recording period 
(P<0.05, 5 h to 25 h). 
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Since LPS at a dose of Img kg-l caused widespread vasodilatations which 
were similar to those caused by LPS at a dose of 3mg kg-l, with relatively 
small changes in blood pressure this was the bolus LPS dose used in 
subsequent experiments. 
5.3.1.4 Cardiovascular changes during a continuous saline or LPS infusion 
(15J.lg kg-I h-I) 
Baseline cardiovascular variables were not different between animals prior to 
the onset of a LPS infusion or a saline infusion; these baseline data are shown 
in Table 5.1. 
The only significant deviation from baseline in saline infused rats was a fall in 
hindquarters vascular conductance from 24 h to 25 h (Figure 5.3.1 a). 
A continuous infusion ofLPS (l5J.lg kg-l hot) caused a tachycardia, which was 
sustained for the entire recording period (P<0.05, Friedman's test) and a 
transient hypotension (P<0.05, 1.25 to 1.75 h). An increase in renal vascular 
conductance was sustained from 0.75 h onwards, whilst mesenteric vascular 
conductance was reduced from 1.5 h to 5.5 h, and hindquarters vascular 
conductance was transiently elevated between 1 hand 2h , and again between 
24 h and 25 h (P<O.05, Friedman's test). 
At the 1.5 h time-point, regional haemodynamics were similar between those 
animals given LPS as a bolus (Img kg-) and 3mg kg-I), and those given LPS as 
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an infusion, except that in the latter there was no change in mesenteric 
vascular conductance. At 6 h the haemodynamic profile in groups treated with 
bolus LPS were similar, but differed from that observed in the LPS-infused 
group inasmuch as the latter displayed no deviation from baseline in blood 
pressure, mesenteric or hindquarters vascular conductance. At 25 h, animals 
given LPS as an infusion were tachycardic ar.d vasodilated in all 3 vascular 
beds, whilst those administered LPS as a bolus were no longer tachycardic, or 
vasodilated in the mesenteric (both LPS doses) or the hindquarters (lmg kg-t 
only) vascular beds. 
5.3.2 Experiment 2: Regional haemodynamic responses to A ~ I I and I ~ / D D
in endotoxaemia 
Baseline cardiovascular measurements were taken in all groups of animals 
before the onset of either saline bolus or infusion or LPS bolus or infusion to 
determine whether there were any differences bctween the groups at rcst 
(Table 5.2, 0 h). The only significant differences were a lower resting heart 
rate prior to LPS bolus administration in the AM group, and a lower renal 
vascular conductance prior to LPS bolus administration in the IMD group 
(P<O.05). 
5.3.2.1 Cardiovascular responses to AMI/MD follOWing an LPS bolus 
Resting values for cardiovascular variables prior to administration of AM 
(3nmol kg-t) 1.5 h, 6 hand 25 h after LPS are given in Table 5.2, and all 
baseline data for experiments in this chapter are summarised in Table 5.3. 
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Control responses to AM in the presence of saline are detailed in Chapter 3; 
briefly, AM (3nmol kg-I) caused tachycardia, a significant fall in blood 
pressure and marked increases in renal, mesenteric and hindquarters vascular 
conductances (Figure 3.3.1). At 1.5 h after administration of LPS (Img kg-1 
i.p.), all cardiovascular responses to AM were blunted (P<O.05 for 0-lOmin 
integrated changes for all variables), the effect being particulady marked in 
the mesenteric and hindquarters vascular beds. At 6 h after LPS, the AM-
induced tachycardia and mesenteric and hindquarters vasodilatations remained 
significantly attenuated compared to control but the renal vasodilatation and 
blood pressure response were no longer different between the groups (P<0.05 
for 0-10 min integrated changes). At 25 h after LPS, the AM-induced increase 
in hindquarters vascular conductance remained reduced in the LPS group but 
there were no other differences between the groups (Figure 5.3.2). 
Resting cardiovascular variables prior to administration of IMD 1.5 h (n=9), 6 
h (n=9) and 25 h (n=9) following saline or LPS bolus administration are 
shown in Table 5.2, and summarised in Table 5.3. 
Control responses to IMD in saline-treated animals are detailed in Chapter 3, 
and comprised a tachycardia, fall in blood pressure and increases in renal, 
mesenteric and hindquarters vascular conductances (Figure 3.3.1). At 1.5 h 
after LPS administration, all cardiovascular responses to IMD were 
significantly attenuated (P<O.05, for O-lOmin integrated changes), this effect 
being most marked in the mesenteric and hindquarters vascular beds where 
IMD-mediated vasodilatations were abolished. Six h after LPS, all 
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cardiovascular responses to IMD remained attenuated but these effects only 
reached significance in the mesenteric and hindquarters vascular beds 
(P<0.05, for O-lOmin integrated changes). At 25 h, the hindquarters 
vasodilator response to IMD remained attenuated (P<0.05), but all other 
responses were not different from those in the saline condition. At this 
juncture, the IMD-mediated fall in blood pressure appeared to be augmented, 
but this effect was not significant (Figure 5.3.3). 
To assess the effects of the mode of LPS administration on vascular responses 
to AM and IMD the above experimental protocol was repeated in animals 
given a continuous LPS infusion (l5JLg kg'l h'l i.v.) . 
5.3.2.2 Cardiovascular responses to AMI/MD during an LPS infusion 
Resting cardiovascular variables prior to the onset of either a saline or LPS 
infusion were not different in those animals that were to receive AM or those 
that were to receive IMD (Table 5.2). Baseline cardiovascular variables prior 
to administration of AM at 1.5 h, 6 hand 25 h are given in Table 5.2, and 
summarised in Table 5.3. 
At 1.5 h from the onset of LPS infusion, all cardiovascular responses to AM 
were significantly attenuated (P<O.05, for 0-10min integrated changes for all 
variables), with AM-mediated vasodilatations in the mesenteric and 
hindquarters vascular beds being most affected. At 6 h, the renal and 
hindquarters vasodilator responses remained attenuated in the LPS-group, 
whilst the mesenteric vasodilatation and tachycardia were no longer 
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significantly altered from control (P>0.05 for 0-10 min integrated changes). 
Interestingly, at 25 h, AM-mediated vasodilatations in the renal and 
mesenteric vascular beds were augmented, but this only reached statistical 
significance in the latter (P<0.05 for 0-10 min integrated changes) (Figure 
5.3.4). 
Baseline cardiovascular measurements 1.5 h, 6 h and 25 h from the onset of a 
saline or LPS infusion in those animals that were to receive IMD are shown in 
Table 5.2, and summarised in Table 5.3. 
When IMD was administered 1.5 h after the onset of LPS infusion, there was 
attenuation of cardiovascular responses to IMD (Figure 5.3.5), with IMD-
mediated mesenteric and hindquarters vasodilatations being abolished. IMD 
• 
caused renal, mesenteric and hindquarters vasodilatations at 6 h which were 
not different from controls, although the tachycardia was significantly 
attenuated whilst the hypotensive response was significantly augmented 
(P<0.05, for 0-10 min changes). In the absence of any enhancement of the 
vasodilator effects of IMD this last result is surprising, but an enhanced IMD-
mediated hypotension was also seen in the LPS groups at 25 h (P<0.05 for 0-
10 min integrated changes), although IMD-mediated renal and mesenteric 
vasodilatations were not significantly enhanced (P>0.05 for 0-10 min 
integrated changes). There was no difference in the IMD-induced tachycardia 
and there was an attenuated vasodilator response in the hindquarters (P<0.05, 
for 0-10 min changes). 
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5.3.3 Experiment 3: Cardiovascular responses to AMzz-5Z in LPS-treated 
rats 
The AM fragment, AM22-52. was used to assess the possible contribution of 
endogenous AM acting at AM22-52-sensitive receptors in LPS-treated rats. 
Prior to administration of AM22-52, there were vasodilatations in the renal and 
hindquarters, but not in the mesenteric, vascular beds (data not shown). At 1.5 
h after LPS, infusion of AM22-52. at a dose shown to antagonise the effects of 
exogenous AM (500nmol kg-1 h-1) (Chapter 4), had no effect on the 
developing, LPS-induced changes in regional haemodynamics (Table 5.4). 
The only significant difference between those animals receiving AM22-52 1.5 h 
after LPS and the time- matched LPS controls was a small tachycardia in the 
AM22-52 group 10 min from the end of the infusion (Table 5.4). 
When AM22-52 was given 6 hand 25 h after LPS (lmg kg-1 i.p.) administration, 
there were no changes in any haemodynamic variable throughout the course of 
AM22-52 infusion at either time-point (Table 5.5). However, lack of a suitable 
LPS time control for these experiments did not permit a full analysis of these 
data; this is acknowledged as a draw-back to this study. 
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Bolus protocol (i.p.) Infusion protocol (i. v.) 
Saline LPS LPS Saline LPS 
(O.5ml) (lmg kg'l) (3mg kg'l) (O.4ml h'l) (15/lg kg'l h'l) 
HR(beats/min) 337±1O 359±7* 349±7 356±11 356±12 
MAP(nunHg) 103±3 107±2 111±4 113±2 114±3 
RVe (units) 97±11 72±7* 91±5 69±5 69±6 
MVe units) 76±10 66±6 62±1 58±7 50±8 
HVC (units) 48±6 41±2 40±5 49±5 45±5 
Table 5.1 Resting cardiovascular variables in groups of rats prior to bolus 
administration of saline (O.5ml i.p.) (n = 7), LPS at a dose of Img kg'! ip. (n=9) or 
3mg kg"l (n=8), and prior to the onset of a saline (O.4ml h'l i. v.) or LPS (15/lg kg,l h'l 
i. v.) infusion in a separate group of rats (n = 10). 
VC=vascular conductance. Units for vc are kHz mmHg'! x J(I. ·P<O.05 vs. saline bolus 
(Kruskall-Wallis test) 
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HR (beats/min) MAP (mmHg) RVe (units) MVC (units) HVe (units) 
Sal LPS Sal LPS Sal LPS Sal LPS Sal LPS 
AM (LPS bolus) Oh 350±5 312±5* 107±2 lO4±2 66±4 66±5 65±5 66±5 45±3 42±3 
1.5h 342±9 434±1O* lO9±3 lOl±3 66±5 81±8 64±5 55±5 46±4 59±4 
6h 351±1l 405±9* lO7±2 98±3* 66±5 97±9* 57±5 85±8* 43±3 60±5* 
25h 351±1l 358±13 114±3 lO7±4* 64±5 81±6* 57±3 71±7* 40±3 57±3* 
AM (LPS infusion) Oh 349±11 354±15 111±2 lO6±3 92±9 90±9 69±6 67±6 48±4 46±1 
1.5h 344±9 400± 13 * lO8±3 9S±4* 98±9 122±lS* 76±9 63±6 4S±6 77±7* 
6h 3S0±9 387±11* 112±2 116±5 94±7 122±12* 69±8 47±5* 43±5 41±7 
25h 342±15 377±17 lO7±3 126±6* 93±8 100±13 66±7 47±7 46±6 52±8 
IMD (LPS bolus) Oh 340±S 334±7 112±3 111±3 94±10 78±8* 67±5 67±6 38±3 34±3 
1.5h 340±8 414±16* 112±4 lO4±4 90±10 lO2±7 71±5 59±9 37±4 46±6 
6h 340±1O 413±16* 111±3 103±3 93±9 126±9* 64±6 86±8* 34±S 49±5* 
25h 323±10 347±8 117±3 111±4 77±7 lO0±7* 57±6 66±6* 29±3 S0±6* 
Oh 339±7 333±lS lO6±l 104±2 84±12 81±12 74±5 77±5 52±6 43±5 
IMD (LPS infusion) 1.5h 339±9 445±lO* lO8±2 96±3* 76±9 lO3±17 66±4 54±6 49±4 75±7* 
6h 348±13 422±12* lO7±3 114±5 S0±8 100±7* 65±4 58±9 43±3 39±5 
25h 337±9 403±22 lO8±1 122±3* 7S±9 81±12 71±5 55±8* 44±4 47±6 
Table 5.2. Resting cardiovascular variables, at selected time points, prior to administration of AM or [MD in rats treated with a 
salinelLPS bolus (lmg kg-I) and a salinelLPS infusion, n=8-10Igroup 
Units/or vascular conductance (VC) are kHz mmHg-1 x ](1. *P<O.05 vs. Saline (Wilcoxon test). 
(a) LPS bolus 
Control AM group IMD group 
1.5h 6h 25h 1.5h 6h 25h 1.5h 6h 25h 
HR (beats min -1) t t +-+ t t +-+ t t +-+ 
MAP (mmHg) ~ ~ +-+ +-+ +-+ t t +-+ +-+ +-+ 
RVe (units) t t ( t) +-+ t t +-+ t t 
MVe (units) t t +-+ +-+ t t +-+ t t 
HVe (units) t t +-+ +-+ t t +-+ t t 
(b) LPS infusion 
Control AM group IMD group 
1.5h 6h 25h 1.5h 6h 25h 1.5h 6h 25h 
HR (beats min -1) t t t t t t t t t 
MAP (mmHg) ~ ~ +-+ +-+ t +-+ t ~ ~ +-+ t 
RVe (units) t t t t t t t t +-+ 
MVe (units) t t +-+ +-+ t +-+ +-+ +-+ t 
HVe (units) t +-+ t t +-+ +-+ t +-+ +-+ 
Table 5.3 Summary of baseline cardiovascular variables at selected time 
points after administration of (a) bolus LPS (lmg kg-I) (b)from the onset of 
LPS infusion (l5Jlg kg- I h-I), in control groups and in animals that were to 
receive peptide challenges. 
+-+ denotes that there was no change in that variable vs. saline time control; t 
denotes an increase and t a decrease. 
VC=vascular conductance. Units for vc are kHz mmHg-1 x 1 rt. 
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+1-AM22-S2 infusion Time from end of infusion 
start end 5min lOmin 15min 20min 25min 30min 
HR (beats/min) +AM22-S2 425±lO 424±IO 415±8 414±8* 436±5 441±8 443±6 446±8 
-
AM22-S2 429±9 435±6 434±9 436±lO 433±11 452±11 455±11 453±11 
MAP (mmHg) +AM22-S2 lO3±3 lO7±4 lO8±3 I08±3 I06±2 I08±4 107±3 105±3 
-AM22-S2 I02±3 I08±2 110±2 111±3 111±2 113±3 111±4 110±4 
RVC (units) +AM22-S2 96±14 95±15 96±15 95±15 lOO±l6 100±15 103±16 lO4±16 
-AM22-S2 88±8 87±9 86±8 85±9 87±8 88±9 84±7 88±7 
MVC (units) + AM22-S2 62±9 47±7 46±7 47±8 47±8 48±7 53±9 55±8 
-AM22-S2 64±9 50±7 45±5 42±4 45±4 46±4 46±3 49±3 
HVC (units) +AM22-S2 62±5 53±6 52±6 50±5 51±5 50±5 52±6 54±6 
-AM22-S2 54±4 48±4 47±4 44±4 45±4 41±3 42±4 41±4 
Table 5.4 Cardiovascular variables 1.5 h after treatment with LPS, in the presence (n=8) and absence (n=8) of AM2Z-52 (500nmol kg-1 h-1,for 6 
m in). Units for vascular conductance (VC) are kHz mmHg-1 x 1 rl. 
·P<O.05 vs. LPS time control (Mann Whitney U test). 
HR (beats min- l ) 6h 
25h 
MAP (mmHg) 6h 
25h 
RVe (units) 6h 
25h 
MVC (units) 6h 
25h 
HVC (units) 6h 
25h 
AM22-S2 infusion 
Start 
426±7 
386±9 
97±5 
105±3 
113±20 
99±15 
113±14 
86±9 
65±10 
56±7 
End 
444±10 
407±12 
101±5 
105±5 
113±5 
104±16 
111±14 
94±1 
65±10 
55±6 
Table 5.5 Cardiovascular changes at the beginning and end 0/ AM22-52 
(500nmol kg-J h-J,/or 6 min) administration, 6 hand 25 h (n=8, each time 
point) from LPS-treatment in conscious rats. 
VC=vascular conductance. Units for vc are kHz mmHg"1 x 1 rI. 
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Figure 5.3.1 Cardiovascular changes in Sprague-Dawley rats, over 25 h following 
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.P<O.05 versus original baseline (Friedman's test) 
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Figure 5.3.5 Integrated (0-10min) cardiovascular changes following IMD (1nmol kg-J Lv.) administration (a) 1.5 h (n=8), (b) 6h (n=9) and (c) 
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5.4 Discussion 
Clinical sepsis is associated with a complex haemodynamic profile. the nature 
of which changes as the severity of the disorder increases. Animal models 
have attempted to mimic some of the haemodynamic manifestations of clinical 
sepsis. commonly using administration of LPS. Whilst high doses of LPS 
reportedly lead to the development of an hypodynamic circulation and rapid 
cardiovascular collapse (for review see Buras et al., 2005), lower doses lead to 
the development of an hyperdynamic circulation which is often observed 
during early clinical sepsis. The present chapter describes the haemodynamic 
profiles associated with three LPS administration protocols in conscIOus. 
Sprague-Dawley rats. 
Each 'model' described here was associated with tachycardia (0-8 h for LPS 
bolus; 0-25 h for LPS infusion), an early, transient fall in blood pressure. 
sustained renal vasodilatation and a biphasic hindquarters vasodilatation. The 
response in the mesenteric vascular bed differed such that that there was a 
biphasic vasodilatation in response to bolus administration of LPS, but a 
marked vasoconstriction (from 1-5 h) when LPS was given as an infusion. The 
mesenteric vascular response in Long-Evans rats infused with LPS at a dose 
lO-fold higher than that used here (Le. 150 Jlg kg-t hot). was somewhat 
intermediate between the different responses reported here, comprising a small 
vasoconstriction from 2-3 h. followed by a small vasodilatation (Gardiner et 
al., 1995). Thus, the response to LPS in this vascular bed appears to be the 
most variable. At the 24 h time-point, the LPS-infused (15Jlg kg-t hot) group 
was dilated in all 3 vascular beds. and was tachycardic, although 
normotensive, thus displaying the hallmarks of a hyperdynamic circulation. 
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Animals given LPS as a bolus were normotensive and somewhat vasodilated 
at 24h, as were the Long-Evans rats studied by Gardiner et al. (1995). 
Regional and temporal differences in vascular conductance suggest that 
opposing vasodilator and vasoconstrictor systems are differentially regulated 
depending upon the LPS administration protocol. 
Since LPS caused changes in haemodynamics which were both regionally and 
temporally variable (see above), peptide challenges were assessed at multiple 
time points from the onset of sepsis to determine whether responses were 
affected in a time-dependent manner. The time points chosen were 1.5 h from 
LPS, representing the first phase of hypotension and vasodilatation, at 6 h, 
representing the second phase of hypotension and vasodilatation, and at 25 h, 
when haemodynamics were stable (infusion model) or are beginning to return 
to normal (bolus model). 
The LPS-administration protocols used in the present study were assessed 
because Sprague-Dawley rats turned out to be more sensitive to the effects of 
LPS than were the Long-Evans rats studied previously in the Nottingham 
Haemodynamics Laboratory (Gardiner et al., 1995). Furthermore, it became 
clear there were differences in the cardiovascular responses to LPS between 
groups in the present study (summarised in Table 5.3). Thus, the control LPS 
bolus (lmg kg-I) group was widely vasodilatated and hypotensive at the 1.5 h 
time point, whilst the LPS-treated groups which were to be administered 
peptide, were not. Since the latter received LPS on Day 3 after catheter 
implantation, and the control LPS group received LPS on Day 1 (see section 
5.2), it is feasible that the differences were due to the different times elapsed 
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after anaesthesia and surgery. Furthennore, whilst the LPS control group were 
naIve to peptides, the AM and IMD groups were not, since these were paired 
experiments, this may also help to explain the baseline differences between the 
groups. Although the haemodynamic response to LPS was qualitatively 
similar between groups, it was not always quantitatively the same at any given 
time point, and this is acknowledged 2.S a drawback to these studies. 
Vascular hyporesponsiveness to AM has been reported in a rat model of 
haemorrhagic shock, 1.5 h after fluid resuscitation (Wu et al., 2005), and 20 h 
from induction of CLP-sepsis, despite increased expression of AM gene and 
protein (Wang et al., 1999; Yang et al., 2002; Zhou et al., 2002). Furthermore, 
evidence suggests that decreased responsiveness to AM is involved in the 
transition from a hyper- to a hypo-dynamic circulation in late CLP-sepsis (Le. 
from 20 h onwards) (Wang et al., 1999). The newly identified AM-like 
peptide, IMD, has also been shown to have marked renal and cardiovascular 
effects (see Chapter 3; Bell & McDermott, 2008), but nothing is presently 
known about the peptide in endotoxaemia. Since IMD has yet to be studied in 
this context, one of the aims of these experiments was to investigate whether 
regional vascular responsiveness to IMD was affected across time from LPS 
treatment, and, if so, how any changes compared to those seen with AM, in 
conscious rats. 
The present work showed a fall in vascular responsiveness to both AM and 
IMD 1.5 h from LPS treatment, prior to the development of regional LPS-
induced vasodilatations (Table 5.1). At 6h there was some return of 
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responsiveness, despite the animals showing renal, mesenteric and 
hindquarters vasodilatations at that stage. Hence, although it might be 
expected that pre-existing vasodilatations would diminish vasodilator 
responses, this was not the case with AM and IMD. By 25 h, responsiveness to 
both peptides had almost returned to control levels, and, although there was 
still a significantly lower resting blood pressure with renal, mesenteric and 
hindquarters vasodilatations in the LPS group, these effects were less marked 
than they were at 6 h (Figure 5.3.2 and 5.3.3; Table 5.1). It is possible that this 
progressive return of vascular responsiveness to AM and IMD was, due to the 
passage of time from bolus administration of LPS, in line with the finding that 
the prolonged presence of LPS in vitro sustains the period of vascular 
hyporeactivity to vasoconstrictors, and is more important than the dose of LPS 
(O'Brien et al., 2001), but it is not known ifvasodilators are affected in similar 
way. 
To determine if the maintained presence ofLPS affected vascular sensitivity to 
AM and IMD in vivo, experiments were repeated in rats treated with a low 
dose LPS-infusion over 24 h vascular hyporesponsiveness to AM and IMD 
was apparent 1.5 h from the onset of a low-dose LPS infusion (15ILg kg- l h- l 
i.v.), as was observed at this juncture in the bolus model. At the 6 h time-point, 
although some loss of responsiveness to AM and !MD was seen in the LPS 
bolus model, regional vasodilator responses were not different from controls in 
animals receiving a low dose LPS infusion (Figure 5.3.4 and 5.3.5), thus 
vascular responsiveness returned more rapidly in this model. Interestingly, at 
this time point, there was an augmented hypotensive response to IMD in the 
LPS-infused group, without any difference in the changes in regional vascular 
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conductance. Since the IMD-mediated tachycardia was also reduced, this 
suggests some depression of cardiac function at this time point in this model. 
At 25 h from the onset of LPS infusion, vasodilator responses to AM and IMD 
were augmented in some vascular beds. Since, mesenteric vascular 
conductance was reduced at this time it is possible that augmentation of 
vasodilator responses was due to this pre-existing vasoconstriction (Table 5.1). 
Results from Chapter 4 indicated that NO was involved in IMD-mediated 
vasodilatation in the mesenteric, and to some extent in the renal, vascular bed 
(Figure 4.3.4). Hence, since IMD-mediated mesenteric vasodilatation was 
impaired to a greatest extent than that to AM 1.5 h from LPS administration, 
and no support of a role for NO was found in AM-mediated vasodilatation, it 
is possible that reduced NO release, possibly via impaired eNDS bioactivity 
(see Introduction), had some involvement in the vascular hyporesponsiveness 
to IMD observed here in LPS-treated rats. Since endothelial-dependent 
vasodilatation is impaired in sepsis, but responses directly stimulating the 
vascular smooth muscle are unaffected (Cameron et al., 1998; Hingorani et al., 
2000; Piepot et al., 2003), this finding may suggest that IMD and AM-
mediated mesenteric and hindquarters vasodilatations are largely endothelium-
dependent, whilst IMD and AM-mediated renal vasodilatation has a 
component which is endothelium-independent. To further study the 
mechanisms responsible, experiments could be conducted using known 
endothelium-dependent (ACh and/or BK) and -independent (SNP) agonists to 
assess whether regional vascular responses were impaired at different time 
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points from LPS exposure. Antagonists of the cGC/cGMP pathway could also 
be employed to determine which (if any) step in this pathway was impaired. 
Excessive activation of KATP channels, and increased channel subunit 
expression are believed to be involved in the development of vascular 
hyporeactivity during endotoxaemia (Sorrentino et al., 1999; Buckley et al., 
2006) and this is linked to enhanced NO production in the early stages. Indeed, 
a role for KATP channels in the development of regional vasodilatations has 
been previously reported within 5 h of LPS treatment, and at 24 h, in both 
conscious and anaesthetised rats, (Gardiner et al., 1999; Sorrentino et al., 
1999) and may be reflected in the baseline vasodilatations reported here in 
LPS-treated animals. It has been suggested that LPS modifies KATP channel 
pharmacology, preventing effective functioning of mediators involved in their 
control (Buckley et al., 2006). While it is possible that LPS-induced changes 
in KATP channel pharmacology or configuration were responsible for the 
changes in responses to AM and IMD observed here, the KATP channel 
blocker, U37883A, had no effect on responses to AM or IMD in normal 
animals (Chapter 4). Thus, it appears unlikely that changes in KATP channels 
underlie changes in responses to AM or IMD following LPs administration 
Alternatively, a receptor-mediated mechanism could account for diminished 
AM and IMD-mediated vasodilatations in LPS-treated rats. Calcitonin family 
peptides signal through a unique receptor system comprising the calcitonin-
receptor-like-receptor (CL) and one of three receptor-activity-modifying-
proteins (RAMPI-3) (as discussed in Chapter 4). Nagoshi et al. (2004) 
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showed that RAMP 1, RAMP2 and CL mRNA levels were significantly 
reduced in human coronary artery smooth muscle cells following incubation 
with TNF-a, which was associated with reduced AM and CGRP receptor 
activity, as determined by an assay for peptide-induced increases in cAMP. 
Hence, TNF-a-mediated inhibition of CURAMP expression could be 
responsible for reducing responses to AM and IMD in the presence to LPS, 
since TNF-a expression is induced by LPS (Nagoshi et al., 2004), and peaks 
by 1.5 h (WaIler et al., 1995). In addition, because CL and RAMP2 levels in 
the lungs of LPS-treated mice declined by 95%, after 12 h, and since the 
majority of CL has been shown to be complexed with RAMP2 in normal mice 
(Gibbons et al., 2006), this could partly account for the loss of vascular 
responsiveness to these peptides 1.5 h after LPS-treatment. A further study 
found reduced RAMP2 expression in the lungs of mice, with progressive falls 
from 0.5 h to 3 h after LPS injection. In terms of AM signalling, this was 
compensated for by a later (from 6 h onwards) increase in RAMP3 mRNA. 
The authors suggest that reduced receptor-bound AM, due to reduced 
expression of receptor components, accounted for the increased plasma 
concentration of AM in early sepsis (Ono et al. 2000). Since AM and IMD 
have been shown to activate the same receptors (Roh et al., 2004; see Chapter 
4), LPS-mediated down-regulation of their receptor components may, in part, 
account for the loss of vascular responsiveness to these peptides, as reported 
here. 
Increased levels of endogenous AM have been reported during the early stages 
of sepsis (for review see Wang et al., 1999), so it is possible that the observed 
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vascular hyporesponsiveness to exogenous AM 1.5 h from LPS-treatment was 
due to increased levels of the endogenous peptide already bound to AM 
receptors. To address this point, the effects of the AM receptor antagonist, 
AM22-52, was assessed in animals treated with LPS (lmg kg-I i.p.). This 
antagonist would be expected to evoke vasoconstriction in regions where 
endogenous AM was causing vasodilatation through AM22_52_sensitive 
receptors, but we found no effect of AM22-s2 on regional haemodynamic 
responses following LPS-treatment in conscious rats (Table 5.2). This may 
suggest that, in this model, endogenous AM was not contributing to the 
regional haemodynamic responses to LPS. However, evidence suggests that 
AM22-S2 has greater selectivity for AMI (CURAMP2) than for AM2 
(CURAMP3) receptors (Hay et al .• 2003). As discussed above, the RAMP2 
component of the AMI receptor is down regulated following exposure to LPS 
(Nagoshi et al., 2004; Gibbons et al., 2006). Therefore, if RAMP2 levels are 
reduced during early endotoxaemia, there is an unavailability of endogenous, 
AM22_s2-sensitive receptors due to them being down regulated rather than to 
their being occupied by endogenous AM. If reduced receptor levels are indeed 
responsible for the reduction of vascular sensitivity to AM during early 
endotoxaemia (i.e. at 1.5 h from onset), then antagonists selective for such 
receptors will tell us little about activity of endogenous peptides at these 
targets. Furthermore, it is possible that high levels of AM were responsible for 
vasodilatation through AM2 receptors and were not affected by AM22-s2• 
Mazzocchi et al. (2000) co-administered AM22-52 (3nmol kg-I) to rats with LPS 
(500J-lg kg-I i.p.) and showed that the LPS-induced fall in blood pressure was 
reduced to 50% of that observed with LPS alone, by 2-3 h from treatment. 
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Between 3 h and 6 h, LPS-induced hypotension was reversed when it was co-
administered with AM22-52 (Mazzocchi et al., 2000). This clearly suggests a 
role for endogenous AM in LPS-induced hypotension. The discrepancy 
between the above study and the one presented here is the method of AM22-52 
administration, with the former giving the antagonist as a pre-treatment prior 
to the rise in plasma AM, whilst in the latter it was given at a time when AM 
levels may already have been high. Thus, it is possible that, at the point AM22-
52 was given in the present study, AM was already acting on its receptors and 
could not be displaced by the antagonist. 
In conclusion, the present studies showed that vascular responsiveness to AM 
and IMD were significantly attenuated 1.5 h from LPS treatment in conscious 
rats, and that responsiveness returned as a function of time after LPS 
administration. Whilst several mechanisms may have been involved (see 
above), until the pharmacology of IMD is more fully characterised, the exact 
role for each in IMD action during endotoxaemia, and any therapeutic value 
this may have, remain to be seen. Since AM has been implicated in the 
development of a hyperdynamic circulation during early sepsis, it is possible 
that there may be a similar role for IMD in the clinical condition. 
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Chapter 6 
Results (IV) 
Cardiovascular responses to adenosine 
receptor activation and antagonism in 
normal and LPS-treated rats 
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Summary 
In this chapter, the regional haemodynamic responses to adenosine agonists 
and antagonists were examined in normal and LPS-treated rats, since studies 
have shown that adenosine-mediated vasodilatations play an important role in 
the maintenance of regional perfusion during sepsis. 
Male Sprague-Dawley rats were chronically instrumented with pulsed 
Doppler flow probes to measure regional haemodynamic responses to 
adenosine-receptor agonists (adenosine, 2 - c h o l o r o - ~ ~-cyclopentyladenosine 
(CCPA}) and antagonists (8-phenyltheophylline (8-PT), 8-cyc1opentyl-l,3-
dipropylxanthine (DPCPX}), at selected time points in control and LPS-treated 
rats. 
The responses to 8-PT were consistent with endogenous adenosine causing 
bradycardia, and renal and hindquarters vasodilatation in control rats, whereas 
in LPS-treated rats, there was evidence for endogenous adenosine causing 
renal (at 1.5 h) and hindquarters (at 6 h) vasoconstriction. In control animals, 
exogenous adenosine caused hypotension, tachycardia and widespread 
vasodilatation, whereas in LPS-treated rats, the adenosine-induced renal (at 
1.5 h) and hindquarters (at 6 h) vasodilatations were abolished. As enhanced 
AI receptor-mediated vasoconstriction could explain the results in LPS-treated 
rats, vascular responsiveness to a selective AI-receptor agonist (CCPA) or 
antagonist (DPCPX) was assessed. There was no evidence for enhanced 
vasoconstrictor responsiveness to CCPA in LPS-treated rats, but DPCPX 
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caused renal vasodilatation, consistent with endogenous adenosine mediating 
renal vasoconstriction under these conditions. 
The results show changes in adenosine receptor-mediated cardiovascular 
effects in endotoxaemia that may have implications for the use of adenosine-
based therapies in sepsis 
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6.1 Introduction 
The development of clinical sepsis is associated with complex haemodynamic 
changes which include a hyperdynamic phase and a hypodynamic stage as the 
severity of the condition increases. During the hyperdynamic phase, patients 
may remain normotensive, despite systemic vasodilatation, due to an increase 
in cardiac output. A role for adenosine in the haemodynamic changes 
associated with sepsis during this early stage has been suggested by a number 
of researchers (Martin et al., 2000; Law et al., 2003; Conlon et al., 2005). 
Adenosine interacts with 4 receptors (A\, A2a• A2b and A3; see Introduction) 
(Fredholm et al., 2001b), and evidence suggests that A\ and A2-receptors are 
primarily responsible for the cardiovascular actions of adenosine (Fredholm et 
al., 2001a). A\-receptors are linked to Gi causing inhibition of cAMP activity, 
which leads to cardiac depression, a reduction in heart rate, renal 
vasoconstriction (Evans et al., 1982; Webb et al., 1990; Fredholm et al., 
2001a; Hansen et al., 2005) and skeletal muscle vasodilatation (Marshall et al., 
1993; Ray et al., 2002; Ray et al., 2006). A2a-receptors are located on vascular 
smooth muscle, endothelial cells and on immune cells, and are linked to Gs, 
leading to cAMP activation (Mubagwa et al., 1996; Fredholm et al., 2001a; 
Nemeth et al., 2006), vasodilatation and immunosuppression (Webb et al., 
1990; Nemeth et al., 2006). A2b receptor activation may also lead to 
regionally-selective vasodilatation, but the lack of pharmacological probes 
selective for A2b receptors means this subtype is poorly characterised 
(Feoktistov et al., 1997). 
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Endogenous adenosine has been shown to contribute to changes in regional 
blood flow distribution during sepsis, thereby contributing to the development 
of a hyperdynamic circulation. For example, Motew et al. (1998) showed that, 
24 h after a septic challenge, the non-selective adenosine receptor antagonist, 
8-phenyltheophylline (8-PT), caused vasoconstriction (selective for skeletal 
muscle, hepatic portal and cerebral circulations), indicating endogenous 
adenosine-mediated vasodilator tone (Motew et al., 1998). However, in that 
study, the animals were not vasodilated at the time of antagonist 
administration, and the antagonist responses were only considered at one time 
point (i.e. 24 h) following the septic challenge. 
To extend those observations, the aim of the present study was to determine 
the effects of adenosine receptor agonism and antagonism at different times, 
in a model of endotoxaemia (lipopolysaccharide (LPS) administration) in 
which regionally and temporally-selective vasodilatation occurs. It was 
hypothesised that adenosine receptor antagonism would cause 
vasoconstriction in regions where endogenous adenosine was acting as a 
vasodilator. However, the results of the first experiments, contrary to 
expectation, were consistent with up-regulation of AI receptor-mediated 
vasoconstrictor effects following LPS administration. Therefore, further 
experiments were performed to assess the hemodynamic responses to AI 
receptor activation and antagonism. It is well reported that At receptor 
activation causes inhibition of renin release (Tagawa et al., 1970; Churchill et 
al., 1985; Weihprecht et al., 1990), and since there was a vasoconstrictor 
effect of At receptor antagonism in the control rats (see Results), a final set of 
experiments was performed in the presence of the angiotensin (AT t) receptor 
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antagonist, losartan, to assess if the vasoconstrictor effects of At receptor 
antagonism were secondary to renin-angiotensin system activation. 
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6.2 Methods 
All experiments were performed in male Sprague-Dawley rats, as outlined in 
Chapter 2. At the first surgical stage, Doppler flow probes (to measure renal, 
mesenteric and hindquarters blood flows) were sutured around the left renal 
artery, the superior mesenteric artery and the distal abdominal aorta below the 
level of the ileocaecal artery (for hindquarters). At least 10 days after probe 
implantation, catheters were inserted in the right jugular vein (up to 3 
catheters) and the peritoneal cavity for substance administration, and in the 
distal aorta (via the caudal artery), for continuous recording of arterial blood 
pressure and heart rate. Experiments began at least 24 h after catheter 
implantation, in unrestrained, conscious animals. 
6.1.1 Experiment 1: Cardiovascular effects of 8-phenyltheophylline (8-PT) 
in normal and LPS-treated rats 
Responses to the non-selective adenosine receptor antagonist, 8-PT (4mg kg-! 
in saline given as a O.lml bolus), were assessed 1.S h, 6 h and 2S h after bolus 
administration of saline (0.5 ml Lp.) (n=9), or LPS (1 mg kg-! i.p.) (n = 9) to 
determine whether endogenous adenosine affected resting vascular tone in 
normal or endotoxaemic animals, and whether any effects of 8-PT changed 
across time. This antagonist shows equal selectivity for A!- and Arreceptors 
(Fredholm et al., 1987), and the dose was that used by Motew et al. (1998). In 
pilot experiments it was shown to fully antagonise the cardiovascular effects 
of adenosine (300 Ilg kg-! min-! Lv.) for up to 60 min. Those pilot experiments 
also indicated that adenosine-mediated responses had returned to normal 
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within 6 h following 8-PT administration. This experimental protocol IS 
illustrated below. 
Day] Day 2 
Oh 1.5 h 6h 25 h 
t t t 
Il 71 t 
Saline infusion 8-PTbolus 8-PTbolus 8-PTbolus 
Day 3 Day 4 
Oh 1.5 h 6h 25 h 
t t t 
/I 
71 t 
LPS bolus 8-PTbolus 8-PTbolus 8-PTbolus 
Figure 6.2.1 Saline was given as a bolus at time 0 on Day 1, and LPS at time 
Oh on Day 3. Animals were administered 8-PT 1.5 h, 6 hand 25 h later. 
6.2.2 Experiment 2: Cardiovascular responses to adenosine in normal and 
LPS-treated rats 
To determine whether the vascular sensitivity to adenosine was altered 
following LPS treatment, cardiovascular changes during 3 min infusions of 
adenosine (300ILg kg-I min-I i.v. in saline 0.15 ml min-I) were assessed 1.5 h, 6 
hand 25 h following bolus administration of saline (0.5 ml i.p.) on day 1 and 
following LPS (1 mg kg-} Lp.) on day 3 (n=9). The dose of adenosine was 
chosen on the basis of pilot studies which showed it to cause robust and 
reproducible vasodilatations in normal animals. 
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Day 1 Day 1 
Oh 1.5 h 6h 25 h 
3 min 3min 3 min 
,.;.-. Ft iT-t t t 
saline bolus adenosine adenosine adenosine 
Day 3 Day 4 
Oh 1.5h 6h 25 h 
3min 3 min 3 min 
t Ft A iT-
LPS bolus adenosine adenosine adenosine 
Figure 6.2.2 Animals were treated with a saline and LPS bolus at time 0 h 
on Day 1 and 3 respectively. and were administered adenosine 1.5 h. 6 hand 
25 h later. 
Since the responses to 8-PT and adenosine had returned to baseline 25 h after 
administration of LPS (see Results), the following experiments were only 
performed at 1.5 h and at 6 h. This protocol is shown in Figure 6.2.2. 
6.2.3 Experiment 3: Cardiovascular responses to 2-choloro-N'-
eyc/opentyladenosine (CCPA) 
Haemodynamic responses during 3 min infusions of the A)-receptor agonist, 
CCPA (1.4 J.tg kg-) min-! i.v. (0.15 ml min- l in vehicle containing 5% 
propylene glycol, 2% Tween-80 in saline) were assessed in one group of 
animals (n=8) at 1.5 h after saline (0.5 ml i.p.) on day 1 and 1.5 h after LPS (l 
mg kg- l i.p.) on day 3, and in another group of animals (n=8) at 6 h after saline 
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(as above) on day 1 and 6 h after LPS (as above) on day 3. Results from pilot 
studies showed that, at the dose used, CCP A caused reproducible changes in 
regional vascular conductances which were consistent with AI-receptor 
activation as reported in the literature. Different animals were used at the 2 
time points because of desensitisation to this agonist (Casati et al., 1994). This 
protocol is illustrated below. 
Oh 1.5h 6h 
3 min 3 min 
Group 1 t Et LJ 
saline CCPA CCPA 
3 min 
Group 2 t [) 
LPS CCPA CCPA 
Figure 6.2.3 Animals were given either saline or LPS at time 0, followed by a 
3 min infusion ofCCPA 1.5 hand 6 h later. 
6.2.4 Experiment 4: Cardiovascular effects of 8-cyclopentyl-l, 3· 
dipropylxanthine (DPCPX) in normal and LPS-treated rats 
Responses to the AI-receptor antagonist, DPCPX (0.1 mg kg-I in 0.1ml of 
vehicle containing 5% propylene glycol, 2% Tween-80 in saline), were 
assessed at 1.5 h and 6 h following saline (0.5 ml i.p.) on Day 1 and at 1.5 h 
and 6 h after LPS (1 mg kg-! Lp.) on Day 3 (n=8). The dose and method of 
delivery of DPCPX was chosen on the basis of the literature showing 
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successful administration of the antagonist in vivo (KeUett et al., 1989; Bryan 
et al., 1999), and on pilot studies conducted prior to beginning these 
experiments. Difficulty in dissolving the antagonist limited its usability when 
given as an infusion, but at the dose given, we were able to completely 
antagonise the effects of CCP A, and the antagonism had reversed by 6 h; this 
time course of action is consistent with the literature (Kellett et al., 1989). 
Oh 1.5h 6h 
Day3 
t f f 
Saline DPCPX DPCPX 
Oh 1.5h 6h 
Day 3 f t f 
LPS DPCPX DPCPX 
Figure 6.2.4 Animals were given saline or LPS at time 0 on Day 1 and Day 3 
respectively, followed by bolus administration o!DPCPX 1.5 hand 6 h later. 
6.2.5 Experiment 5: Cardiovascular effects of DPCPX following pre-
treatment with losartan 
Antagonism of Al receptors can cause renin release, and hence any 
cardiovascular effect could be secondary to activation of the renin-angiotensin 
system (Tagawa et al., 1970; Jackson et al., 1991). To assess whether the 
regional haemodynamic responses to DPCPX were due to direct A1-receptor 
antagonism or due to renin-angiotensin system activation, the effects of 
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DPCPX were measured in the presence of the angiotensin (AT I) receptor 
antagonist losartan (10 mg kg- I in distilled water given as a 0.1 ml Lv. bolus). 
Losartan was given 30 min prior to Lp. administration of saline or LPS (as 
above) and DPCPX (0.1 mg kg- I as above) was given 1.5 hand 6 h later. In 
pilot experiments it became clear that the marked effects of losartan on 
baseline haemodynamic status in LPS-treated rats confounded interpretation of 
results using DPCPX and therefore, only results from control animals are 
presented. 
Day] 
Day 3 
30min 1.5 h t ~ t t f 
Losartan Saline DPCPX 
30min 
.. . 
t f 
Losartan LPS 
1.5 h 
f 
DPCPX 
6h 
f 
DPCPX 
6h 
f 
DPCPX 
Figure 6.2.5 Animals were pre-treated with losartan before administration of 
saline on Day 1 and LPS on Day 3. DPCPXwas then given 1.5 hand 6 h 
later. 
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6.3 Results 
6.3.1 Experiment 1: Cardiovascular effects of 8-PT in normal and LPS-
treated rats 
Cardiovascular responses to the non-selective adenosine receptor antagonist, 
8-PT (4mg kg') Lv. bolus) after LPS or saline treatment are shown in Figure 2. 
In saline-treated animals, administration of 8-PT at all 3 time points caused 
significant tachycardia, which was sometimes accompanied by a rise in blood 
pressure (P<0.05 at 6 hand 25 h), a fall in renal vascular conductance (P<0.05 
at 6 h and 25 h) and a rise in hindquarters vascular conductance (P<0.05 at 1.5 
hand 25 h). 
At 1.5 h after LPS treatment, 8-PT caused tachycardia, hypotension, renal and 
hindquarters vasodilatation (Figure 6.3.1 a); the integrated (0-10 min) changes 
in blood pressure and renal vascular conductance were significantly different 
from those seen in the saline-treated rats (Figure 6.3.1 a). At 6 h after LPS 
treatment, 8-PT caused no tachycardia but there was hypotension and 
hindquarters vasodilatation (Figure 6.3.1 b); the integrated (0-10 min) changes 
in heart rate, blood pressure and hindquarters vascular conductance were 
significantly different from those seen in the saline-treated rats. The integrated 
(0-10 min) change in renal vascular conductance in response to 8-PT was also 
different in LPS-treated rats at this juncture; inasmuch as the renal 
vasoconstrictor responses seen in the controls was absent. Twenty-five h 
following LPS treatment, the integrated (0-10 min) responses to 8-PT were not 
different between the saline and LPS-treated animals (Figure 6.3.1 c). 
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6.3.2 Experiment 2: Cardiovascular responses to adellosille in 
Ilormai and LPS-treated rats 
Cardiovascular responses to adenosine (300JLg kg-I min-I) are shown in Figure 
6.3.2. In saline-treated rats, adenosine caused tachycardia, a fall in blood 
pressure, and increases in vascular conductance in the renal, mesenteric and 
hindquarters vascular beds. 
At 1.5 h following LPS-treatment (Figure 6.3.2a), the adenosine-induced 
tachycardia was abolished and this was accompanied by a hypotension which 
took longer to develop than in the saline group. There was a tendency for an 
initial renal vasoconstriction but there was a small vasodilatation by the end of 
the infusion, and robust increases in mesenteric and hindquarters vascular 
conductances. The integrated (0-3min) changes in heart rate and renal 
vascular conductance in response to adenosine at 1.5 h were significantly 
(P<0.05) less in the LPS group than in the control group, but the integrated 
changes in mesenteric and hindquarters vascular conductance were not 
significantly different in the 2 groups. At 6 h after LPS (Figure 6.3.2b), 
adenosine caused a slight tachycardia although the integrated (0-3 min) change 
was still less than the control. The accompanying hypotension was again 
slower in onset but the integrated change was not different from the control. 
At this juncture, the renal vasodilatation was still significantly different from 
control, the mesenteric vasodilatation was not different from control, but the 
hindquarters vasodilator response to adenosine was lost (Figure 6.3.2b). By 25 
h after the administration of LPS the cardiovascular responses to adenosine 
were not different between the saline and LPS-treated groups (Figure 6.3.2c). 
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6.3.3 Experiment 3. Cardiovascular responses to CCPA 
Separate groups of animals were given CCP A at 1.5 h or 6 h since others 
(Casati et al., 1994; Saura et al., 1998) found evidence of desensitisation 
following repeated administration of this agonist. 
In saline-treated animals, CCP A caused bradycardia, hypotension, mesenteric 
and renal vasoconstriction and hindquarters vasodilatation (Figure 6.3.3). For 
no obvious reason, although the changes were qualitatively similar at 1.5 hand 
at 6 h, the magnitude of change in blood pressure, heart rate and renal and 
mesenteric vascular conductances in response to CCP A were smaller at 6 h 
than at 1.5 h (P<0.05 for integrated 0-3min responses in both saline and LPS-
groups), despite the use of naive animals at the 2 time points (Figure 6.3.3). 
At 1.5 h after LPS administration, the integrated (0-3 min) bradycardic 
response to CCP A was greater, but the hypotension and mesenteric 
vasoconstriction were less than in the saline-treated animals at that time 
(Figure 6.3.3a). At 6 h after LPS treatment, the integrated bradycardia was still 
greater, but the renal and mesenteric vasoconstrictions were also greater than 
those in the corresponding saline control (Figure 6.3.3b). The hindquarters 
vasodilator response to CCP A did not differ between saline- and LPS-treated 
rats at any stage. 
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6.3.4 Experiment 4: Cardiovascular effects of DPCPX in normal and LPS-
treated rats 
Haemodynamic responses to DPCPX treatment in saline and LPS-treated 
animals are shown in Figure 6.3.4. In the saline-treated group, responses were 
quite variable but DPCPX caused a small (significant at 1.5h only) rise in 
blood pressure with mesenteric and hindquarters vasoconstriction (significant 
at both time points). 
In the LPS-treated group, at 1.5 h, the integrated (0-10 min) mesenteric and 
hindquarters vasoconstrictor responses to DPCPX were not different from the 
saline-treated group but there was renal vasodilatation (not seen in the control 
group) and the pressor response was lost (Figure 6.3.4a). Six h after LPS 
treatment, there were no significant changes in any haemodynamic variable 
following administration of DPCPX (Figure 6.3.4b), and the integrated (0-10 
min) changes in blood pressure and renal and hindquarters vascular 
conductances were significantly less than in the saline-treated rats. 
6.3.5 Experiment 5: Cardiovascular effects of DPCPX following pre-
treatment with losartan 
In losartan-treated rats, 1.5 h and 6 h after saline, resting cardiovascular 
variables were: heart rate 358±6 and 368±IS beats min-t, blood pressure 
100±3 and 95±2 mmHg, renal vascular conductance (1 09± 1 0 and 11 O± 10 
(kHz mmHg-1)10\ mesenteric vascular conductance (7S±5 and 89±10 (kHz 
mmHg-1)103) hindquarters vascular conductance (49±5 and 53±4 (kHz mmHg-
1)10\ 
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In the presence of losartan, DPCPX had no significant effect on blood pressure 
or heart rate, but caused a fall in mesenteric vascular conductance (P<0.05 at 
1.5 hand 6 h), and a fall in hindquarters vascular conductance (P<0.05 at 1.5 h 
only). At 1.5 h, the integrated (0-10 min) fall in mesenteric vascular 
conductance in response to DPCPX was significantly smaller following 
losartan (-76 ± 20%) than in the control condition (-136 ± 24%), and at both 
times, the DPCPX-induced fall in hindquarters vascular conductance was 
smaller after losartan (at 1.5 h -67± 16%, at 6 h -31 ± 18%) than in the control 
condition (-97 ± 20%, -100 ± 15% respectively) although the difference was 
only significant at 6h. 
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Expt 1 Expt2 Expt3a Expt3b Expt4 
1.Sh Sal LPS Sal LPS Sal LPS Sal LPS Sal LPS 
Heart rate (beats/min) 347±7 402±16* 340±1O 429±14* 336±6 385±8* 352±7 427±9* 351±7 415±1O* 
Mean BP (mmHg) 113±3 lO4±5 I02±2 104±2 110±2 I08±5 I09±9 I03±3* 110±2 116±6 
Renal VC (units) 77±10 99±9 75±8 87±1O 94±5 I09±7 74±8 90±9* 91±9 95±5 
Mesenteric VC (units) 69±8 59±5 77±9 49±7* 66±5 50±9 72±7 62±8* 64±4 35±4* 
Hindquarters VC (units) 44±4 62±7* 54±3 56±5 45±5 52±6 45±6 47±9 47±2 53±4 
6h Sal LPS Sal LPS Sal LPS Sal LPS Sal LPS 
Heart rate (beats/min) 353±12 445±12* 343±IO 429±14* 337±8 399±14* 360±11 416±6* 340±7 399±8* 
Mean BP (mmHg) 112±3 92±6* I02±2 92±3 107±1 I02±3 111±3 99±3 111±2 114±7 
Renal VC (units) 78±1O 134±15* 74±7 109±16* 89±3 112±6* 75±8 98±U* 96±9 107±14 
Mesenteric VC (units) 57±6 128±IO* 83±9 I08±14* 62±2 84±9* 70±8 106±1* 59±5 57±9 
Hindquarters VC (units) 43±4 67±6* 52±3 67±3* 42±4 48±6 42±5 53±5* 42±2 45±3 
2Sh Sal LPS Sal LPS 
Heart rate (beats/min) 351±7 383±21 356±10 352±11 
Mean BP (mmHg) 114±3 IOI±4* 107±1 I00±2 
Renal VC (units) 79±7 87±5 70±9 81±14 Table 6.1 Cardiovascular variables prior to administration of adenosine agonists and antagonists. Values are mean ± s.e.m. Units 
Mesenteric VC (units) 68±7 83±7 68±11 76±9 for vascular conductance (VC) are kHzlrnmHg x 103• n = 8-9/group 
Hindquarters VC (units) 43±4 61±6* 45±3 63±4* 
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HR MAP RVC MVC HVC 
8-PT t +-+ +-+ +-+ t 
Adenosine t , t t t 
CCPA , , , , t 
DPCPX +-+ t +-+ , , 
Table 6.2 Summary of the cardiovascular responses to adenosine receptor 
agonists and antagonists. t denotes an increase from baseline; 'denotes a 
decrease from baseline; +-+ denotes no change from baseline. Responses taken 
from the 1.5 h time point, 1 minfrom administration. 
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6.4 Discussion 
The haemodynamic responses to adenosine are complex and involve 
interaction of the nucleoside with four cell-surface G-protein coupled 
adenosine receptors (A), A2a, A2b, A3)' Cardiovascular responses to adenosine 
vary depending upon which receptor is activated, the local concentration of 
adenosine, and the relative density of each receptor subtype. Studies suggest 
that physiological levels of endogenous adenosine are low and contribute little 
to resting vascular tone. To assess this in normal animals, the non-selective 
adenosine receptor antagonist 8-PT was used. In saline-treated animals, the 
effects of 8-PT were consistent with endogenous adenosine causing 
bradycardia (Evoniuk et al., 1987) and vasodilatation in the hindquarters. The 
magnitude of the responses to 8-PT varied across time (Figure 6.3.1), possibly 
due to variations in levels of endogenous adenosine which may reflect changes 
in the energy status of animals following surgery. These responses differed 
from those caused by exogenous adenosine which led to marked 
vasodilatations in the renal, mesenteric and hindquarters vascular beds, a 
robust hypotension and tachycardia, which were reproducible across time. 
Whilst the responses mediated by endo- and exogenous adenosine appear to be 
contradictory, both are consistent with the opposing effccts of AI and A2 
receptors mediated by activation at low and high concentrations of adcnosine, 
respectively (see Chapter 1.3). 
To delineate the role of the adenosine AI receptor in the cardiovascular 
responses to both endogenous and exogenous adenosine, the selective Al 
agonist, 2-choloro-N> -cyclopentyladcnosine (CCP A), and antagonist, 8-
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cyclopentyl-1, 3-dipropylxanthine (DPCPX), were used. Administration of the 
AI-selective agonist to normal animals caused bradycardia, hypotension, renal 
and mesenteric vasoconstriction and hindquarters vasodilatation. These 
findings are consistent with those reported by Webb et al. in spontaneously 
hypertensive rats (Webb et al., 1990), showing that A) receptor-mediated 
vasoconstriction (Tagawa et al., 1970; Barrett et al., 1993; Hansen et al., 
2005) is not restricted to the renal vasculature. The hindquarters vasodilator 
response to CCPA is also consistent with reports by others showing AI 
receptor-mediated vasodilatation in skeletal muscle (Marshall et al., 1993; Ray 
et al., 2002; Ray et al., 2006). 
In the final set of experiments, DPCPX was used to study endogenous AI-
receptor activation, and in normal animals, caused a modest increase in blood 
pressure, together with mesenteric and hindquarters vasoconstriction, with no 
significant effect on renal vascular conductance. The decrease in hindquarters 
vascular conductance following administration of DPCPX is internally 
consistent with the hindquarters vasodilatation elicited by CCP A. Collectively, 
these data indicate a role for A)-receptor activation in mediating hindquarters 
blood flow. Furthermore, the effects of DPCPX and CCPA on blood pressure 
support a hypotensive role for adenosine acting via AI-receptors. Since the 
mesenteric and hindquarters vasoconstrictor effects of DPCPX were reduced 
by losartan, it is likely that these responses were, in part, secondary to the 
removal of A)-mediated inhibition of renin release (Tagawa et al., 1970; 
lackson et al., 1991). The lack of response to DPCPX in the renal vasculature 
indicates that levels of endogenous adenosine were insufficient to activate 
renal A)-receptors in normal animals. This is in line with a study by Kellet et 
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al. (Kellett et al., 1989) who found that DPCPX had no effect on renal blood 
flow under nonnal conditions, and suggests that the observed responses to 8-
PT in control animals may have been mediated by inhibition of A2 receptors. 
These responses are summarised in Table 6.2. 
Previous reports have shown a vasodilator role for adenosine 24 h after the 
induction of sepsis by caecal slurry injection (Motew et al., 1998, Sam et al., 
2000a and b). To extend those observations, the present studies were designed 
to investigate the role of adenosine in the early cardiovascular changes seen in 
a rat model of endotoxaemia which is characterised by regionally-selective 
vasodilatation, the pattern of which varies across time (Chapter 5). 
In LPS-treated animals, there were some notable changes in responses to 8-PT 
which, in this condition, caused hypotension associated with renal 
vasodilatation at 1.5 h, and hindquarters vasodilatation at 6 h. By 25 h after 
LPS administration, responses to 8-PT had returned to nonnal. Since Motew et 
al. reported vasoconstriction in response to 8-PT in sepsis (Motew et al., 
1998), our results showing 8-PT-induced vasodilatation were unexpected. 
These findings would be consistent with enhanced vasoconstriction and/or 
impaired vasodilatation in response to endogenous adenosine in LPS-treated 
animals, mediated by Al or A2 receptors, respectively. In addition, we found 
that the vasodilator response to exogenous adenosine in nonnal animals was 
lost in the renal vascular bed 1.5 h after LPS administration, and was absent in 
the hindquarters vascular bed 6 h after LPS administration. Others have 
described AI-receptor-mediated constriction of renal afferent arterioles in 
nonnal animals (Tagawa et al., 1970; Webb et al., 1990; Tang et al., 1999), 
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and here we also found that, in the control animals, adenosine caused some fall 
in renal vascular conductance prior to development of the vasodilatation. The 
findings of attenuated vasodilator responses to adenosine in the renal vascular 
bed at 1.5 h, and in the hindquarters at 6 h following LPS administration are 
internally consistent with the effects of 8-PT (see above), and suggest either an 
LPS-induced enhancement of Al-receptor-mediated vasoconstriction or 
impairment of A2-receptor-mediated vasodilatation. Interestingly, adenosine-
induced tachycardia as observed in normal animals was also substantially 
reduced in the LPS group. Since there was a resting tachycardia following LPS 
treatment (Table 1), one explanation for this difference is that the resting heart 
rate was already at its upper limit. However, this is unlikely as the LPS group 
showed tachycardic responses to 8-PT (Experiment 1), and from previous 
experiences, the level of heart rate in the LPS-treated rats in this experiment 
(-420 beats min-l) was not maximal for a conscious rat. 
Because adenosine caused a similar fall in blood pressure in control and LPS-
treated rats, the lack of tachycardia in the latter could indicate some 
impairment of the baroreflex, reduction of the direct effects of A2-receptors on 
the heart (Lappe et al., 1992) and/or enhanced direct action of Al-receptors on 
the heart. 
Since one interpretation of the findings from the experiments using 8-PT and 
adenosine was that there were enhanced Al-receptor-mediated responses in 
LPS-treated rats, further experiments were performed using CCP A and 
DPCPX in endotoxaemic rats. In the light of experiments with 8-PT and 
adenosine (see above), it was hypothesised that there would be enhanced 
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CCP A-induced renal vasoconstriction 1.5h after LPS treatment, enhanced 
hindquarters vasoconstriction (or diminished vasodilatation) 6h after LPS, and 
enhanced bradycardia at both time-points. The data did indeed show enhanced 
CCPA-induced bradycardia in the LPS-treated group which is consistent with 
enhancement of AI-receptor-mediated negative chronotropic actions. 
However, there was no enhancement of the CCP A-induced renal 
vasoconstriction at 1.5h, and no change in the hindquarters vascular response 
at 6 h after LPS. Similarly, 6 h after LPS administration, there was no 
evidence for enhanced At-mediated vasoconstriction in the hindquarters. 
Interestingly, 1.5h after LPS, the mesenteric vasoconstrictor response to 
CCPA was diminished at a time when the bradycardia was enhanced and yet 
the hypotension was unaffected. This must indicate differential changes in 
cardiac output in response to CCPA in control vs. LPS-treated rats at this time, 
with a larger reduction in cardiac output in the former, possibly due to the 
larger increase in afterload secondary to the greater mesenteric 
vasoconstriction. 
In contrast to the results from the previous experiment, DPCPX caused renal 
vasodilatation at 1.5 h in the LPS group, consistent with the results from the 
experiments with 8-PT. This suggests that endogenous adenosine was acting at 
renal AI-receptors to cause vasoconstriction. However, unlike 8-PT, DPCPX 
did not cause vasodilatation in the hindquarters vascular bed at 6 h after LPS 
which suggests that the results with 8-PT and adenosine may be explained by 
reduced Armediated vasodilatation in this instance. 
It was noted that rats given DPCPX at 1.5h did not develop mesenteric 
vasodilatation across the 2-6 h period following LPS treatment (Table 6.1), 
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suggesting that the earlier AI-receptor antagonism blunted the development of 
the hyperdynamic circulation. One explanation for this attenuated baseline 
vasodilatation in the DPCPX-treated group is that there was increased 
activation of the renin-angiotensin system, consequent upon removal of the 
normal AI receptor-mediated inhibition of this system (Weihprecht et al., 
1990; Lappe et aI., 1992). 
Adenosine receptors are widely distributed throughout the central nervous 
system and A2a receptors are implicated in control of baroreceptor-mediated 
reflexes (Thomas et al., 2000). Furthermore, Schindler et al. (2005) showed 
that in conscious rats, whilst the hypotensive and bradycardic effects of i.p. AI 
receptor agonist administration were due to peripheral AI receptor activation, 
receptor-mediated hypotension was due to activation of peripheral receptors, 
but the tachycardia was, at least in part, due to activation of centrally located 
receptor (Schindler et al., 2005). Therefore, it is possible that some of the 
results presented here reflect activation of central as well as peripheral 
adenosine receptors. Indeed, since, the integrity of the blood brain barrier is 
compromised during sepsis; an increased involvement of centrally located 
adenosine receptors following LPS treatment in our studies is feasible. 
Whilst adenosine-based compounds are not currently used in the treatment of 
sepsis; their potential usefulness is under discussion (for reviews see Skrabanja 
et al., 2005; Sands & Palmer, 2005). The present studies show that the 
regional haemodynamic effects of adenosine receptor activation and 
antagonism change in a regionally distinct manner, across time, following 
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LPS-treatment in conscious rats. These results show that enhancement of A1-
receptor-mediated effects could only partly explain the changed cardiovascular 
response to adenosine at 1.5 hand 6 h after LPS treatment, and we therefore 
suggest that impaired A2 receptor mediated action may also have been 
involved. Thus, the cardiovascular effects of adenosine during LPS-induced 
endotoxaemia appear to vary according to the receptor activated, the vascular 
bed, and the time elapsed since LPS exposure. 
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Chapter 7 
Results (V) 
Interactions between adenosine, 
adrenomedullin and intermedin in the 
cardiovascular system of conscious rats 
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Summary 
Evidence suggests that the vasodepressor effect of adenosine is potentiated in 
the presence of several other vasoactive mediators, including AM. In this 
Chapter, possible synergism between the regional haemodynamic responses to 
adenosine, AM and IMD was investigated in vivo. 
Sprague Dawley rats were chronically implanted with miniature pulsed 
Doppler flow probes and intravascular catheters, to measure changes in 
regional blood flows along with blood pressure and heart rate. 
In the presence of a low dose infusion of AM, responses to adenosine were not 
different from those in the presence of saline. Similarly, the regional 
haemodynamic responses to AM were not changed when administered in the 
presence of a low-dose infusion of adenosine. However, when adenosine 
challenges were given in the presence of a low-dose infusion of IMD, there 
was attenuation of adenosine-mediated mesenteric vasodilatation. The 
inhibitory interaction between these two agents was also observed in the 
cardiovascular response to adenosine in the presence of IMD. 
In conclusion, these results do not support a synergistic relationship between 
adenosine and AM, but they do indicate a possible inhibitory interaction 
between adenosine and IMD. The reason(s) for this remain to be determined 
but highlight an interesting difference between AM and IMD. 
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7.1 Introduction 
Endogenous mediators such as peptides, neuropeptides and amines interact to 
maintain cardiovascular homeostasis by controlling regional blood flow. The 
mediators include those acting in an endocrine manner to control peripheral 
blood flow, and those acting in an autocrine andlor paracrine fashion in 
response to local fluctuations in energy requirements. Adenosine is an 
example of a vasoactive mediator which acts locally; it is a nucleoside which 
possesses potent vasodilatory and hypotensive actions, and is released by the 
hydrolysis of ATP in metabolically active tissues, coupling the energy 
requirements of the cell to blood flow (for review see Fredholm et al., 2001). 
There is some evidence to suggest that adenosine-mediated hypotension is 
potentiated in the presence of other mediators, including vasoactive intestinal 
peptide (VIP), CGRP and AM; this interaction is believed to involve KATP 
channels. Thus, in a series of experiments, Sakai and Saito (1998a, b, c, d) 
showed that adenosine-mediated hypotension could be enhanced in 
anesthetised rats during infusion of CGRP, at a dose which, by itself, had no 
effect on blood pressure. They further demonstrated that VIP, CGRP and 
adenosine could interact synergistically to lower blood pressure, an effect 
which could be blocked by pretreatment with the KATP channel blocker, 
glibenclamide. Furthermore, infusion of the KATP channel opener, 
levcromakalim, significantly enhanced the depressor effects of VIP, CGRP 
and adenosine, indicating that activation of KATP channels was central to this 
effect. Further evidence came from the finding that co-infusion of the anti-
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anginal drug nicorandil, which activates of KATP channels, with sub-depressor 
doses of VIP or CGRP further potentiated the adenosine-mediated fall in blood 
pressure. These studies also demonstrated that the hypotensive action of 
adenosine could be potentiated by infusing rats with AM, at a dose which by 
itself had no effect on blood pressure. This effect appeared to be mediated by 
KATP channel activation since the interaction was not seen following treatment 
with glibenc1amide (Sakai et al., 1998d). Furthermore, a study in open-chest 
dogs, demonstrated that AM-mediated increases in coronary blood flow could 
be inhibited be addition of the KATP channel blocker, U37883A, indicating that 
KATP channels were involved in AM-mediated vasodilatation. Interestingly, 
the vasodilator action of AM in the coronary artery could also be inhibited by 
addition of the non-selective adenosine-receptor antagonist, xanthine amine 
congener (XAC), leading the authors to speculate that AM-mediated coronary 
vasodilatation was mediated by AM-induced opening ofKATP channels via the 
prior activation of adenosine receptors (Sabates et al., 1997). These results are 
at odds with those found here, which showed no role for KATP channel 
activation in mediating the vasorelaxant effects of AM (Chapter 5). However, 
the different vascular bed and different species studied may, in part, account 
for these discrepancies. 
Since the above studies suggest there may be some synergism between AM 
and adenosine in anaesthetised animals, with a possible role for adenosine 
receptors and KATP channels, the present study was designed to assess whether 
any such interaction exists in conscious animals. Furthermore, whilst 
synergism was demonstrated for the hypotensive actions of these agents, 
nothing is known about these interactions with regard to regional 
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haemodynamics, i.e., it is not known if the synergistic effects on blood 
pressure were due to synergistic vasodilatation in the same, or in different, 
vascular beds. Thus, the first set of experiments aimed to measure the regional 
haemodynamic response to adenosine (see Chapter 6) in the absence and 
presence of a sub-depressor dose of AM. Since the newly identified peptide, 
IMD, has been shown to share some of the cardiovascular actions of AM 
(Chapter 3), and has been shown to activate the same receptor system (Chapter 
4), we extended the above experiment to assess the effect of a sub-depressor 
dose of IMD on the cardiovascular responses to adenosine. For completeness, 
the second set of experiments was designed to determine if a sub-depressor 
dose of adenosine had any effect on the cardiovascular responses to AM and 
IMD in the conscious, freely moving rat. 
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7.2 Methods 
Male Sprague-Dawley rats were chronically instrumented with pulsed Doppler 
flow probes to allow continuous measurements of regional (renal, mesenteric 
and hindquarters) haemodynamics, as described in Chapter 2. Briefly, under 
anaesthesia, 3 miniaturised probes were sutured around the left renal artery, 
superior mesenteric artery and distal aorta to allow changes in renal, 
mesenteric and hindquarters vascular conductances to be assessed. Animals 
then underwent a recovery period of 10-14 days before being anaesthetised 
again to allow implantation of intravascular catheters. Up to 3 catheters were 
placed in the jugular vein for administration of drugs and 1 was placed in the 
caudal artery and advanced into the distal aorta to allow continuous recording 
of blood pressure and heart rate. Animals were fitted with a harness and 
attached to a swivel system, allowing them to move freely throughout the 
experimental period, which began 24 h after catheter implantation. 
7.2.1 Cardiovascular responses to adenosine during infusion of AM or 
IMD 
A group (n=9) of animals was infused with saline (O.4ml h'! i.v.) on Day 1, 
with AM (lng kg'! min'! i.v.) on Day 2 and with IMD (lng kg'! min'!) on Day 
3, for 20 min prior to 3 min challenges of adenosine (300llg kg'! min'! i.v.). 
The saline or peptide infusions continued during the adenosine challenge. The 
dose of adenosine was chosen because it was used in previous studies (see 
Chapter 6), and is known to cause robust cardiovascular responses. The dose 
of peptides was the same as the dose of AM used by Sakai & Saito (1998), 
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which they showed to have no effect on blood pressure but was able to 
enhance adenosine-mediated hypotension. This experimental protocol is 
outlined in Figure 7.2.1. 
15 min 20 min 3 min 
~ ~
Day 1 f f f 
Saline Saline Ado Ado 
on in on otT 
15 min 20 min 3 min 
Day 2 ~ ~f f f 
AM AM Ado Ado 
on in on otT 
15 min 20min 3min 
~ ~
Day 3 f f f 
IMD IMD Ado Ado 
on in on otT 
Figure 7.2.1 Animals were pre-treatedfor 20 min with saline on Day 1, with 
AM on Day 2, and with IMD on Day 3, prior to a 3 min challenge of 
adenosine (Ado). The 15 min period at the start of the saline/AMI/MD infusion 
represents the time taken for the solution to advance through the dead space of 
the catheter (i. e. 0.1 ml) 
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7.2.2 Cardiovascular responses to A1U & IMD during infusion of 
adenosine 
To assess whether adenosine had any effect on the cardiovascular response to 
AM and IMD, a group (n=ll) of animals received a pre-treatment of saline 
(D.4ml h-1 i.v.) or adenosine ( 3 ~ g g kg-1 min-I Lv.), infused for 2D min prior to 
administration of peptide. AM (3nmol kg-I Lv.) or IMD (tnmol kg-I i.v.) were 
then given as a 0.1 ml bolus and cardiovascular responses were recorded for 
30 min during which animals continued to receive saline or adenosine. The 
dose of adenosine was that used by Sakai et a1. (1998) and the doses of 
peptides were those used in previous studies (see Chapters 3-5), in which they 
caused robust cardiovascular responses. Since AM and IMD at the doses given 
cause marked vasodilatations, the above protocol was repeated using lower 
doses of pep tides (AM Inmol kg-I; IMD 0.3nmol kg-I i.v.), as any synergism 
could have been be difficult to observe if peptide administration had caused 
maximal vasodilatation. The protocol was randomised, such that each animal 
received all treatments over the 4 day experimental period, with 1 treatment 
each morning, and 1 treatment each afternoon. In cases where animals 
received 2 doses of a peptide in 1 day, they were always given the lower dose 
in the morning and the higher dose in the afternoon. An example protocol is 
illustrated in Figure 7.2.2. 
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Saline 
on 
Ado 
on 
Saline 
on 
Ado 
on 
15 min 20min 60min 
t t 
Saline AM 
in (1 or 3nmolkg- l ) 
15 min 20min 60min 
t t 
Ado AM 
in (1 or 3nmol kg-I) 
15 min 20min 60 min 
t t 
Saline IMD 
in (0.3 or Inmol kg"l) 
15 min 
t 
Ado 
in 
20 min 60 min 
t 
IMD 
(0.3 or Inmol kg-I) 
Figure 7.2.2 Animals were pre-treated for 20 min with saline, or adenosine 
(Ado), prior to administration of either AM or IMD, cardiovascular changes 
were measured for 60 min during which the saline/adenosine infusion was 
present. The 15 min period at the start of the saline/Ado infusion represents 
the time taken for the solution to advance through the dead space of the 
catheter (i.e. O.lml). 
226 
7.3 Results 
7.3.1 Cardiovascular responses to adenosine during infusion of A ~ I I or 
IMD 
Baseline cardiovascular variables, pnor to the onset of saline/ AMlIMD 
infusion, and prior to administration of adenosine are given in Table 7.1. There 
were no differences in any groups indicating that low dose AM or IMD 
infusion had no effect on baseline blood pressure or regional haemodynamics. 
The cardiovascular changes during a 3 min adenosine infusion, in the presence 
of saline were the same as those reported in Chapter 6, namely, tachycardia 
and hypotension, and renal, mesenteric and hindquarters vasodilatations 
(Figure 7.la). The cardiovascular response to adenosine was not changed in 
the presence of AM infusion (P>0.05, for 0-3 min integrated changes for all 
variables), although there appeared to be some attenuation of adenosine-
mediated mesenteric vasodilatation, this was not statistically significant 
(Figure 7.la). 
Cardiovascular changes during a 3 min infusion of adenosine in the presence 
of an infusion of IMD are shown in Figure 7.1 b, which illustrates that the 
adenosine-mediated fall in blood pressure and renal vasodilatation were 
significantly attenuated (P<0.05, for 0-3 min integrated changes). There was 
also some attenuation of IMD-mediated vasodilatation in the mesenteric and 
hindquarters vascular beds, but this failed to reach significance (P>0.05, for 
integrated changes). 
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7.3.2 Cardiovascular responses to AM & lAID during infusion of 
adenosine 
Responses to AM in the presence of adenosine 
Baseline haemodynamics preceding saline or adenosine infusion and 
administration of peptides are given in Tahle 7.2. There were no significant 
differences between groups indicating that pre-treatment with low dose 
adenosine had no effect on cardiovascular variables. 
Cardiovascular responses to AM (1 and 3nmol kg-I) during a saline infusion 
are shown in Figure 7.2. Cardiovascular responses to AM, at each dose, were 
similar to those reported previously (Chapter 3-5), i.e., a fall in blood pressure 
and tachycardia with increases in renal, mesenteric and hindquarters vascular 
conductances; these effects were sustained for a longer period time following 
administration of AM at the higher dose. Cardiovascular responses to AM in 
the presence of a low-dose infusion of adenosine, are shown in Figure 7.2; 
they were not different from those observed during infusion of saline (P>0.05, 
for 0-30 min integrated changes for all variables). 
Responses to IMD in the presence of low-dose adenosine 
Resting cardiovascular variables prior to administration of IMD are shown in 
Table 7.2. Intermedin at a dose of 0.3nmol kg-) caused a modest fall in blood 
pressure and a tachycardia, and increases in renal, mesenteric and hindquarters 
vascular conductances; all variables returned to baseline values by 10-20 min 
(Figure 7.3a). At a dose of Inmol kg-I, IMD caused a fall in blood pressure 
and tachycardia and increases in renal, mesenteric and hindquarters vascular 
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conductances which were significantly more marked than those evoked by the 
lower dose (P<0.05, for 0-10 min integrated changes for each variable) 
(Figure 7.3b), as noted in Chapter 3- 5. In the presence of adenosine there was 
no change in the cardiovascular response to IMD at a dose of 0.3nmol kg-I 
(P>0.05, for 0-10 min integrated changes for each variable). However, at the 
higher dose of !MD (lnmol kg-I), low dose adenosine caused significant 
attenuation of !MD-mediated mesenteric, but not renal or hindquarters 
vasodilatation. Furthermore, although there was no significant IMD-mediated 
fall in blood pressure in the presence of adenosine (Friedman's test), the 
integrated (0-10 min) change was not significantly different from the blood 
pressure response in the saline-infused condition. The effect of !MD on heart 
rate was not changed in the presence of adenosine (Figure 7.3). 
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+ saline infusion + AM infusion + IMD infusion 
(a) (b) (a) (b) (a) (b) 
HR (beats min-1) 372±1O 364±12 355±1l 348±11 343±9 360±8 
MAP (mmHg) 114±4 116±5 115±5 114±4 I05±2 107±2 
RVC (units) 79±8 77±7 76±9 74±7 76±9 76±8 
MVC (units) 7I±8 64±6 65±8 63±8 73±9 74±8 
HVC (units) 42±4 38±3 43±2 40±1 49±4 48±4 
Table 7.1 Baseline cardiovascular variables prior to the onset of saline or AA! or [MD infusion (a) and prior to administration of 
adenosine (b) in conscious rats (n=9). Values are mean ± SE. 
Units for vascular conductance (VC) are kHz mmHg-1 x Id. 
Saline+AM Adenosine + AM 
Inmol kg-1 3nmol kg-1 Inmol kg-1 3nmol kg-t 
(a) (b) (a) (b) (a) (b) (a) (b) 
HR (beats min-I) 328±8 325±6 320±7 341±1O* 320±8 325±7 337±12 330±8 
MAP (mmHg) I02±1 I02±2 I00±2 I04±3 I02±2 I06±2 lO2±2 I03±3 
RVC (units) 73±9 71±9 71±9 71±9 73±7 70±7 78±7 75±7 
MVC (units) 73±7 73±7 70±4 71±8 7l±6 7l±7 74±7 72±8 
HVC (units) 45±2 43±3 43±2 43±3 42±3 41±2 44±3 44±3 
Saline+IMD Adenosine + IMD 
O.3nmol kg- t Inmol kg- t O.3nmol kg-I Inmol kg-I 
(a) (b) (a) (b) (a) (b) (a) (b) 
HR (beats min-I) 331± 7 334± 1 0 323±6 323±4 333±17 333±16 323±5 327±9 
MAP (mmHg) I03±4 I05±4 99±2 101±2 I03±3 I05±5 101±2 lO0±2 
RVC (units) 75±11 81±1O 76±8 75±8 77±11 79±9 72±7 71±8 
MVC(units) 67±11 73±10 72±9 7l±9 75±8 74±9 72±6 73±7 
HVC (units) 46±4 46±3 47±3 42±3 45±3 43±2 41±2 42±2 
Table 7.2 Resting cardiol'ascularvariables prior to the onset of saline or adenosine infusion (a) and prior to administration of A}'[ or IMD (b) in 
conscious rats (n= J J). Values are mean ± SE. Units for vascular conductance (VC) are kHz mmHg-1 x ](/. 
·P<O.05 vs. value at onset of saline/adenosine infusion. 
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Figure 7.1 Cardiovascular responses to adenosine (300pg kg-I mine] i. v.) during continuous infusion of saline (open circles), (a) AA! (lng kg-J 
min-J) (closed circles) or (b) rMn (lng kg-I min-I) (closed circles) in conscious rats (n=JJ). 
·P<O.05 versus original baseline (Friedman'S test). #P<O.05 vs. saline {JJ'ilcoxon test}. 
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Figure 7.2 Cardiovascular responses to (a) ~ f f 1 nmol kg-1 and (b) 3nmol kg-1 during a continuous infusion of saline (open circles) or 
adenosine (3pg kg-1 min-I i. v.) (closed circles) in conscious rats (n=9). 
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Figure 7.3 Cardiovascular responses to (a) lAID O.3nmol kg-1 and (b) InmoI kg-I during a continuous infusion o/saline (open circles) or 
adenosine (3pg kg-1 min-I i.v.) (closed circles) in conscious rats (n=9). 
*P<O.05 versus original baseline (Friedman's test). flp<O.05 versus saline (Wilcoxon test) 
7.4 Discussion 
In a series of experiments, Sakai and Saito. (1998) showed that adenosine, 
VIP, CGRP and AM could reciprocally interact, such that they enhanced each 
other's vasodepressor actions: this effect was mediated via the activation of 
KATP channels (Sakai et al., 1998a,b,c,d). The present study aimed to replicate 
these findings in conscious, freely moving rats, and to extend this by 
detennining if there was any synergism between adenosine, AM and IMD in 
the cardiovascular system. Thus, responses to adenosine were assessed in the 
presence of a sub-depressor dose of AM or IMD, and the cardiovascular 
responses to AM and IMD were assessed in the presence of a sub-depressor 
dose of adenosine. Contrary to the findings of Sakai et al. (1998), no evidence 
was found for a synergistic interaction between adenosine and AM. Thus, the 
regional haemodynamic responses to both low (lnmol kg-I) and high (3nmol 
kg-I) dose AM were not different between animals receiving an infusion of 
adenosine and those receiving saline. Furthermore, the cardiovascular 
response to adenosine was not changed when co-infused with AM, further 
indicating that there was no synergistic interaction between these two agents. 
In their studies, Sakai & Saito (1998) showed that the reciprocal interaction 
between AM and adenosine was mediated via the opening ofKATP channels in 
a manner which caused amplification of membrane hyperpolarisation (Sakai et 
al., 1998d). This was shown following Lv. administration of adenosine and 
AM, and in isolated smooth muscle cells isolated from rat mesenteric vascular 
bed. The role of KATP channels in AM-mediated vasodilatation and 
hypotension has been confirmed in some studies (Sabates et al., 1997; Goto et 
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al., 2000) but not in others (M iura et al., 1995; Terata et al., 2000). Using the 
KATP channel blocker, U37783A, no role for KATP channels was found in AM-
mediated renal, mesenteric or hindquarters vasodilatation (Chapter 4). Thus, 
the present results are internally consistent, i.e., there was no evidence for 
KATP-channe1 involvement in AM-signalling (Chapter 4), and no synergism 
was found between AM and adenosine (this Chapter). Since Sakai et al. 
(1998) used anaesthetised animals in their studies, whereas conscious rats 
were used in the present experiments, it is possible that this may account for 
the disparate findings. 
The experiments reported here also assessed possible synerglsm betwecn 
adenosine and !MD, which shares some sequence homology with AM and has 
effects on the cardiovascular system similar to those of AM (Chapters 3-5; 
Takei et al., 2005; Roh et al., 2004). The cardiovascular responses to the low 
dose of !MD (O.3nmol kg-I) were unaffected in the presence of adenosine, but, 
contrary to expectation, adenosine infusion caused a significant attenuation of 
the mesenteric vasodilatation induced by the high dose of IMD (lnmol kg-I). 
The inhibitory interaction between these two agents was also obscrved in the 
cardiovascular response to adenosine in the presence of IMD. In these 
experiments there was significant attenuation of adenosine-mediated 
vasodilatation in the renal vascular bed, and to some extent in the mesentery 
and hindquarters, although in the case of the latter two this failed to reach 
statistical significance. Furthermore, the reduced adenosine-mediated 
vasodilatations were reflected in the blood-pressure response, such that in the 
presence of !MD, adenosine-mediated hypotension was abolished. Since, at 
the doses used, neither adenosine nor IMD pretreatment had any effect on 
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resting cardiovascular variables (Table 7.1 and 7.2), the observed negative 
synergism between IMD and adenosine can not be explained by any 
differences in baseline haemodynamics between the groups. Interestingly, 
despite the lack of hypotensive response to IMD in the presence of adenosine, 
there was still a significant tachycardia, which suggests IMD may have some 
positive chronotropic effect on the heart (Chapter 3). The exact physiological 
role of IMD in the heart remains speCUlative, but our findings are suggestive 
of a direct action of IMD on the heart, and support those of Dong et al. (2006) 
who showed that IMD had a direct effect on myocyte contractile function, and 
those of Fujisawa et al. (2006) who showed that there was a residual IMD-
induced increase in heart rate following surgical denervation of aortic 
baroreceptors in rats (Dong et al., 2006; Fujisawa et al., 2006). 
There are relatively few studies examining the effects of IMD on regional 
haemodynamics, and the mechanisms through which IMD leads to 
vasorelaxation remain unclear. Others have identified IMD as a non-selective 
agonist of the CURAMP receptor system, which also binds CGRP and AM in 
a selective manner (Roh et al., 2004; Pan et al., 2005; Kandilci et al., 2006; 
Dong et al., 2006; Chapter 4). We have identified that IMD-mcdiatcd 
vasodilatation is sensitive to AM22.52 in the renal and mesenteric vascular beds 
(Chapter 4), and others have found a role for CGRPs.37-senstive rcccptors 
(Kobayashi et al., 2004; Roh et al., 2004; Taylor et al., 2004; Kandi1ci et al., 
2006, 2008; Ren et al., 2006). We have also demonstrated that a component 
of IMD-mediated vasodilatation in the renal and mesenteric vascular beds is 
sensitive to L-NAME, (Chapter 4), although no such role was found for NO in 
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AM-mediated vasodilatation in this study. As adenosine can influence 
vascular tone in an endothelial manner via production of NO (Barrett & 
Droppleman, 1983; Ray et al., 2002; Hansen et al., 2005), it is possible that 
limitation of the available NO is responsible for the observed functional 
antagonism between IMD and adenosine. 
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Chapter 8 
General Discussion 
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8.1 Summary of main findings 
In Chapter 3, the regional haemodynamic responses to AM and IMD were 
assessed and compared. Intennedin evoked widespread vasodilatations which 
were sufficient to cause a fall in blood pressure and an increase in heart rate, 
consistent with the findings of others (Roh et al., 2004; Takei et al., 2004; 
Charles et al., 2006; Ren et al., 2006; Fujisawa et al., 2007; Chauhan et al., 
2007). These responses were similar, but more marked, than those caused by 
equimolar (lnmol kg-I) AM, which at this dose failed to cause a reproducible 
fall in blood pressure. In an attempt to match the responses, AM at a dose of 
3nmol kg-I was used. At this dose, AM caused marked hypotension 
accompanied by widespread vasodilatation, which was more marked than that 
caused by IMD in the renal vasculature. 
In Chapter 4, IMD-mediated vasodilatation was shown to be attenuated by 
AM22-52 and L-NAME in the renal and mesenteric, and renal vascular beds, 
respectively. This suggests that activation of AM22_srsensitive receptors and 
release of NO were involved in mediating some of the vascular effects of 
!MD. L-NAME attenuated but did not abolish the vasodilator action of IMD, 
suggesting that the peptide stimulates both endothelial-dependent and -
independent pathways. While some aspects of AM signalling were affected by 
AM22-s2, (renal and mesenteric vasodilatation), they were unaffected by L-
NAME. Thus, evidence was found of IMD-mediated endothelial dependent 
vasodilatation, but not AM. No role for KATP channels was found for either 
peptide, although there was an enhanced vasodilatation response to AM in the 
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renal and mesenteric vasculature following treatment with U37883A. With 
the use of losartan, it was shown that this response was mediated by inhibition 
of the renin-angiotensin system. Several studies have shown that IMD is a 
non-selective agonist of the CURAMP system, and its cardiovascular effects 
are sensitive to the CORPI receptor antagonist CORPg•37 (Kobayashi et al., 
2004; Roh et al., 2004; Taylor et al., 2004; Ren et al., 2006; Kandilci et al., 
2006; 2008). However, we found no role for this receptor in mediating the 
vascular effects of either peptide. 
Although interest in this group of pep tides is high, research is difficult due to a 
lack of selective agonists and antagonists. Knockout mice have been of some 
value in the study of AM function, and have shown it to be essential for 
vascular development. Furthermore, mice heterozygous for the AM gene have 
increased blood pressure and reduced levels of NO, suggesting that AM is 
involved in cardiovascular homeostasis in normal animals (Shindo et al., 
2001). Since RAMP2 was found to be essential for this function of AM 
(Shindo et al., 2008), and we (chapter 4), and others (see above) have shown 
IMD can activate RAMP2-containing AM receptors, it is possible that this 
function is shared by IMD. 
In Chapter 5, vascular responsiveness to AM and IMD was assessed across 
time in LPS-treated rats. By itself, LPS (lmg kg-I i.p.) led to the development 
of widespread vasodilatations, the pattern of which was both temporally and 
spatially distinct, without a corresponding fall in blood pressure. When given 
1.5 h after LPS-administration, there was a significant loss of vascular 
responsiveness to both AM and IMD; but responses had almost recovered by 
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25 h. The next set of experiments aimed to replicate these results in rats treated 
with a continuous low dose LPS infusion, to determine whether the gradual 
return in responsiveness to the peptides was a consequence of the waning 
effects of LPS. At 1.5 h there was vascular hyporesponsiveness to both AM 
and !MD, but responsiveness returned sooner than was found following LPS 
bolus administration, and peptide responses were augmented in some cases hy 
the 25 h time point. Enhanced vascular tone at baseline could have explained 
these results, perhaps due to enhanced involvement of vasoconstrictor systems, 
such as endothelin. 
Increased production of AM following stimulation with LPS could have 
accounted for the vascular hyporesponsiveness to exogenous AM at 1.5 h after 
LPS and to investigate this, the AM receptor antagonist, AM22.s2, was 
administered 1.5 h from the onset of endotoxaemia. There was no response to 
the antagonist, but this could have been either because endogenous AM was 
not exerting a tonic effect at this time point, or because the rcccptor 
components to which this antagonist binds were down regulated. Thus, 
downregulation of RAMP2 could explain the loss of vascular responsiveness 
to AM and !MD (since we show in chapter four that AM receptors comprised 
of this accessory protein are involved in both AM and !MD-mediated 
vasodilatation), and the lack of results with AM22.S2. 
In Chapter 6, the role of adenosine in the cardiovascular sequelae of 
endotoxaemia was examined. Using the non-selective adenosine-receptor 
antagonist, 8-PT, a clear role was demonstrated for endogenous adenosine in 
the maintenance of vascular tone in normal, conscious animals, and in the 
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changing cardiovascular response to LPS. The response to exogenous 
adenosine was altered in the presence ofLPS in such a way that it could have 
been due to either an up-regUlation of adenosine AI receptor responses, andlor 
to a down-regulation of adenosine A2 mediated responses. To investigate this 
further, the selective AI receptor agonist, CCP A, and the antagonist DPCPX 
were used. The results indicated that whilst altered AI receptor function could 
account for some of the altered responses to adenosine in LPS-treated rats, it 
could not account for them all. Hence, a changing influence of both AI and A2 
adenosine receptors is likely in this model of endotoxaemia. 
Finally, in Chapter 7, experiments were perfonned which were designed to 
replicate the findings of Sakai et al. (1998a,b,c), who showed that the 
vasodepressor response to adenosine was potentiated in the presence of sub-
depressor doses of a number of vasoactive peptides, including AM. However, 
no evidence was found for synergism between adenosine and AM. Contrary 
to the results with adenosine and AM, a negative interaction between 
adenosine and !MD was observed. The reasons for these remain to be 
explored, but the findings highlight an interesting difference between the two 
peptides. 
In summary, the work contained within this thesis is consistent with other 
studies which have shown !MD to have comparable effects on the 
cardiovascular system to AM, due, in part to IMD's ability to activate the 
same receptors. However, the lack of phannacological tools to study this 
receptor system limits the extent to which it can be studied, and the true 
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contribution of each receptor in mediating the haemodynamic effects of IMD 
remain to be determined. This work has also extended previous findings by 
the haemodynamic group at the University of Nottingham, which have shown 
changing vascular responses to vasoactive mediators during LPS-induced 
endotoxaemia in conscious rats. As both adenosine receptor ligands and AM 
are being studied as potential novel treatments in clinical sepsis, these 
findings are important, because they indicate that the point in the progression 
of sepsis should be considered together with putative regional haemodynamic 
effects, as well as the region targeted. 
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8.2 Suggestions for further research 
In the future, the following studies would be of interest to extend the work 
contained within this thesis: 
1. To measure levels of AM, IMD and adenosine in plasma and tissues taken 
from LPS-treated rats. 
2. Determination of the mechanisms responsible for the loss of vascular 
responsiveness to AM and IMD 1.5 h from the onset of endoxaemia. This 
could be achieved in the following ways: 
a) Assessment of responses to agents which cause vasodilatation by a 
known mechanism. For example, the extent of endothelial dysfunction 
could be detennined using known endothelial-dependent vasodilators, 
such as salbutamol and acetylcholine. The role of the NO pathway 
could be assessed using the NO donor, SNP, and LCK could be used to 
assess the function ofKATP channels. 
b) Molecular and/or cellular biology techniques could be used to measure 
the levels of CURAMP receptor components in harvested tissues taken 
from rats 1.5 h from the onset of endotoxaemia (and to quantify levels 
of adenosine receptors at each time point, see Chapter six). 
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c) As co-administration of AM and AMBP-l has been shown to reverse 
endothelial dysfunction in models of sepsis, AMBP-l could be 
administered with AM or IMD, to determine if this combination 
restored vascular responsiveness to these peptides at the 1.5 h time 
point. It would also be of interest to assess the impact of AMBP-l on 
IMD function; indeed, it is not known whether !MD binds with this, or 
a similar, binding protein. Furthermore, if vascular responsiveness is 
restored at the 1.5 h time point by AMI AMBP-l co-administration, it 
would be of interest to administer AMBP-l as a pre-treatment and then 
to assess whether this combination was able to restore vascular 
responsiveness in a global fashion. 
3. To determine if regional loss of vascular responSlveness to peptidcs 
(and/or other agents) occurred in the conscious rat in other models of 
sepsis. This would identify common features of such models which may 
have clinical relevance. 
4. To develop a Gram-positive model of sepsis. This has increasing clinical 
relevance due to the spread of hospital-acquired infections. 
246 
References 
247 
Abdelrahman, AM, Pang, CC (2006). Effect of intermedinladrenomedullin-2 
on venous tone in conscious rats. Naunyn-Schmiedeberg's Arch.s Pharmacol 
373: 376-380. 
Abdelrahman, AM, Pang, CC (2007). Vasodilator mechanism of 
intermedinladrenomedullin-2 in anesthetized rats. Proc. West. Pharmacol. 
Soc 50: 43-46. 
Ackland, G, Grocott, MP, Mythen, MG (2000). Understanding 
gastrointestinal perfusion in critical care: so near, and yet so far. Crit. Care 
4: 269-281. 
Adanin, S, Yalovetskiy, IV, Nardulli, BA, Sam, AD, 2nd, Jonjev, ZS, Law, 
WR (2002). Inhibiting adenosine deaminase modulates the systemic 
inflammatory response syndrome in endotoxemia and sepsis. Am. J. Physiol. 
282: R1324-R1332. 
Albertin, G, Carraro, G, Nussdorfer, GG (2005). Human adrenomedullin 
gene silencing by short interfering RNAs: a preliminary study. Int. J. Mol. 
Med .15: 579-583. 
Angus, DC, Linde-Zwirble, WT, Lidicker, J, Clermont, G, Carcilto, J, 
Pinsky, MR (2001). Epidemiology of severe sepsis in the United States: 
analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 
29: 1303-1310. 
Balk, RA (2002). Endotoxemia in critically ill patients: why a reliable test 
could be beneficial. Crit Care 6: 289-290. 
Barrett, RJ, Droppleman, DA (1993). Interactions of adenosine Al receptor-
mediated renal vasoconstriction with endogenous nitric oxide and ANG 11. 
Am. J. Physiol. 265: F651-659. 
Beasley, D, Cohen, RA, Levinsky, NG (1990). Endotoxin inhibits 
contraction of vascular smooth muscle in vitro. Am. J. Physiol. 258: H1187-
1192. 
248 
Belardinelli, L, Shryock, J, West, GA, Clemo, HF, DiMarco, JP, Berne, RM 
(1984). Effects of adenosine and adenine nucleotides on the atrioventricular 
node of isolated guinea pig hearts. Circulation 70: 1083-1091. 
Belardinelli, L, Giles, WR, West, A (1988). Ionie mechanisms of adenosine 
actions in pacemaker cells from rabbit heart. J. Physiol. 405: 615-633. 
Bell, D, Zhao, Y, McCoy, FP, Devine, A, McDermott, BJ (2008). Expression 
of the counter-regulatory peptide intermedin is augmented in the presence of 
oxidative stress in hypertrophied cardiomyocytes. Cell. Physiol. Biochem. 
21: 409-420. 
Belloni, FL, Belardinelli, L, Halperin, C, Hintze, TH (1989). An unusual 
receptor mediates adenosine-induced SA nodal bradycardia in dogs. Am. J. 
Physiol. 256: HI553-1564. 
Bennett, T, Mah aj an, RP, March, JE, Kemp, PA, Gardincr, SM (2004). 
Regional and temporal changes in cardiovascular responses to 
norepinephrine and vasopressin during continuous infusion of 
lipopolysaccharide in conscious rats. Br. J. Anaesth. 93: 400-407. 
Berne, RM (1963). Cardiac nucleotides in hypoxia: possible role In 
regulation of coronary blood flow. Am. J. Physiol. 204: 317-322. 
Beutler, B, Rietschel, ET (2003). Innate immune sensing and its roots: the 
story of endotoxin. Nat. Rev. Immunol. 3: 169-176. 
Blair, R, Fisbman, B, Amit, Z, Weeks, JR (1980). A simple double channel 
swivel for infusions of fluids into unrestrained animals. Pharmacol. 
Biochem. Behav. 12: 463-466. 
Bone, RC, Balk, RA, Cerra, FB, Dellinger, RP, Fein, AM, Knaus, WA, 
Schein, RM, Sibbald, WJ (1992). Definitions for sepsis and organ failure and 
guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM 
Consensus Conference Committee. American College of Chest 
Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655. 
Bone, RC, Sibbald, WJ, Sprung, CL (1992). The ACCP-SCCM consensus 
conference on sepsis and organ failure. Chest 101: 1481-1483. 
249 
Borovikova, LV, Ivanova, S, Zhang, M, Yang, H, Botchkina, GI, Watkins, 
LR, Wang, H, Abumrad, N, Eaton, JW, Tracey, KJ (2000). Vagus nerve 
stimulation attenuates the systemic inflammatory response to endotoxin. 
Nature 405: 458-462. 
Brain, SD, Grant, AD (2004). Vascular actions of calcitonin gene-related 
peptide and adrenomedullin. Physiol. Rev. 84: 903-934. 
Brierley, J, Peters, MJ (2008). Distinct hemodynamic patterns of septic shock 
at presentation to pediatric intensive care. Pediatrics 122: 752-759. 
Brown, ZW, Amit, Z, Weeks, JR (1976). Simple flow-thru swivel for 
infusions into unrestrained animals. Pharmacol. Biochem. Behav. 5: 363-
365. 
Bryan, PT, Marshall, JM (1999). Adenosine receptor subtypes and 
vasodilatation in rat skeletal muscle during systemic hypoxia: a role for Al 
receptors.1. Physiol. 514: 151-162. 
Buckley, JF, Singer, M, Clapp, LH (2006). Role of KATP channels in sepsis. 
Cardiovasc. Res. 72: 220-230. 
Buras, JA, Holzmann, B, Sitkovsky, M (2005). Animal models of sepsis: 
setting the stage. Nat. Rev. Drug. Discov. 4: 854-865. 
Cameron, EM, Wang, SY, Fink, MP, Sellke, FW (1998). Mesenteric and 
skeletal muscle microvascular responsiveness in subacute sepsis. Shock 9: 
184-192. 
Carre, JE, Singer, M (2008). Cellular energetic metabolism in sepsis: the 
need for a systems approach. Biochim. Biophys. Acta. 1777: 763-771. 
Carrizo, GJ, Wu, R, Cui, X, Dwivedi, AJ, Simms, HH, Wang, P (2007). 
Adrenomedullin and adrenomedullin-binding protein-l downregulate 
inflammatory cytokines and attenuate tissue injury after gut ischemia-
reperfusion. Surgery 141: 245-253. 
250 
Casati, C, Monopoli, A, Dionisotti, S, Zocchi, C, Bonizzoni, E, Ongini, E 
(1994). Repeated administration of selective adenosine Al and A2 receptor 
agonists in the spontaneously hypertensive rat: tolerance develops to Al-
mediated hemodynamic effects. 1. Pharmacol. Exp. Ther. 268: 1506-1511. 
Champion, HC, Erickson, CC, 3rd, Simoneaux, ML, Bivalacqua, TJ, 
Murphy, WA, Coy, DH, Kadowitz, PJ (1996). Proadrenomedullin NH2-
terminal 20 peptide has cAMP-mediated vasodilator activity in the 
mesenteric vascular bed of the cat. Peptides 17: 1379-1387. 
Champion, HC, Santiago, JA, Murphy, WA, Coy, DH, Kadowitz, PJ (1997). 
Adrenomedullin (22-52) antagonizes vasodilator responses to CGRP but not 
adrenomedullin in the cat. Am. 1. Physiol. 272: R234-R242. 
Champion, HC, Pierce, RL, Bivalacqua, TJ, Murphy, WA, Coy, DB, 
Kadowitz, PJ (2001). Analysis of responses to hAmylin, hCGRP, and hADM 
in isolated resistance arteries from the mesenteric vascular bed of the rat. 
Peptides 22: 1427-1434. 
Chang, CL, Roh, J, Hsu, SY (2004). Intermedin, a novel calcitonin family 
peptide that exists in teleosts as well as in mammals: a comparison with othcr 
calcitonin/intermedin family peptides in vertebrates. Peptides 25: 1633-1642. 
Charles, CJ, Rademaker, MT, Richards, AM, Cooper, GJ, Coy, DH, Jing, 
NY, Nicholls, MG (1997). Hemodynamic, hormonal, and renal effccts of 
adrenomedullin in conscious sheep. Am. 1. Physio/. 272: R2040-2047. 
Charles, CJ, Lainchbury, JG, Nicholls, MG, Rademaker, MT, Richards, AM, 
Troughton, RW (2003). Adrenomedullin and the renin-angiotensin-
aldosterone system. Regul. Pept. 112: 41-49. 
Charles, CJ, Rademaker, MT, Richards, AM (2006). Hemodynamic, 
hormonal, and renal actions of adrenomedullin-2 in normal conscious sheep. 
Endocrinology 147: 1871-1877. 
Chauhan, M, Ross, GR, Yallampalli, V, Yallampalli, C (2007). 
Adrenomedullin-2, a novel calcitonin/calcitonin-gene-related peptide family 
peptide, relaxes rat mesenteric artery: influence of pregnancy. Endocriflology 
148: 1727-1735. 
251 
Cheung, BM, Hwang, IS, Li, CV, 0, WS, Tsang, KW, Leung, RY, Kumana, 
CR, Tang, F (2004). Increased adrenomedullin expression in lungs in 
endotoxaemia. J. Endocrinol. 181: 339-345. 
Churchill, PC, Churchill, MC (1985). Al and A2 adenosine receptor 
activation inhibits and stimulates renin secretion of rat renal cortical slices. J. 
Pharmacol. Exp. Ther. 232: 589-594. 
Churchill, PC, Bidani, AK, Schwartz, MM (1987). Renal effects of 
endotoxin in the male rat. Am. J. Physiol. 253: F244-250. 
Cohen, ES, Law, WR, Easington, CR, Cruz, KQ, Nardulli, BA, Balk, RA, 
Parrillo, JE, Hollenberg, SM (2002). Adenosine deaminase inhibition 
attenuates microvascular dysfunction and improves survival in sepsis. Am. J. 
Respir. Cri!. Care Med. 166: 16-20. 
Cohen, J (2002). The immunopathogenesis of sepsis. Nature 420: 885-891. 
Cohen, J (2000). The detection and interpretation of endotoxaemia. Intensive 
Care Med. 26: S51-56. 
CoB in, M, Murch, 0, Thiemermann, C (2006). Peroxisome proliferator-
activated receptor-gamma antagonists GW9662 and T0070907 reduce the 
protective effects of lipopolysaccharide preconditioning against organ failure 
caused by endotoxemia. Cri!. Care Med. 34: 1131-1138. 
Conlay, LA, Evoniuk, G, Wurtman, RJ (1988). Endogenous adenosine and 
hemorrhagic shock: effects of caffeine administration or caffeine withdrawal. 
Proc. Natl. Acad. Sci. USA 85: 4483-4485. 
Conlon, BA, Ross, JD, Law, WR (2005). Advances in understanding 
adenosine as a plurisystem modulator in sepsis and the systemic 
inflammatory response syndrome (SIRS). Front. Biosci. 10: 2548-2565. 
Connelly, L, Madhani, M, Hobbs, AJ (2005). Resistance to endotoxic shock 
in endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-
inflammatory role for eNOS-derived no in vivo. J. BioI. Chem. 280: 10040-
10046. 
252 
Cotter, G, Dittrich, HC, Weatherley, BD, Bloomfield, DM, O'Connor, CM, 
Metra, M, Massie, BM (2008). The PROTECT pilot study: a randomized, 
placebo-controlled, dose-finding study of the adenosine Al receptor 
antagonist rolofylline in patients with acute heart failure and renal 
impainnent. J. Card. Fail. 14: 631-640. 
Cronstein, BN, Levin, RI, Phi lips, M, Hirschhom, R, Abramson, SB, 
Weissmann, G (1992). Neutrophil adherence to endothelium is enhanced via 
adenosine Al receptors and inhibited via adenosine A2 receptors. J. 
Immunol. 148: 2201-2206. 
Cui, H, Kohsaka, A, Waki, H, Gouraud, S, Nakamura, T, Yukawa, K, 
Hatada, A, Bhuiyan, ME, Maeda, M (2008). Adrenomedullin 2 
microinjection into the nucleus tractus solitarius elevates arterial pressure and 
heart rate in rats. Auton. Neurosci. 142: 45-50. 
Cui, X, Wu, R, Zhou, M, Dong, W, Ulloa, L. Yang, H, Wang, H, Tracey, KJ. 
Simms, HH, Wang, P (2005). Adrenomedullin and its binding protein 
attenuate the proinflammatory response after hemorrhage. Cri!. Care Med. 
33: 391-398. 
Cui, Y, Ji, Y, Wu, R, Zhou, M, Wang, P (2006). Adrenomedullin binding 
protein-l is downregulated during polymicrobial sepsis in the rat. Int J Mol 
Med 17: 925-929. 
Cunha, RA (2001). Adenosine as a neuromodulator and as a homcostatic 
regulator in the nervous system: different roles, different sources and 
different receptors. Neurochem. Into 38: 107-125. 
Czaika, G, Gingras, Y, Zhu, E, Comtois, AS (2000). Induction of the ATP-
sensitive potassium (uK(ATP)-I) channel by endotoxemia. Muscle Nerve. 
23: 967-969. 
Dabisch, PA, Liles, JT, Taylor, JT, Sears, BW, Saenz, R, Kadowitz, PJ 
(2004). Role of potassium channels in the nitric oxide-independent 
vasodilator response to acetylcholine. Pharmacol. Res. 49: 207-215. 
Dackor, R, Caron, K (2007). Mice heterozygous for adrenomedullin exhibit a 
more extreme inflammatory response to endotoxin-induced septic shock. 
Peptides 28(11): 2164-2170. 
253 
Danialou, G, Vicaut, E, Sambe, A, Aubier, M, Boczkowski, J (1997). 
Predominant role of Al adenosine receptors in mediating adenosine induced 
vasodilatation of rat diaphragmatic arterioles: involvement of nitric oxide and 
the ATP-dependent K + channels. Br. J. Pharmacol. 121: 1355-1363. 
Danner, RL, Elin, RJ, Hosseini, JM, Wesley, RA, Reilly, JM, Parillo, JE 
(1991). Endotoxemia in human septic shock. Chest 99: 169-175. 
DiMarco, JP, Sellers, TD, Berne, RM, West, GA, Belardinelli, L (1983). 
Adenosine: electrophysiologic effects and therapeutic use for terminating 
paroxysmal supraventricular tachycardia. Circulation 68: 1254-1263. 
Dixon, AK, Gubitz, AK, Sirinathsinghji, DJ, Richardson, PJ, Freeman, TC 
(1996). Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. 
Pharmacol. 118: 1461-1468. 
Dong, F, Taylor, MM, Samson, WK, Ren, J (2006). Intermedin 
(adrenomedullin-2) enhances cardiac contractile function via a protein kinase 
C- and protein kinase A-dependent pathway in murine ventricular myocytes. 
J. Appl. Physiol. 101: 778-784. 
Drury, AN, Szent-Gyorgyi, A (1929). The physiological activity of adenine 
compounds with especial reference to their action upon the mammalian heart. 
J. Physiol. 68: 213-237. 
Dwivedi, AJ, Wu, R, Nguyen, E, Higuchi, S, Wang, H, Krishnasastry, K, 
Marini, CP, Ravikumar, TS, Wang, P (2007). Adrenomedullin and 
adrenomedullin binding protein-l prevent acute lung injury after gut 
ischemia-reperfusion. J. Am. Coil. Surg. 205: 284-293. 
Dyson, A, Stidwill, R, Taylor, V, Singer, M (2007). Tissue oxygen 
monitoring in rodent models of shock. Am J Physiol. 293: HS26-S33. 
Eastridge, BJ, Darlington, DN, Evans, JA, Gann, DS (1994). A circulating 
shock protein depolarizes cells in hemorrhage and sepsis. Ann. Surg. 219: 
298-305. 
Elhawary, AM, Poon, J, Pang, CC (1995). Effects of calcitonin gene-related 
peptide receptor antagonists on renal actions of adrenomedullin. Br. J. 
Pharmacol. 115: 1133-1140. 
254 
Elsasser, TH, Kahl, S, Martinez, A, Montuenga, LM, Pio, R, Cuttitta, F 
(1999). Adrenomedullin binding protein in the plasma of multiple species: 
characterization by radioligand blotting. Endacrinalagy 140: 4908-4911. 
Ertmer, C, Morelli, A, Rehberg, S, Lange, M, Hucklenbruch, C, Van Aken, 
H, Booke, M, Westphal, M (2007). Exogenous adrenomedullin prevents and 
reverses hypodynamic circulation and pUlmonary hypertension in ovine 
endotoxaemia. Br. 1. Anaesth. 99: 830-836. 
Evans, DB, Schenden, JA, Bristol, JA (1982). Adenosine receptors mediating 
cardiac depression. Life Sci. 31: 2425-2432. 
Evoniuk, G, Jacobson, KA, Shamim, MT, Daly, JW, Wurtman, RJ (1987). 
AI- and A2-selective adenosine antagonists: in vivo characterization of 
cardiovascular effects. 1. Pharmacal. Exp. Ther. 242: 882-887. 
Farmer, MR, Roberts, RE, Gardiner, SM, Ralevic, V (2003). Effects of in 
vivo lipopolysaccharide infusion on vasoconstrictor function of rat isolated 
mesentery, kidney, and aorta. 1. Pharmacal. Exp. Ther. 306: 538-545. 
F eoktistov, I, Biaggioni, I (1997). Adenosine A2B receptors. Pharmacol. 
Rev. 49: 381-402. 
Femandes, D, da Silva-Santos, JE, Duma, D, Villela, CG, Barja-Fidalgo, e, 
Assreuy, J (2006). Nitric oxide-dependent reduction in soluble guanylate 
cyclase functionality accounts for early lipopolysaccharide-induced changes 
in vascular reactivity. Mol Pharmacal 69: 983-990. 
Fowler, DE, Wang, P (2002). The cardiovascular response in sepsis: 
proposed mechanisms of the beneficial effect of adrenomcdullin and its 
binding protein (review). Int. 1. Mol. Med. 9: 443-449. 
Fowler, DE, Yang, S, Zhou, M, Chaudry, HI, Simms, HH, Wang, P (2003). 
Adrenomedullin and adrenomedullin binding protein-I: their role in the 
septic response. J. Surg. Res. 109: 175-181. 
Fozard, JR, Hannon, JP (1999). Adenosine receptor ligands: potential as 
therapeutic agents in asthma and eOPD. Pulm. Pharmacol. Ther. 12: 111-
114. 
255 
Fredholm, BB, Ap, D, Jacobson, KA, Klotz, KN, Linden, J (2001). 
International Union of Pharmacology. XXV. Nomenclature and classification 
of adenosine receptors. Pharmacol. Rev. 53: 527-552. 
Fredholm, BB, Jacobson, KA, Jonzon, B, Kirk, KL, Li, YO, Daly, JW 
(1987). Evidence that a novel 8-phenyl-substituted xanthine derivative is a 
cardioselective adenosine receptor antagonist in vivo. J. Cardiovasc. 
Pharmacol. 9: 396-400. 
Fredholm, BB, Irenius, E, KuIl, B, Schulte, G (2001). Comparison of the 
potency of adenosine as an agonist at human adenosine receptors expressed 
in Chinese hamster ovary cells. Biochem. Pharmaco/. 61: 443-448. 
Fritz-Six, KL, Dunworth, WP, Li, M, Caron, KM (2008). Adrenomedullin 
signaling is necessary for murine lymphatic vascular development. J. Clin. 
Invest. 118: 40-50. 
Fuentes, JM, Talamini, MA, Fulton, WB, Hanly, EJ, Aurora, AR, De Maio, 
A (2006). General anesthesia delays the inflammatory response and increases 
survival for mice with endotoxic shock. Clin. Vaccine. Immllllol. 13: 281-
288. 
Fujisawa, Y, Nagai, Y, Miyatake, A, Takei, Y, Miura, K, Shoukouji, T, 
Nishiyama, A, Kimura, S, Abe, Y (2004). Renal effects of a new member of 
adrenomedullin family, adrenomedullin2, in rats. Eur. J. Pharmacol. 497: 
75-80. 
Fujisawa, Y, Nagai, Y, Miyatake, A, Miura, K, Shokoji, T, Nishiyama, A, 
Kimura, S, Abe, Y (2006). Roles of adrenomedutlin 2 in regulating the 
cardiovascular and sympathetic nervous systems in conscious rats. Am. J. 
Physiol. 290: HI120-HII27. 
Fujisawa, Y, Nagai, Y, Miyatake, A, Miura, K, Nishiyama, A, Kimura, S, 
Abe, Y (2007). Effects of adrenomedullin 2 on regional hemodynamics in 
conscious rats. Europeanjournal of ph arm acology 558: 128-132. 
GaIlos, G, Ruyle, TD, Emala, CW, Lee, HT (2005). At adenosine receptor 
knockout mice exhibit increased mortality, renal dysfunction, and hepatic 
injury in murine septic peritonitis. Am. J.Physiol. 289: F369-F376. 
256 
Gardiner, SM, Compton, AM, Bennett, T (1989). Regional hemodynamic 
changes following hypovolemia in conscious rats. Am. J. Physiol. 256: 
R1076-RI083. 
Gardiner, SM, Compton, AM, Kemp, PA, Bennett, T (1991). Effects ofNG-
nitro-L-arginine methyl ester or indomethacin on differential regional and 
cardiac haemodynamic actions of arginine vasopressin and lysine 
vasopressin in conscious rats. Br. J. Pharmacol. 102: 65-72. 
Gardiner, SM, Kemp, PA, Bennett, T (1991). Effects ofNG-nitro-L-arginine 
methyl ester on vasodilator responses to acetylcholine, 5'-N-
ethylcarboxamidoadenosine or salbutamol in conscious rats. Br. J. 
Pharmacol. 103: 1725-1732. 
Gardiner, SM, Kemp, PA, Bennett, T (1991). Effects ofNG-nitro-L-arginine 
methyl ester on vasodilator responses to adrenaline or BRL 38227 in 
conscious rats. Br. J. Pharmacol. 104: 731-737. 
Gardiner, SM, Kemp, P A, March, JE, Bennett, T (1995). Cardiac and 
regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and 
the effects of NOS inhibitors in conscious, endotoxaemic rats. Br. J. 
Pharmacol. 116: 2005-2016. 
Gardiner, SM, Kemp, P A, March, JE, Bennett, T (1995). Regional 
haemodynamic effects of human and rat adrenomedullin in conscious rats. 
Br. J. Pharmacol. 114: 584-591. 
Gardiner, SM, Kemp, PA, March, JE, Bennett, T (1996). Temporal 
differences between the involvement of angiotensin II and endothelin in the 
cardiovascular responses to endotoxaemia in conscious rats. Br. J. 
Pharmacol. 119: 1619-1627. 
Gardiner, SM, Kemp, P A, March, JE, Bennett, T (1999). Regional 
haemodynamic responses to infusion of lipopolysaccharide in conscious rats: 
effects of pre- or post-treatment with glibenclamide. Br. J. Pharmacol. 128: 
1772-1778. 
Gardiner, SM, March, JE, Kemp, PA, Bennett, T (1999). Influence ofCGRP 
(8-37), but not adrenomedullin (22-52), on the haemodynamic responses to 
lipopolysaccharide in conscious rats. Br. J. Pharmacol. 127: 1611-1618. 
257 
Gardiner, SM, March, JE, Kemp, PA, Bennett, T (2006). Effects of nitric 
oxide synthase inhibition with or without cyclooxygenase-2 inhibition on 
resting haemodynamics and responses to exendin-4. Br. J. Pharmacol. 149: 
802-809. 
Ghai, G, Francis, JE, Williarns, M, Dotson, RA, Hopkins, MF, Cote, DT, 
Goodman, FR, Zimmerman, MB (1987). Pharmacological characterization of 
CGS 15943A: a novel nonxanthine adenosine antagonist. J. Pharmacol. Exp. 
Ther. 242: 784-790. 
Gibbons, C, Dackor, R, Dunworth, W, Fritz-Six, K, Caron, KM (2006). 
"RAMP"ing up Adrenomedullin Signaling. Mol. Endocrinol. 21: 783-796. 
Goldfarb, RD, Glock, D, Kumar, A, McCarthy, RJ, Mei, J, Guynn, T, 
Matushek, M, Trenholme, G, Parrillo, JE (1996). A porcine model of 
peritonitis and bacteremia simulates human septic shock. Shock 6: 442-451. 
Goto, K, Fujii, K, Onaka, U, Abe, I, Fujishima, M (2000). Effects of 
adrenomedullin and P AMP on membrane potential and neurotransmission. 
Peptides 21: 257-263. 
Graier, WF, Myers, PR, Rubin, LJ, Adarns, HR, Parker, JL (1994}. 
Escherichia coli endotoxin inhibits agonist-mediated cytosolic Ca + 
mobilization and nitric oxide biosynthesis in cultured endothelial cells. Circ. 
Res. 75: 659-668. 
Granger, HJ, Norris, CP (1980). Role of adenosine in local control of 
intestinal circulation in the dog. Circ. Res. 46: 764-770. 
Grant, AD, Tarn, CW, Lazar, Z, Shih, MK, Brain, SD (2004). The calcitonin 
gene-related peptide (CGRP) receptor antagonist BIBN4096BS blocks 
CGRP and adrenomedullin vasoactive responses in the microvasculature. Br. 
J. Pharmacol. 142: 1091-1098. 
Harnid, SA, Baxter, GF (2006). A critical cytoprotective role of endogenous 
adrenomedullin in acute myocardial infarction. J. Mol. Cell Cardiol. 41: 360-
363. 
258 
Hansen, PB, Hashimoto, S, Oppennann, M, Huang, Y, Briggs, JP, 
Schnennann, J (2005). Vasoconstrictor and vasodilator effects of adenosine 
in the mouse kidney due to preferential activation of Al or A2 adenosine 
receptors. J. Pharmacol. Exp. Ther. 315: 1150-1157. 
Harrison, DA, Welch, CA, Eddleston, JM (2006). The epidemiology of 
severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: 
secondary analysis of a high quality clinical database, the ICNARC Case 
Mix Programme Database. Cri!. Care 10: R42. 
Hartley, CJ, Cole, JS (1974). An ultrasonic pulsed Doppler system for 
measuring blood flow in small vessels. J. Appl. Physiol. 37: 626-629. 
Hasko, G, Cronstein, BN (2004). Adenosine: an endogenous regulator of 
innate immunity. Trends. Immunol. 25: 33-39. 
Hattori, Y, Murakami, Y, Atsuta, H, Minamino, N, Kangawa, K, Kasai, K 
(1998). Glucocorticoid regulation of adrenomedullin in a rat model of 
endotoxic shock. Life Sci. 62: PLI81-PLI89. 
Hay, DL, Howitt, SG, Conner, AC, Schindler, M, Smith, DM, Poyner, DR 
(2003). CURAMP2 and CLlRAMP3 produce phannacologicaUy distinct 
adrenomedullin receptors: a comparison of effects of adrenomedullin22.52, 
CGRPS.37 and BIBN4096BS. Br. J. Pharmacol. 140: 477-486. 
Haywood, JR, Shaffer, RA, Fastenow, C, Fink, GD, Brody, MJ (1981). 
Regional blood flow measurement with pulsed Doppler flowmeter in 
conscious rat. Am. J. Physiol. 241: H273-H278. 
He, H, Bessho, H, Fujisawa, Y, Horiuchi, K, Tomohiro, A, Kita, T, Aki, Y, 
Kimura, S, Tamaki, T, Abe, Y (1995). Effects of a synthetic rat 
adrenomedullin on regional hemodynamics in rats. Eur. J. Pharmacol. 273: 
209-214. 
Heaton, J, Lin, B, Chang, JK, Steinberg, S, Hyman, A, Lippton, H (1995). 
Pulmonary vasodilation to adrenomedullin: a novel peptide in humans. Am. 
J. Physiol. 268: H2211-H2215. 
259 
Hiley, CR, Bottrill, FE, Wamock, J, Richardson, PJ (1995). Effects of pH on 
responses to adenosine, CGS 21680, carbachol and nitroprusside in the 
isolated perfused superior mesenteric arterial bed of the rat. Br. J. 
Pharmacal. 116: 2641-2646. 
Hingorani, AD, Cross, J, Kharbanda, RK, Mullen, MJ, Bhagat, K, Taylor, M, 
Donald, AE, Palacios, M, Griffin, GE, Deanfield, JE, MacAllister, RJ, 
Vallance, P (2000). Acute systemic inflammation impairs endothelium-
dependent dilatation in humans. Circulation 102: 994-999. 
Hintze, TH, Belloni, FL, Harrison, JE, Shapiro, GC (1985). Apparent 
reduction in baroreflex sensitivity to adenosine in conscious dogs. Am. J. 
Physiol. 249: H554-H559. 
Hirata, Y, Hayakawa, H, Suzuki, Y, Suzuki, E, Ikenouchi, H, Kohmoto, 0, 
Kimura, K, Kitamura, K, Eto, T, Kangawa, K, et al. (1995). Mechanisms of 
adrenomedullin-induced vasodilation in the rat kidney. Hypertension 25: 
790-795. 
Hofbauer, KH, Schoof, E, Kurtz, A, Sandner, P (2002). Inflammatory 
cytokines stimulate adrenomedullin expression through nitric oxide-
dependent and -independent pathways. Hypertension 39: 161-167. 
Humphrey, SJ, Ludens, JH (1998). K-ATP-blocking diuretic PNU-37883A 
reduces plasma renin activity in dogs. J. Cardiovasc. Pharmacal. 31: 894-
903. 
Hurley, JC (1994). Concordance of endotoxemia with gram-negative 
bacteremia in patients with gram-negative sepsis: a meta-analysis. J. Clin. 
Microbial. 32: 2120-2127. 
Hurley, JC (1995). Endotoxemia: methods of detection and clinical 
correlates. Clin. Microbial. Rev. 8: 268-292. 
Ichikawa-Shindo, Y, Sakurai, T, Kamiyoshi, A, Kawate, H, Iinuma, N, 
Yoshizawa, T, Ko yam a, T, Fukuchi, J, Iimuro, S, Moriyama, N, Kawakami, 
H, Murata, T, Kangawa, K, Nagai, R, Shindo, T (2008). The GPCR 
modulator protein RAMP2 is essential for angiogenesis and vascular 
integrity. J. Clin. Invest. 118: 29-39. 
260 
Ishimitsu, T, Ono, H, Minami, J, Matsuoka, H (2006). Pathophysiologic and 
therapeutic implications of adrenomedullin in cardiovascular disorders. 
Pharmacol. Ther. 111: 909-927. 
Jackson, EK (1991). Adenosine: a physiological brake on renin release. 
Annu. Rev. Pharmacol. Toxieo!. 31: 1-35. 
Jackson, EK, Zhu, C, Tofovic, SP (2002). Expression of adenosine receptors 
in the preglomerular microcircu1ation. Am. J. Physiol. 283: F41-F51. 
Jackson, EK, Mi, Z, Zacharia, LC, Tofovic, SP, Dubey, RK (2007). The 
pancreatohepatorenal cAMP-adenosine mechanism. J. Pharmacol. Exp. 
Ther. 321: 799-809. 
James, TN (1965). The chronotropic action of ATP and related compounds 
studied by direct perfusion of the sinus node. J. Pharmacol. Exp. Ther. 149: 
233-247. 
Jeukendrup, AE, Vet-Joop, K, Sturk, A, Stegen, JH, Senden, J, Saris, WH, 
Wagenmakers, AJ (2000). Relationship between gastro-intestinal complaints 
and endotoxaemia, cytokine release and the acute-phase reaction during and 
after a long-distance triathlon in highly trained men. Clin Sci (Lond) 98: 47-
55. 
Johansson, B, Halldner, L, Dunwiddie, TV, Masino, SA, Poelchen, W, 
Gimenez-Llort, L, Escorihuela, RM, Fernandez-Teruel, A, Wiesenfeld-
Hallin, Z, Xu, XJ, Hardemark, A, Betsholtz, C, Herlenius, E, Fredholm, BB 
(2001). Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in 
mice lacking the adenosine Al receptor. Proc. Natl. A cad. Sci. USA 98: 
9407-9412. 
Jolly, L, March, JE, Kemp, PA, BeI}nett, T, Gardiner, SM (2008). Regional 
haemodynamic responses to adenosine receptor activation vary across time 
following lipopolysaccharide treatment in conscious rats. Br. J. Pharmacol. 
154: 1600-1610. 
Jolly, L, March, JE, Kemp, PA, Bennett, T, Gardiner, SM (2009). 
Mechanisms involved in the regional haemodynamic effects of intermedin 
(adrenomedullin 2) compared with adrenomedullin in conscious rats. Br J 
Pharmaeol157: 1502-1513. 
261 
Kaiser, SM, Quinn, RJ (1999). Adenosine receptors as potential therapeutic 
targets. Drug Diseov. Today 4: 542-551. 
Kandilci, HB, Gumusel, B, Wasserman, A, Witriol, N, Lippton, H (2006). 
Intennedinladrenomedullin-2 dilates the rat pulmonary vascular bed: 
Dependence on CGRP receptors and nitric oxide release. Peptides 27: 1390-
1396. 
Kandilci, HB, Gumusel, B, Lippton, H (2008). Intermedinladrenomedullin-2 
(IMD/ AM2) relaxes rat main pulmonary arterial rings via cGMP-dependent 
pathway: role of nitric oxide and large conductance calcium-activated 
potassium channels (BK(Ca». Peptides 29: 1321-1328. 
Kapas, S, Martinez, A, Cuttitta, F, Hinson, JP (1998). Local production and 
action of adrenomedullin in the rat adrenal zona glomerulosa. J. Endoerinol. 
156: 477-484. 
Kato, J, Tsuruda, T, Kita, T, Kitamura, K, Eto, T (2005). Adrenomedullin: a 
protective factor for blood vessels. Arterioscle. Thromb. Vase Bioi. 25: 2480-
2487. 
Kellett, R, Bowmer, CJ, Collis, MG, Yates, MS (1989). Amelioration of 
glycerol-induced acute renal failure in the rat with 8-cyc1opentyl-l,3-
dipropylxanthine. Br. J. Pharmacol. 98: 1066-1074. 
Kirschning, CJ, Wesche, H, Merrill Ayres, T, Rothe, M (1998). Human to11-
like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J. Exp. 
Med. 188: 2091-2097. 
Kitamura, K, Kangawa, K. Kawamoto, M, Ichiki, Y, Nakamura, S, Matsuo, 
H, Eto, T (1993). Adrenomedullin: a novel hypotensive peptide isolated from 
human pheochromocytoma. Biochem. Biophys. Res. Commun. 192: 553-560. 
Kitamura, K, Sakata, J, Kangawa, K, Kojima, M, Matsuo, H, Eto, T (1993). 
Cloning and characterization of cDNA encoding a precursor for human 
adrenomedullin. Bioehem. Biophys. Res. Commun. 194: 720-725. 
Kobayashi, Y, Liu, YJ, Gonda, T, Takei, Y (2004). Coronary vasodilatory 
response to a novel Peptide, adrenomedullin 2. Clin. Exp. Pharmacol. 
Physiol. 31: S49-S50. 
262 
Koo, DJ, Zhou, M, Chaudry, IH, Wang, P (2001). The role of 
adrenomedullin in producing differential hemodynamic responses during 
sepsis. J. Surg. Res. 95: 207-218. 
Kristof, AS, Noorhosseini, H, Hussain, SN (1997). Attenuation of 
endothelium-dependent hyperpolarizing factor by bacterial 
lipopolysaccharides. Eur. J. Pharmacol. 328: 69-73. 
Kuan, CJ, Herzer, WA, Jackson, EK (1992). An experimental paradigm for 
investigating the role of endogenous adenosine/AI receptor interactions in 
vivo. J. Pharmacol. Exp. Ther. 263: 657-662. 
Kumar, A, Brar, R, Wang, P, Dee, L, Skorupa, G, Khadour, F, Schulz, R, 
Parrillo, JE (1999). Role of nitric oxide and cGMP in human septic serum-
induced depression of cardiac myocyte contractility. Am. J. Physioi. 276: 
R265-R276. 
Kumar, A, Paladugu, B, Mensing, J, Parrillo, JE (2007). Transforming 
growth factor-beta 1 blocks in vitro cardiac myocyte depression induced by 
tumor necrosis factor-alpha, interleukin-I beta, and human septic shock 
serum. Cri!. Care Med. 35: 358-364. 
Kumar, A, Thota, V, Dee, L, Olson, J, Uretz, E, Parrillo, JE (1996). Tumor 
necrosis factor alpha and interleukin 1 beta are responsible for in vitro 
myocardial cell depression induced by human septic shock serum. J. Exp. 
Med. 183: 949-958. 
Lappe, RW, Sheldon, JH, Cox, BF (1992). Selective adenosine-2 agonist 
produces both direct and reflex tachycardia in normotensive rats. J. 
Cardiovasc. Pharmacol. 19: 460-463. 
Law, WR (2006). Adenosine receptors in the response to sepsis: what do 
receptor-specific knockouts tell us? Am. J. Physioi. 291: R957-R958. 
Law, WR, Valli, VE, Conlon, BA (2003). Therapeutic potential for transient 
inhibition of adenosine deaminase in systemic inflammatory response 
syndrome. Cri!. Care Med. 31: 1475-1481. 
263 
Lee, HT, Kim, M, 100, ID, Gallos, G, Chen, JF, Emala, CW (2006). A3 
adenosine receptor activation decreases mortality and renal and hepatic 
injury in murine septic peritonitis. Am. 1. Physiol. 291: R959-R969. 
Lepper, PM, Held, TK, Schneider, EM, BOlke, E, Gerlach, H, Trautmann, M 
(2002). Clinical implications of antibiotic-induced endotoxin release in septic 
shock. Intensive Care Med. 28: 824-833. 
Li, YY, Wong, LY, Cheung, BM, Hwang, IS, Tang, F (2005). Differential 
induction of adrenomedullin, interleukins and tumour necrosis factor-alpha 
by lipopolysaccharide in rat tissues in vivo. Clin. Exp. Pharmacol. Physiol. 
32: 1110-1118. 
Li, YY, Cheung, BM, Wong, LY, Hwang, IS, Kumana, CR, Tang, F (2005). 
Adrenomedullin gene expression and levels in the cardiovascular system 
after treatment with lipopolysaccharide. Neuropeptides 39: 73-80. 
Linden, J (2001). Molecular approach to adenosine receptors: receptor-
mediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol. 
41: 775-787. 
Lippton, H, Chang, JK, Hao, Q, Summer, W, Hyman, AL (1994). 
Adrenomedullin dilates the pulmonary vascular bed in vivo. 1. Appl. Physiol. 
76: 2154-2156. 
Llewelyn, MJ, Cohen, J (2007). Tracking the microbes in sepsis: 
advancements in treatment bring challenges for microbial epidemiology. 
Clin. Infect. Dis. 44: 1343-1348. 
Londos, C, Cooper, DM, Wolff, J (1980). Subclasses of external adenosine 
receptors. Proc. Natl. Acad. Sci. USA 77: 2551-2554. 
Lorenz, E, Mira, JP, Frees, KL, Schwartz, DA (2002). Relevance of 
mutations in the TLR4 receptor in patients with gram-negative septic shock. 
Arch. Intern. Med. 162: 1028-1032. 
Luodonpaa, M, Leskinen, H, Ilves, M, Vuolteenaho, 0, Ruskoaho, H (2004). 
Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin 
II in conscious rats. Am. 1. Physiol. 286: R1085-RI092. 
264 
Lynge, J, Hellsten, Y (2000). Distribution of adenosine AI, A2A and A2B 
receptors in human skeletal muscle. Acta. Physiol. Scand. 169: 283-290. 
MacKenzie, IM (2001). The haemodynamics of human septic shock. 
Anaesthesia 56: 130-144. 
Marshall, lC, Walker, PM, Foster, DM, Harris, D, Ribeiro, M, Paice, J, 
Romaschin, AD, Derzko, AN (2002). Measurement of endotoxin activity in 
critically ill patients using whole blood neutrophil dependent 
chemiluminescence. Crit. Care 6: 342-348. 
Marshall, JM, Thomas, T, Turner, L (1993). A link between adenosine, ATP-
sensitive K + channels, potassium and muscle vasodilatation in the rat in 
systemic hypoxia. J. Physiol. 472: 1-9. 
Martin, C, Leone, M, Viviand, X, Ayem, ML, Guieu, R (2000). High 
adenosine plasma concentration as a prognostic index for outcome in patients 
with septic shock. Crit. Care Med. 28: 3198-3202. 
Martinez, A, Oh, HR, Unsworth, EJ, Bregonzio, C, Saavedra, JM, Stetler-
Stevenson, WG, Cuttitta, F (2004). Matrix metalloproteinase-2 cleavage of 
adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem. J. 
383: 413-418. 
Mathot, RA, van Schaick, EA, Langemeijer, MW, Soudijn, W, Breimer, DD, 
Ijzerman, AP, Danhof, M (1994). Pharmacokinetic-pharmacodynamic 
relationship of the cardiovascular effects of adenosine Al receptor agonist 
N6-cyclopentyladenosine in the rat. J. Pharmacol. Exp. Ther. 268: 616-624. 
Matsuda, N, Rattori, Y (2007). Vascular biology in sepsis: 
pathophysiological and therapeutic significance of vascular dysfunction. J. 
Smooth Muscle Res. 43: 117-137. 
Mazzocchi, G, Albertin, G, Nussdorfer, GG (2000). Adrenomedullin (AD M), 
acting through ADM (22-52)-sensitive receptors, is involved in the 
endotoxin-induced hypotension in rats. Life Sci 66: 1445-1450. 
265 
McLatchie, LM, Fraser, NJ, Main, MJ, Wise, A, Brown, J, Thompson, N, 
Solari, R, Lee, MG, Foord, SM (1998). RAMPs regulate the transport and 
ligand specificity of the calcitonin-receptor-like receptor. Nature 393: 333-
339. 
Merkel, LA, Lappe, RW, Rivera, LM, Cox, BF, Perrone, MH (1992). 
Demonstration of vasorelaxant activity with an AI-selective adenosine 
agonist in porcine coronary artery: involvement of potassium channels. 1. 
Pharmacol. Exp. Ther. 260: 437-443. 
Merx, MW, Weber, C (2007). Sepsis and the heart. Circulation 116: 793-
802. 
Mian, R, Marshall, JM (1995). The role of adenosine in mediating 
vasodilatation in mesenteric circulation of the rat in acute and chronic 
hypoxia. 1. Physiol. 489: 225-234. 
Miksa, M, Wu, R, Cui, X, Dong, W, Das, P, Simms, HH, Ravikumar, TS, 
Wang, P (2007). Vasoactive hormone adrenomedullin and its binding 
protein: anti-inflammatory effects by up-regulating peroxisome proliferator-
activated receptor-gamma. 1. Immunol. 179: 6263-6272. 
Miura, K, Ebara, T, Okumura, M, Matsuura, T, Kim, S, Yukimura, T, Iwao, 
H (1995). Attenuation of adrenomedullin-induced renal vasodilatation by 
NG-nitro L-arginine but not glibenclamide. Br. J. Pharmacol. 115: 917-924. 
Morimoto, R, Satoh, F, Murakami, 0, Totsune, K, Suzuki, T, Sasano, H, Ito, 
S, Takahashi, K (2007). Expression of adrenomedullin2/intermedin in human 
brain, heart, and kidney. Peptides 28: 1095-1103. 
Motew, SJ, Sam, AD, Mourelatos, MO, Sharrna, AC, Alden, KJ, Ferguson, 
JL, Law, WR (1998). Adenosine receptor antagonism affects regional resting 
vascular resistance during rat peritoneal sepsis. 1. Surg. Res. 80: 326-332. 
Mubagwa, K, Mullane, K, Flameng, W (1996). Role of adenosine in the 
heart and circulation. Cardiovasc. Res. 32: 797-813. 
Murray, RD, Churchill, PC (1984). Effects of adenosine receptor agonists in 
the isolated, perfused rat kidney. Am. 1. Physiol. 247: H343-H348. 
266 
Murray, RD, Churchill, PC (1985). Concentration dependency of the renal 
vascular and renin secretory responses to adenosine receptor agonists. J 
Pharmacol Exp Ther 232: 189-193. 
Nagoshi, Y, Kuwasako, K, Cao, YN, Imamura, T, Kitamura, K, Eto, T 
(2004). Tumor necrosis factor-alpha downregulates adrenomeduIlin receptors 
in human coronary artery smooth muscle cells. Peptides 25: 1115-1121. 
Nandha, KA, Taylor, GM, Smith, DM, Owji, AA, Byfield, PG, Ghatei, MA, 
Bloom, SR (1996). Specific adrenomeduIlin binding sites and hypotension in 
the rat systemic vascular bed. Regul. Pept. 62: 145-151. 
Nemeth, ZH, Csoka, B, Wilmanski, J, Xu, D, Lu, Q, Ledent, C, Deitch, EA, 
Pacher, P, Spolarics, Z, Hasko, G (2006). Adenosine A2A receptor 
inactivation increases survival in polymicrobial sepsis. J. Immunol. 176: 
5616-5626. 
Newby, AC (1984). Adenosine and the concept of retaliatory metabolites. 
Trends Biochem. Sci. 9. 
Nieri, P, Martinotti, E, Calderone, V, Breschi, MC (2001). Adenosine-
mediated hypotension in in vivo guinea-pig: receptors involved and role of 
NO. Br. J. Pharmacol. 134: 745-752. 
Nishikimi, T, Karasawa, T, Inaba, C, Ishimura, K, Tadokoro, K, Koshikawa, 
S, Yoshihara, F, Nagaya, N, Sakio, H, Kangawa, K, Matsuoka, H (2009). 
Effects of long-term intravenous administration of adrenomedullin (AM) 
plus hANP therapy in acute decompensated heart failure. Circ. J. 73: 892-
898. 
Nishiyama, A, Miura, K, Miyatake, A, Fujisawa, Y, Yue, W, Fukui, T, 
Kimura, S, Abe, Y (1999). Renal interstitial concentration of adenosine 
during endotoxin shock. Eur. J. Pharmacol. 385: 209-216. 
Nuki, e, Kawasaki, H, Kitamura, K, Takenaga, M, Kangawa, K, Eto, T, 
Wada, A (1993). Vasodilator effect of adrenomedulIin and calcitonin gene-
related peptide receptors in rat mesenteric vascular beds. Biochem. Biophys. 
Res. Commun. 196: 245-251. 
267 
O'Brien, AJ, Wilson, AJ, Sibbald, R, Singer, M, Clapp, LH (2001). Temporal 
variation in endotoxin-induced vascular hyporeactivity in a rat mesenteric 
artery organ culture model. Br. 1. Pharmacol. 133: 351-360. 
O'Brien, JM, Jr., Ali, NA, Aberegg, SK, Abraham, E (2007). Sepsis. Am. 1. 
Med. 120: 1012-1022. 
Ogoshi, M, Inoue, K, Naruse, K, Takei, Y (2006). Evolutionary history of the 
calcitonin gene-related peptide family in vertebmtes revealed by comparative 
genomic analyses. Peptides 27: 3154-3164. 
Ogoshi, M, Inoue, K, Takei, Y (2003). Identification of a novel 
adrenomedullin gene family in teleost fish. Biochem. Biophys. Res. Commun. 
311: 1072-1077. 
Ohnishi, A, Biaggioni, I, Deray, G, Branch, RA, Jackson, EK (1986). 
Hemodynamic effects of adenosine in conscious hypertensive and 
normotensive rats. Hypertension 8: 391-398. 
Ohta, A, Sitkovsky, M (2001). Role of G-protein-coupled adenosine 
receptors in downregulation of inflammation and protection from tissue 
damage. Nature 414: 916-920. 
Ono, Y, Okano, I, Kojima, M, Okada, K, Kangawa, K (2000). Decreased 
gene expression of adrenomedullin receptor in mouse lungs during sepsis. 
Biochem. Biophys.Res. Commun. 271: 197-202. 
Owji, AA, Chabot, JG, Dumont, Y, Quirion, R (2008). AdrenomeduI1in-
2/intermedin induces cAMP accumulation in dissociated rat spinal cord cells: 
evidence for the existence of a distinct class of sites of action. 1. Mol. 
Neurosci. 35: 355-361. 
Pan, CS, Yang, JH, Cai, DY, Zhao, J, Gems, H, Yang, J, Chang, JK, Tang, 
CS, Qi, YF (2005). Cardiovascular effects of newly discovered peptide 
intermedinladrenomedullin 2. Peptides 26: 1640-1646. 
Parker, JL, Myers, PR, Zhong, Q, Kim, K, Adams, HR (1994). Inhibition of 
endothelium-dependent vasodilation by Escherichia coli endotoxemia. Shock 
2: 451-458. 
268 
Parker, MM, Cunnion, RE, Parrillo, JE (1985). Echocardiography and 
nuclear cardiac imaging in the critical care unit. JAMA 254: 2935-2939. 
Parker, SJ, Watkins, PE (2001). Experimental models of gram-negative 
sepsis. Br. J. Surg. 88: 22-30. 
Parkes, DG (1995). Cardiovascular actions of adrenomedullin in conscious 
sheep. Am. J. Physiol. 268: H2574-H2578. 
Parkes, DG, May, CN (1997). Direct cardiac and vascular actions of 
adrenomedullin in conscious sheep. Br. J. Pharmacol. 120: 1179-1185. 
Parratt, JR (1998). Nitric oxide in sepsis and endotoxaemia. J. Antimicrob. 
Chemother. 41: 31-39. 
Parrillo, JE (1989). The cardiovascular pathophysiology of sepsis. Annu. Rev. 
Med. 40: 469-485. 
Pennanen, MF, Bass, BL, Dziki, AJ, Harmon, JW (1994). Adenosine: 
differential effect on blood flow to subregions of the upper gastrointestinal 
tract. J. Surg. Res. 56: 461-465. 
Piepot, HA, Groeneveld, AB, van Lambalgen, AA, Sipkema, P (2003). 
Endotoxin impairs endothelium-dependent vasodilation more in the coronary 
and renal arteries than in other arteries of the rat. J. Surg. Res. 110: 413-418. 
Pio, R, Martinez, A, Unsworth, EJ, Kowalak, JA, Bengoechea, JA, Zipfel, 
PF, Elsasser, TH, Cuttitta, F (2001). Complement factor H is a serum-
binding protein for adrenomedullin, and the resulting complex modulates the 
bioactivities of both partners. J. BioI. Chem. 276: 12292-12300. 
Porciatti, F, Pelzmann, B, Cerbai, E, Schaffer, P, Pino, R, Bernhart, E, Koidl, 
B, Mugelli, A (1997). The pacemaker current I(f) in single human atrial 
myocytes and the effect of beta-adrenoceptor and A I-adenosine receptor 
stimulation. Br. J. Pharmacol. 122: 963-969. 
Poulsen, SA, Quinn, RJ (1998). Adenosine receptors: new opportunities for 
future drugs. Bioorg. Med. Chem. 6: 619-641. 
269 
Poyner, DR, Sexton, PM, Marshall, I, Smith, DM, Quirion, R, Born, W, 
Muff, R, Fischer, JA, Foord, SM (2002). International Union of 
Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, 
adrenomedullin, amyl in, and calcitonin receptors. Pharmacol. Rev. 54: 233-
246. 
Prentice, DJ, Payne, SL, Rourani, SM (1997). Activation of two sites by 
adenosine receptor agonists to cause relaxation in rat isolated mesenteric 
artery. Br. J. Pharmacol. 122: 1509-1515. 
Quartin, AA, Schein, RM, Kett, DR, Peduzzi, PN (1997). Magnitude and 
duration of the effect of sepsis on survival. Department of Veterans Affairs 
Systemic Sepsis Cooperative Studies Group. JAMA 277: 1058-1063. 
Ray, CJ, Abbas, MR, Coney, AM, Marshall, JM (2002). Interactions of 
adenosine, prostaglandins and nitric oxide in hypoxia-induced vasodilatation: 
in vivo and in vitro studies. J. Physiol. 544: 195-209. 
Ray, CJ, Marshall, JM (2006). The cellular mechanisms by which adenosine 
evokes release of nitric oxide from rat aortic endothelium. 1. Physiol. 570: 
85-96. 
Ray, CJ, Marshall, JM (2005). Measurement of nitric oxide release evoked 
by systemic hypoxia and adenosine from rat skeletal muscle in vivo. J. 
Physiol. 568: 967-978. 
Ray, CJ, Marshall, JM (2009). Nitric oxide (NO) does not contribute to the 
generation or action of adenosine during exercise hyperaemia in rat hindlimb. 
J. Physiol. 587: 1579-1591. 
Remick, DG, Newcomb, DE, Bolgos, GL, Call, DR (2000). Comparison of 
the mortality and inflammatory response of two models of sepsis: 
lipopolysaccharide vs. cecalligation and puncture. Shock 13: 110-116. 
Remick, DG, Ward, P A (2005). Evaluation of endotoxin models for the study 
of sepsis. Shock 24: 7-11. 
Ren, YS, Yang, JR, Zhang, J, Pan, CS, Yang, J, Zhao, J, Pang, YZ, Tang, 
CS, Qi, YF (2006). Intermedin 1-53 in central nervous system elevates 
arterial blood pressure in rats. Peptides 27: 74-79. 
270 
Riccardi, A, Arboscello, E, Ghinatti, M, Minuto, P, Lerza, R (2008). 
Adenosine in the treatment of supraventricular tachycardia: 5 years of 
experience (2002-2006). Am. J. Emerg. Med. 26: 879-882. 
Riedemann, NC, Guo, RP, Ward, PA (2003). Novel strategies for the 
treatment of sepsis. Nat. Med. 9: 517-524. 
Rittirsch, D, Flierl, MA, Ward, P A (2008). Harmful molecular mechanisms 
in sepsis. Nat. Rev. Immunol. 8: 776-787. 
Rittirsch, D, Hoesel, LM, Ward, PA (2007). The disconnect between animal 
models of sepsis and human sepsis. J. Leukoc. Bioi. 81: 137-143. 
Rivkees, SA, Zhao, Z, Porter, G, Turner, C (2001). Influences of adenosine 
on the fetus and newborn. Mol. Genet. Metab. 74: 160-171. 
Roh, J, Chang, CL, Bhalla, A, Klein, e, Hsu, SY (2004). Intermedin is a 
calcitonin/calcitonin gene-related peptide family peptide acting through the 
calcitonin receptor-like receptor/receptor activity-modifying protein receptor 
complexes. J. Bioi. Chem. 279: 7264-7274. 
Ross, GR, Yallampalli, e (2007). Vascular hyperresponsiveness to 
adrenomedullin during pregnancy is associated with increased generation of 
cyclic nucleotides in rat mesenteric artery. Bioi. Reprod. 76: 118-123. 
Ryzhov, S, Zaynagetdinov, R, Goldstein, AE, Novitskiy, SV, Blackburn, 
MR, Biaggioni, I, Feoktistov, I (2008). Effect of A2B adenosine receptor 
gene ablation on adenosine-dependent regulation of proinflammatory 
cytokines. J. Pharmacol. Exp. Ther. 324: 694-700. 
Sabates, BL, Pigott, JD, Choe, EU, Cruz, MP, Lippton, HL, Hyman, AL, 
Flint, LM, Ferrara, JJ (1997). Adrenomedullin mediates coronary 
vasodilation through adenosine receptors and KA TP channels. J. Surg. Res. 
67: 163-168. 
Sair, M, Etherington, PJ, Curzen, NP, Win love, CP, Evans, TW (1996). 
Tissue oxygenation and perfusion in endotoxemia. Am. J. Physiol. 271: 
HI620-HI625. 
271 
Sakai, K, Saito, K, Akima, M (1998). Synergistic effect of calcitonin gene-
related peptide on adenosine-induced vasodepression in rats. Eur. J. 
Ph arm acol. 344: 153-159. 
Sakai, K, Saito, K (1998). Reciprocal interactions among neuropeptides and 
adenosine in the cardiovascular system of rats: a role of K(ATP) channels. 
Eur. J. Pharmacol. 345: 279-284. 
Sakai, K) Saito, K (1998). Synergism between low-dose nicorandil and 
neuropeptides on adenosine-induced vasodepression in rats. Eur. J. 
Pharmacol. 352: 229-236. 
Sakai, K, Saito, K, Ishizuka, N (1998). Adrenomedullin synergistically 
interacts with endogenous vasodilators in rats: a possible role of K(ATP) 
channels. Europeanjournal of pharmacology 359: 151-159. 
Sakata, J, Shimokubo, T, Kitamura, K, Nakamura, S, Kangawa, K, Matsuo, 
H, Eto, T (1993). Molecular cloning and biological activities of rat 
adrenomedullin, a hypotensive peptide. Biochem. Biophys. Res. Commun. 
195: 921-927. 
Sam, AD, 2nd, Sharma, AC, Rice, AN, Ferguson, JL, Law, WR (2000). 
Adenosine and nitric oxide regulate regional vascular resistance via 
interdependent and independent mechanisms during sepsis. Crit. Care Med. 
28: 1931-1939. 
Samson, WK (1999). Adrenomedullin and the control of fluid and electrolyte 
homeostasis. Annu. Rev. Physiol. 61: 363-389. 
Sands, W A, Palmer, TM (2005). Adenosine receptors and the control of 
endothelial cell function in inflammatory disease. Immunol. Left. 101: 1-11. 
Santiago, JA, Garrison, E, Pumell, WL, Smith, RE, Champion, HC, Coy, 
DH, Murphy, WA, Kadowitz, PJ (1995). Comparison of responses to 
adrenomedullin and adrenomedullin analogs in the mesenteric vascular bed 
of the cat. Eur.J. Pharmacol. 272: 115-118. 
Saura, CA, Mallol, J, Canela, El, Lluis, C, Franco, R (1998). Adenosine 
deaminase and Al adenosine receptors internalize together following 
agonist-induced receptor desensitization. J. BioI. Chem. 273: 17610-17617. 
272 
Schindler, CW, Karcz-Kubicha, M, Thomdike, EB, Muller, CE, Tella, SR, 
Ferre, S, Goldberg, SR (2005). Role of central and peripheral adenosine 
receptors in the cardiovascular responses to intraperitoneal injections of 
adenosine Al and A2A subtype receptor agonists. Br. 1. Pharmacol. 144: 
642-650. 
Senna, AA, Zed an, M, e1-Salam, GE, el-Mashad, AI (2008). Study of plasma 
adrenomedullin level in normal pregnancy and preclampsia. Medscape. 1. 
Med. 10: 29. 
Shindo, T, Kurihara, H, Maemura, K, Kurihara, Y, Kuwaki, T, Izumida, T, 
Minamino, N, Ju, KH, Morita, H, Oh-hashi, Y, Kumada, M, Kangawa, K, 
Nagai, R, Yazaki, Y (2000). Hypotension and resistance to 
lipopolysaccharide-induced shock in transgenic mice overexpressing 
adrenomedullin in their vasculature. Circulation 101: 2309-2316. 
Shindo, T, Kurihara, Y, Nishimatsu, H, Mori yam a, N, Kakoki, M, Wang, Y, 
Imai, Y, Ebihara, A, Kuwaki, T, Ju, KH, Minamino, N, Kangawa, K, 
Ishikawa, T, Fukuda, M, Akimoto, Y, Kawakami, H, Imai, T, Morita, H, 
Yazaki, Y, Nagai, R, Hirata, Y, Kurihara, H (2001). Vascular abnormalities 
and elevated blood pressure in mice lacking adrenomedullin gene. 
Circulation 104: 1964-1971. 
Shoji, H, Minamino, N, Kangawa, K, Matsuo, H (1995). Endotoxin markedly 
elevates plasma concentration and gene transcription of adrenomedullin in 
rat. Biochem. Biophys. Res. Commun. 215: 531-537. 
Sibbald, WJ, Fox, G, Martin, C (1991). Abnormalities of vascular reactivity 
in the sepsis syndrome. Chest 100: 155S-159S. 
Simpson, AJ (2001). Melioidosis: a clinical model for gram-negative sepsis. 
1. Med. Microbiol. SO: 657-658. 
Skrabanja, AT, Bouman, EA, Dagnelie, PC (2005). Potential value of 
adenosine 5'-triphosphate (ATP) and adenosine in anaesthesia and intensive 
care medicine. Br. 1. Anaesth. 94: 556-562. 
Somani, SM, Gupta, P (1988). Caffeine: a new look at an age-old drug. Int. J. 
CUn. Pharmacol. Ther. Toxicol. 26: 521-533. 
273 
Sorrentino, R, d'Emmanuele di Villa Bianca, R, Lippolis, L, Sorrentino, L, 
Autore, G, Pinto, A (1999). Involvement of ATP-sensitive potassium 
channels in a model of a delayed vascular hyporeactivity induced by 
lipopolysaccharide in rats. Br. J. Pharmacol. 127: 1447-1453. 
Sugo, S, Minamino, N, Shoji, H, Kangawa, K, Kitamura, K, Eto, T, Matsuo, 
H (1995). InterIeukin-l, tumor necrosis factor and lipopolysaccharide 
additively stimulate production of adrenomedllllin in vascular smooth muscle 
cells. Biochem. Biophys. Res. Commun. 207: 25-32. 
Sullivan, GW, Fang, G, Linden, J, Scheld, WM (2004). A2A adenosine 
receptor activation improves survival in mouse models of endotoxemia and 
sepsis. J. Infect. Dis. 189: 1897-1904. 
Surah-Narwal, S, Xu, SZ, McHugh, D, McDonald, RL, Hough, E, Cheong, 
A, Partridge, C, Sivaprasadarao, A, Beech, DJ (1999). Block of human aorta 
Kir6.1 by the vascular KATP channel inhibitor V37883A. Br. J. Pharmacol. 
128: 667-672. 
Tagawa, H, Vander, AJ (1970). Effects of adenosine compounds on renal 
function and renin secretion in dogs. Circ. Res. 26: 327-338. 
Takahashi, K, Kikuchi, K, Maruyama, Y, Urabe, T, Nakajima, K, Sasano, H, 
Imai, Y, Murakami, 0, Totsune, K (2006). Immunocytochemical localization 
of adrenomedullin 2/intermedin-like immunoreactivity In human 
hypothalamus, heart and kidney. Peptides 27: 1383-1389. 
Takei, Y, Hashimoto, H, Inoue, K, Osaki, T, Yoshizawa-Kumagaye, K, 
Tsunemi, M, Watanabe, TX, Ogoshi, M, Minamino, N, Veta, Y (2008). 
Central and peripheral cardiovascular actions of adrenomedullin 5, a novel 
member of the calcitonin gene-related peptide family, in mammals. J. 
Endocrinol. 197: 391-400. 
Takei, Y, Hyodo, S, Katafuchi, T, Minamino, N (2004). Novel fish-derived 
adrenomedullin in mammals: structure and possible function. Peptides 25: 
1643-1656. 
Takei, Y, Inoue, K, Ogoshi, M, Kawahara, T, Bannai, H, Miyano, S (2004). 
Identification of novel adrenomedullin in mammals: a potent cardiovascular 
and renal regulator. FEBS letters 556: 53-58. 
274 
Tang, L, Parker, M, Fei, Q, Loutzenhiser, R (1999). Afferent arteriolar 
adenosine A2a receptors are coupled to KA TP in in vitro perfused 
hydronephrotic rat kidney. Am J Physiol277: F926-F933. 
Tarpey, SB, Bennett, T, Randall, MD, Gardiner, SM (1998) Differential 
effects of endotoxaemia on pressor and vasoconstrictor actions of angiotensin 
11 and arginine vasopressin in conscious rats. Br. 1. Pharmacol. 123: 1367-
1374. 
Taveira da Silva, AM, Kaulbach, HC, Chuidian, FS, Lambert, DR, 
Suffredini, AF, Danner, RL (1993). Brief report: shock and multiple-organ 
dysfunction after self-administration of Salmonella endotoxin. N. Engl. J. 
Med. 328: 1457-1460. 
Tawfik, HE, Teng, B, Morrison, RR, Schnennann, J, Mustafa, SJ (2006). 
Role of Al adenosine receptor in the regulation of coronary flow. Am. J. 
Physiol. 291: H467-H472. 
Taylor, MM, Bagley, SL, Samson, WK (2005). Intennedinladrenomedullin-2 
acts within central nervous system to elevate blood pressure and inhibit food 
and water intake. Am. J. Physiol. 288: R919-R927. 
Terata, K, Miura, H, Liu, Y, Loberiza, F, Gutterman, DD (2000). Human 
coronary arteriolar dilation to adrenomedullin: role of nitric oxide and K(+) 
channels. Am. J. Physiol. 279: H2620-H2626. 
Thomas, T, St Lambert, JH, Dashwood, MR, Spyer, KM (2000). 
Localization and action of adenosine A2a receptors in regions of the 
brainstem important in cardiovascular control. Neuroscience 95: 513-518. 
Toltl, LJ, Shin, LY, Liaw, PC (2007). Activated protein C in sepsis and 
beyond: update 2006. Front. Biosci. 12: 1963-1972. 
Troughton, RW, Lewis, LK, Yandle, TG, Richards, AM, Nicholls, MG 
(2000). Hemodynamic, honnone, and urinary effects of adrenomedullin 
infusion in essential hypertension. Hypertension 36: 588-593. 
Trzeciak, S, Cinel, I, Phillip Dellinger, R, Shapiro, NI, Arnold, RC, Parrillo, 
JE, Hollenberg, SM (2008). Resuscitating the microcirculation in sepsis: the 
275 
central role of nitric oxide, emerging concepts for novel therapies, and 
challenges for clinical trials. Acad. Emerg. Med. 15: 399-413. 
Tsiotou, AG, Sakorafas, GH, Anagnostopoulos, G, Bramis, J (2005). Septic 
shock; current pathogenetic concepts from a clinical perspective. Med. Sci. 
Monit. 11: RA76-RA85. 
Vallon, V, Albinus, M, Blach, D (1998). Effect of KATP channel blocker 
U37883A on renal function in experimental diabetes mellitus in rats. J. 
Pharmacol. Exp. Ther. 286: 1215-1221. 
Vallon, V, Muhlbauer, B, Osswald, H (2006). Adenosine and kidney 
function. Physiol. Rev. 86: 901-940. 
Vincent, JL, Sakr, Y, Sprung, CL, Ranieri, VM, Reinhart, K, Gerlach, H, 
Moreno, R, Cartet, J, Le Gall, JR, Payen, D (2006). Sepsis in European 
intensive care units: results of the SOAP study. Cri!. Care Med. 34: 344-353. 
VD, PA, Lad, B, Tomlinson, JA, Francis, S, Ahluwalia, A (2005). 
autoregulatory role of endothelium-derived nitric oxide (NO) on 
Lipopolysaccharide-induced vascular inducible NO synthase expression and 
function. J. Bioi. Chem. 280: 7236-7243. 
Wakefield, ID, March, JE, Kemp, P A, Valentin, JP, Bennett, T, Gardiner, 
SM (2003). Comparative regional haemodynamic effects of the nitric oxide 
synthase inhibitors, S-methyl-L-thiocitrulline and L-NAME, in conscious 
rats. Br. J. Pharmacol. 139: 1235-1243. 
Wall er, J, Gardiner, SM, Bennett, T (1994). Regional haemodynamic 
responses to acetylcholine, methoxamine, salbutamol and bradykinin during 
lipopolysaccharide infusion in conscious rats. Br. J. Pharmacol. 112: 1057-
1064. 
Waller, J, Gardiner, SM, Jose, J, Bennett, T (1995). Lack of effect of TNF 
antibodies on the cardiovascular sequelae of lipopolysaccharide infusion in 
conscious rats. BrJ Pharmacol1l6: 2487-2495. 
Walsh, MP, Marshall, JM (2006). The role of adenosine in the early 
respiratory and cardiovascular changes evoked by chronic hypoxia in the rat. 
J. Physiol. 575: 277-289. 
276 
Walsh, MP, Marshall, JM (2006). The early effects of chronic hypoxia on the 
cardiovascular system in the rat: role of nitric oxide. J Physial575: 263-275. 
Wang, JE, Dahle, MK, McDonald, M, Foster, SJ, Aasen, AO, Thiemermann, 
C (2003). Peptidoglycan and lipoteichoic acid in gram-positive bacterial 
sepsis: receptors, signal transduction, biological effects, and synergism. 
Shack 20: 402-414. 
Wang, P (2001). Andrenomedullin and cardiovascular responses in sepsis. 
Peptides 22: 1835-1840. 
Wang, P, Chaudry, I (1998). A Single Hit Model of Polymicrobial Sepsis: 
Cecal Ligation and Puncture. Sepsis 227-233. 
Wang, P, Yoo, P, Zhou, M, Cioffi, WG, Ba, ZF, Chaudry, IH (1999). 
Reduction in vascular responsiveness to adrenomedullin during sepsis. J. 
Surg. Res. 85: 59-65. 
Watt, AH (1986). Adenosine in atrial arrhythmias. 1. Am. Call. Cardial. 8: 
463-464. 
Webb, RL, McNeal, RB, Jr., Barclay, BW, Yasay, GD (1990). 
Hemodynamic effects of adenosine agonists in the conscious spontaneously 
hypertensive rat. 1. Pharmacal. Exp. Ther. 254: 1090-1099. 
Weihprecht, H, Lorenz, IN, Schnermann, J, Skott, 0, Briggs, JP (1990). 
Effect of adenosinel-receptor blockade on renin release from rabbit isolated 
perfused juxtaglomerular apparatus. 1. Clin. Invest. 85: 1622-1628. 
Wellman, GC, Barrett-Jolley, R, Koppel, H, Everitt, D, Quayle, JM (1999). 
Inhibition of vascular K(ATP) channels by U-37883A: a comparison with 
cardiac and skeletal muscle. Br. J. Pharmacal. 128: 909-916. 
White, MM, Samson, WK. (2007). Intermedin 17-47 does not function as a 
full intermedin antagonist within the central nervous system or pituitary. 
Peptides 28: 2171-2178. 
Worm aId, A, Bowmer, CJ, Yates, MS, Collis, MG (1989). Pharmacokinetics 
of 8-phenyltheophylline in the rat. 1. Pharm. Pharmacal. 41: 418-420. 
277 
Wu, CC, Chen, SJ, Garland, CJ (2004). NO and KATP channels underlie 
endotoxin-induced smooth muscle hyperpolarization in rat mesenteric 
resistance arteries. Br. J. Pharmacol. 142: 479-484. 
Wu, R, Zhou, M, Wang, P (2003). Adrenomedullin and adrenomedullin 
binding protein-l downregulate TNF-alpha in macrophage cell line and rat 
Kupffer cells. Regul. Pept. 112: 19-26. 
Wu, R, Cui, X, Dong, W, Zhou, M, Simms, HH, Wang, P (2005). 
Mechanisms responsible for vascular hyporesponsiveness to adrenomedullin 
after hemorrhage: the central role of adrenomedullin binding protein-I. Ann. 
Surg. 242: 115-123. 
Wu, R, Dong, W, Zhou, M, Cui, X, Simms, HR, Wang, P (2005). A novel 
approach to maintaining cardiovascular stability after hemorrhagic shock: 
beneficial effects of adrenomedullin and its binding protein. Surgery 137: 
200-208. 
Wu, R, Dong, W, Qiang, X, Ji, Y, Cui, T, Yang, J, Zhou, M, Blau, S, Marini, 
CP, Ravikumar, TS, Wang, P (2008). Human vasoactive hormone 
adrenomedullin and its binding protein rescue experimental animals from 
shock. Peptides 29: 1223-1230. 
Wu, R, Higuchi, S, Dong, W, Ji, Y, Zhou, M, Marini, CP, Ravikumar, TS, 
Wang, P (2009). Reversing established sepsis in rats with human vasoactive 
hormone adrenomedullin and its binding protein. Mol Med 15: 28-33. 
Yaar, R, Jones, MR, Chen, JF, Ravid, K (2005). Animal models for the study 
of adenosine receptor function. J. Cell Physiol. 202: 9-20. 
Yamaguchi, N, Jesmin, S, Zaedi, S, Shimojo, N, Maeda, S, Gando, S, 
Koyama, A, Miyauchi, T (2006). Time-dependent expression of renal vaso-
regulatory molecules in LPS-induced endotoxemia in rat. Peptides 27: 2258-
2270. 
Yamaguchi, T, Baba, K, Doi, Y, Yano, K (1995). Effect of adrenomedullin 
on aldosterone secretion by dispersed rat adrenal zona glomerulosa cells. Life 
Sci. 56: 379-387. 
278 
Yamaguchi, T, Baba, K, Doi, Y, Yano, K, Kitamura, K, Eto, T (1996). 
Inhibition of aldosterone production by adrenomedullin, a hypotensive 
peptide, in the rat. Hypertension 28: 308-314. 
Yang, JR, Jia, YX, Pan, CS, Zhao, J, Ouyang, M, Yang, J, Chang, JK, Tang, 
CS, Qi, YF (2005). Effects of intermedin(I-53) on cardiac function and 
ischemiaireperfusion injury in isolated rat hearts. Biochem. Biophys. Res. 
Commun. 327: 713-719. 
Yang, JR, Qi, YF, Jia, YX, Pan, CS, Zhao, J, Yang, J, Chang, JK, Tang, CS 
(2005). Protective effects of intermedinladrenomedullin2 on 
ischemiaireperfusion injury in isolated rat hearts. Peptides 26: 501-507. 
Yang, RB, Mark, MR, Gray, A, Ruang, A, Xie, MH, Zhang, M, Goddard, A, 
Wood, WI, Gurney, AL, Godowski, PJ (1998). Toll-like receptor-2 mediates 
lipopolysaccharide-induced cellular signalling. Nature 395: 284-288. 
Yang, S, Zhou, M, Chaudry, IH, Wang, P (2002). Novel approach to prevent 
the transition from the hyperdynamic phase to the hypodynamic phase of 
sepsis: role of adrenomedullin and adrenomedullin binding protein-I. Ann. 
Surg. 236: 625-633. 
Yang, S, Zhou, M, Chaudry, rn, Wang, P (2001). The role of 
lipopolysaccharide in stimulating adrenomedullin production during 
polymicrobial sepsis. Biochim. Biophys. Acta. 1537: 167-174. 
Yang, S, Zhou, M, Fowler, DE, Wang, P (2002). Mechanisms of the 
beneficial effect of adrenomedullin and adrenomedullin-binding protein-l in 
sepsis: down-regulation of proinflarnmatory cytokines. Cri!. Care Med. 30: 
2729-2735. 
Yang, JH, Pan, CS, Jia, YX, Zhang, J, Zhao, J, Pang, YZ, Yang, J, Tang, CS, 
Qi, YF (2006). Intermedinl-53 activates L-arginine/nitric oxide 
synthase/nitric oxide pathway in rat aortas. Biochemical and biophysical 
research communications 341: 567-572. 
Zaks-Zilberman, M, Salkowski, CA, Elsasser, T, Cuttitta, F, Vogel, SN 
(1998). Induction of adrenomedullin mRNA and protein by 
lipopolysaccharide and paclitaxel (Taxol) in murine macrophages. Infect. 
Immun. 66: 4669-4675. 
279 
Zeng, Q, Yuan, Y, Wang, X, Wu, HM, Fan, L, Qi, YF, Tang, CS, Cai, Y, 
Pan, CS (2009). Upregulated expression of intennedin and its receptor in the 
myocardium and aorta in spontaneously hypertensive rats. Peptides 30: 391-
399. 
Zhang, JG, Hepbum, L, Cruz, G, Bonnan, RA, Clark, KL (2005). The role of 
adenosine A2A and A2B receptors in the regulation ofTNF-alpha production 
by human monocytes. Biochem. Pharmacol. 69: 883-889. 
Zhao, G, Linke, A, Xu, X, Ochoa, M, Belloni, F, Belardinelli, L. Hintze. TH 
(2003). Comparative profile of vasodilation by CVT-3146, a novel A2A 
receptor agonist, and adenosine in conscious dogs. J. Pharmacol. Exp. Ther. 
307: 182-189. 
Zhao, Y. Bell, D, Smith, LR, Zhao, L, Devine. AB. McHenry, EM, Nicholls. 
DP, McDermott, BJ (2006). Differential expression of components of the 
cardiomyocyte adrenomedullinlintermedin receptor system following blood 
pressure reduction in nitric oxide-deficient hypertension. J. Pharmacol. Exp. 
Ther. 316: 1269-1281. 
Zhou. M, Wang, P, Chaudry, rn (1997). Endothelial nitric oxide synthase is 
downregulated during hyperdynamic sepsis. Biochim Biophys Acta 1335: 
182-190. 
Zhou, M, Ba, ZF, Chaudry. rn, Wang, P (2002). Adrenomedullin binding 
protein-l modulates vascular responsiveness to adrenomedullin in late sepsis. 
Am. J. Physiol. 283: R553-RS60. 
Zhou, M. Simms, HH, Wang, P (2004). Adrenomedullin and adrenomedullin 
binding protein-l attenuate vascular endothelial cell apoptosis in sepsis. Ann. 
Surg. 240: 321-330. 
Zhou, M, Maitra, SR. Wang, P (2007). Adrenomedullin and adrenomedullin 
binding protein-l protect endothelium-dependent vascular relaxation in 
sepsis. Mol. Med. 13: 488-494. 
280 
281 
282 
